Discovery of an effective antidote for Amanita Phalloides poisoning by Juliana Cristina Venera Garcia
  
 
 
 
 
 
 
 
 
DISCOVERY OF AN EFFECTIVE ANTIDOTE 
FOR AMANITA PHALLOIDES POISONING 
 
 
 
 
 
 
 
 
Juliana Cristina Venera Garcia 
 
 
TESE APRESENTADA PARA ADMISSÃO A PROVAS DE 
DOUTORAMENTO À FACULDADE DE FARMÁCIA DA UNIVERSIDADE 
DO PORTO 
 
 iii 
The candidate performed the experimental work supported by a PhD grant (SFRH / BD / 74979 / 
2010) of Fundação para a Ciência e Tecnologia.  
The Faculty of Pharmacy of the University of Porto, the Faculty of Sciences of University of Porto 
and the Faculty of Sport, University of Porto, Portugal provided the facilities and logistical support 
for the experimental work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
  
 v 
 
 
 
Juliana Cristina Venera Garcia 
 
 
DISCOVERY OF AN EFFECTIVE ANTIDOTE FOR AMANITA PHALLOIDES 
POISONING 
 
 
 
 
Tese do 3º Ciclo de Estudos Conducente ao Grau de Doutor em Ciências 
Farmacêuticas – Especialidade: Toxicologia 
 
 
 
 
 
Orientador: Professor Doutor Félix Carvalho  
(Professor Catedrático da Faculdade de Farmácia da Universidade do Porto) 
  
Co-orientadora: Professora Doutora Maria de Lourdes Pinho de Almeida 
Souteiro Bastos 
(Professora Catedrática da Faculdade de Farmácia da Universidade do Porto) 
 
Co-orientadora: Professora Doutora Vera Marisa Costa 
(Professora da Faculdade de Farmácia da Universidade do Porto) 
 
 
 
Porto 
Abril, 2015
  
 vii 
DE ACORDO COM A LEGISLAÇÃO EM VIGOR, NÃO É PERMITIDA A 
REPRODUÇÃO DE QUALQUER PARTE DESTA TESE.
   
 ix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
À minha Mãe Carminda e irmã Márcia 
Às minhas Tias Mimi e São 
Ao Zé 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi 
ACKNOWLEDGMENTS / AGRADECIMENTOS 
 
Esta tese não é resultado apenas de um esforço individual. Ela nasce de significativas 
contribuições que recolhi durante a minha trajetória profissional, acadêmica e como 
cidadã, ao lidar com pessoas que tanto contribuíram para que este trabalho fosse 
desenvolvido. Foram 4 anos de intenso trabalho e dedicação, e sem dúvida são 4 anos de 
puro orgulho por tudo o que consegui conquistar e alcançar. Cresci, aprendi e mergulhei 
no mundo da ciência com a ânsia de poder ser um pouco melhor todos os dias. Todas as 
pessoas que aqui mencionarei deram um pouquinho delas e levaram um pouco de mim.  
 
Em primeiro lugar expresso a minha profunda gratidão ao meu Orientador Professor Félix 
Carvalho. Foi, sem dúvida um honra conhecê-lo como pessoa e profissional. É das pessoas 
mais entusiastas que conheço transmitindo os seu conhecimentos de forma absolutamente 
admirável. Obrigada por acreditar em mim e por me ter dado oportunidade de conhecer o 
mundo da toxicologia de uma forma notável. Foi uma longa caminhada e sei que nada 
disto era possível sem todo o apoio que prestou nestes 4 anos. Levo comigo todos os 
ensinamentos transmitidos, toda a força de vencer qualquer obstáculo e todo o ânimo de 
saber que posso ser capaz. Obrigada professor por me ter tornado uma pessoa melhor. 
 
À minha co-orientadora, Professora Doutora Maria de Lourdes Bastos pelo carinho, pelas 
palavras entusiastas e pelo apoio que transmitiu nestes 4 anos. Sinto uma profunda 
admiração por si e pelo trabalho que tem desenvolvido na toxicologia. É notável a forma 
como abraça todos os alunos e lhe transmite tanto e tão inigualável conhecimento. Não só 
a nível profissional, como também a nível pessoal contribui para que sejamos pessoas 
melhores. Obrigada pelo sentido crítico, pela inspiração e pela esperança que deposita em 
nós que tanto a admiramos.  
 
À minha co-orientadora, Professora Doutora Vera agradeço-lhe todo o carinho e dedicação 
com que abraçou este projecto. Admiro o seu profissionalismo e a forma como lida dia-a-
dia com a toxicologia. Obrigada pelas palavras e pelo apoio que sempre demonstrou. Fez 
nascer em mim um sentido crítico que até então desconhecia, e sem dúvida tornou-me 
melhor profissional nesta caminhada que é o doutoramento. Por vezes sentia que o meu 
mundo estava a desmororar e a professora conseguiu dar-me a mão e caminhou lado-a-
lado comigo dando me força e alento para vencer mais uma etapa da minha vida. Muito 
obrigada professora por pertencer ao mundo da toxicologia e por transmitir todos os 
conhecimentos (que são muitos) aos alunos que consigo trabalham. 
 
  xii 
À Senhora Engenheira Maria Elisa agradeço do fundo do coração todo o apoio prestado 
nestes 4 anos de intenso trabalho. Tenho tanto que lhe agradecer Senhora Engenheira. As 
suas palavras e carinho fizeram me crescer enquanto pessoa e profissional. Foi o meu 
porto abrigo, a minha inspiração e o meu ânimo nestes 4 anos. Levo comigo todos os 
ensinamentos que de forma maternal os transmitiu. Obrigada Senhora Engenheira por 
existir e por fazer parte do grupo de toxicologia. 
 
À Professora Doutora Paula Baptista agradeço todo o apoio que sempre prestou nestes 4 
anos. Agradeço por ter acreditado em mim e por me ter impulsionad0 para este mundo 
que é o doutoramento. Tive o privilégio de trabalhar consigo e de conhecer a pessoa 
admirável que é. Muito obrigada por ter feito parte desta fase da minha vida. 
 
Ao Professor Doutor Fernando Remião agradeço toda a ajuda imprescindível no HPLC. 
Consigo inicíamos o mundo da toxicologia em aulas que fizeram despertar em mim um 
gosto que até então desconhecia. As suas aulas são o espelho do profissional que é e por 
isso é impossível imaginar a toxicologia sem o professor. Obrigada por nos incutir o gosto 
pela toxicologia. 
 
À Professora Doutora Helena agradeço as aulas que fizeram com que o meu gosto pela 
toxicologia se intensificasse. É uma professora admirável não só pelo seu profissionalismo, 
como também pela pessoa que é.   
 
À Doutora Alexandra e ao Doutor Daniel pelos ensinamentos e por por todo o trabalho do 
in silico que tive oportunidade de desenvolver. A amizade com que sempre me abraçaram 
jamais esquecerei. Xaninha sempre tiveste a palavra certa na hora certa, foi um privilégio 
trabalhar contigo e conhecer a profissional que és. Daniel sempre acreditaste em mim e 
fizeste-me sentir quase que uma expert (muito longe disso) no in silico. Agradeço aos dois 
todos os lanches, almoços e jantares que partilhamos, as conversas, as confidências, os 
sorrisos. Obrigada estais sempre no meu coração.  
 
Ao Professor Doutor José Duarte porque me apresentou o mundo da histologia que tanto 
admiro e gosto. Consigo tive oportunidade de conhecer e admirar a histologia, e hoje 
posso dizer que é das análises que mais gosto de fazer. Obrigada por transmitir tantos e 
tão ingualáveis conhecimentos.  
 
  xiii 
Aos meus co-autores Professor Doutor Ricardo Dinis, Doutor Ricardo Silvestre e 
Professora Doutora Paula Pinho agradeço toda a ajuda que sempre prestaram para atingir 
os meus objectivos.  
 
À Cátia Faria e Margarida pela ajuda, pelo suporte técnico e logístico que sempre 
disponibilizaram. Obrigada por fazerem do laboratório de toxicologia um lugar melhor. 
 
À Dona Celeste agradeço toda a ajuda com os ratinhos e a histologia. Levarei sempre 
comigo todos os ensinamentos que tão amavelmente tem partilhado. São muitos os alunos 
que consigo trabalham e que certamente a levarão sempre no coração. 
 
Aos restantes colegas de laboratório, em especial à Mariline, Ana Oliveira, Teresa Baltazar, 
Vânia, e Maria João, que apesar de pouco tempo de convivência deixaram um carinho 
muito especial. Obrigada Mariline pelos sorrisos, pelas palavras e pela amizade. Obrigada 
Ana Oliveira pelas horas infindáveis no HPLC e a ti Teresa por teres teres feito parte do 
meu trabalho.  
 
Marcelo já sabes o quanto te agradeço toda a ajuda que me deste. Quando me lembrar dos 
estudos in vivo vou certamente lembrar de todos os ensinamentos e de toda a paciência 
que tiveste comigo. Mas além do trabalho foram tantos os momentos que partilhamos, 
almoços no bugo, gelados na cremosi e infindáveis conversas das quais tenho tantas 
saudades.  
 
Emanuele (Manu) és uma pessoa cheia de garra, muito profissional e, sem dúvida uma 
química de excelência, tens tudo para brilhar na toxicologia e acredito que vais conseguir. 
Obrigada pelos miminhos (aquele bolinho de côco ainda faz parte da minha memória), e 
por seres uma pessoa cheia de energia e boa disposição que tanto te caracteriza. 
 
À Doutora Sara agradeço a amizade e carinho. Levo comigo todos os ensinamentos de 
química que amavelmente se prontificou a partilhar. Tive o privilégio de trabalhar consigo 
e conhecer a pessoa maravilhosa que é. 
 
Ao Daniel por ser a pessoa que é e por ter tido o privilégio de partilhar uma amizade 
contigo. És das melhores pessoas que já conheci e que levarei para sempre no meu 
coração. Dificil de imaginar a toxicologia sem um Daniel. Tanto a nível profissional como 
pessoal és admirável e cheio de talento. Recordo com saudades as nossas conversas, os 
nossos almoços e os teus conselhos sempre tão sábios.  
  xiv 
À Renata pela amizade e sorrisos que sempre partilhamos. Foste um apoio quando mais 
precisei e levo para sempre comigo todos os momentos que partilhamos. És uma excelente 
profissional e amiga, com a qual podemos sempre contar. A toxicologia não seria a mesma 
sem o teu entusiasmo, a tua dedicação e o teu profissionalismo. 
 
A ti Rita Azevedo porque foste e és uma pessoa muito importante para mim. Admiro o teu 
profissionalismo e a tua forma de ser. Terás um futuro brilhante e eu estarei na primeira 
fila para te aplaudir Ritinha. Trago na memória noites de intenso trabalho no laboratório, 
em que pude partilhar a bancada de trabalho contigo e que numa cumplicidade só nossa 
partilhávamos conversas mergulhadas de gargalhadas (a história da laranja ainda hoje me 
faz sorrir). Levo tantos e tão grandes momentos que serão eternos pela intensidade com 
que os vivemos. Obrigada pelos miminhos, pelas brincadeiras, pelas conversas sérias, por 
me ouvires e aconselhares, e sobretudo por estares aí. 
 
Ao José Luís porque és simplesmente o Zé. Não me vou esquecer das nossas conversas de 
surdos mudos, dos momentos que partilhamos na biologia molecular, das confidências, da 
cumplicidade e sem dúvida da amizade que nos une e unirá sempre. És um grande 
profissional Zé e o teu gosto pela toxicologia é admirável. Sei que terás um grande futuro e 
serás reconhecido por isso. É com saudade que recordo os nossos cafés, almoços e jantares 
e aos quais trouxeste sempre a alegria que tanto te caracteriza. As tuas teorias infindáveis 
um dia darão um livro Zé (best seller), pois fazem com que os nossos dias sejam um pouco  
melhores.    
 
A ti Chiara porque és e sempre serás uma das minha melhores amigas. Partilhamos tanto e 
vivemos tanto. És aquela que sei que posso contar e que estará sempre aí para me ouvir. 
Obrigada minha flor pelas palavras que tanto me encorajaram e me fizeram sentir que era 
capaz. Contigo partilhei histórias que são apenas nossas e que tanta saudade me trazem.   
 
A ti João pelo ânimo e entusiasmo que sempre demonstraste. És um grande profissional e 
é admiravel a forma como lutas pelas teus objectivos. És um exemplo para todos os que 
lidam contigo e eu tive a sorte de poder cruzar-me contigo e partilhar tantos e tão grandes 
momentos. Obrigada João por tudo.  
 
Ao Paulo porque os amigos são a segunda família que escolhemos e eu tive o privilégio de 
te conhecer. Obrigada por todas as palavras de entusiasmo e por todo o apoio nesta fase da 
minha vida. É tão bom podermos contar com amigos como tu. Sempre tão positivo, tão 
entusiasta e tão determinado, fazes-me sempre acreditar que tudo é possível.   
  xv 
 
À Ana Teixeira pela ajuda que sempre prestou, o que seriam das minhas imagens sem a 
tua opinião e ajuda. Tens a arte dentro de ti e um talento surpreendente que partilhas sem 
pedir nada em troca. Obrigada Ana não só pela ajuda mas por toda a amizade, foram 
muitas as noites de trabalho em que tu amavelmente cedeste um pouco do teu tempo para 
tornar isto possível. É notável o teu altruísmo e és admirável por isso.  
 
À Diana Gesto (minha Deehzinha), por todo o carinho e amizade que ao longo destes 4 
anos partilhamos. A minha estadia na faculdade de Ciências não teria sido a mesma senão 
te tivesse conhecido. Recordo com saudades a nossa viagem a Girona em que te conheci 
um pouco melhor e pude constatar a pessoa maravilhosa que és. Trago sempre comigo a 
memória dos nossos lanches, das nossas conversas e dos grandes momentos que temos 
partilhado. 
 
Aos meus amigos Cristiana Gaspar, Liliana e Richard por toda a amizade que sempre 
depositaram em mim.  
 
Ao Ricardo Malheiro porque inicíamos juntos esta jornada que é o doutoramento e 
durante este tempo qualquer dúvida que surgisse sei que podia recorrer a ti. Esse teu 
espírito de entreajuda ficou bem patente logo no primeiro curso que frequentamos juntos 
(SPSS lembraste?). Obrigada Ricardo por ter o privilégio de te incluir na minha tese. 
 
À Elsa, amiga desde a primária, já são 20 anos juntas e amizade sempre nos acompanhou. 
Tu és a irmã que escolhi e que faz parte do meu coração. Não são laços de sangue que nos 
unem, mas são laços de coração que jamais serão apagados. Já são 20 anos que sei que 
estás ai e que o que caminhas lado a lado de mãos juntas comigo. Tive o privilégio de te ter 
na minha vida e é com orgulho que escrevo este agradecimento a ti. Obrigada minha 
amorinha por existires e por fazeres parte de todos os momentos da minha vida. És a 
minha jornalista preferida e como tu costumas dizer um dia seremos velhinhas com um 
monte de histórias para partilhar. E esta é mais uma. Termino com uma célebre frase 
“Distância não significa nada quando alguém significa tudo”. 
 
À minha mãe Carminda porque devo tudo o que sou. É com muito amor que te dedico a 
minha tese. Foste mãe e pai e por isso orgulho-me muito de ti. Tiveste as palavras certas 
na hora certa e isso fez me crescer e lutar por tudo o que já consegui. Agradeço todo o 
esforço que fizeste para conseguirmos alcançar os nossos sonhos. Muito obrigada Mami 
por existires e por fazeres de nós as pessoas que somos.  
  xvi 
 
À minha irmã Márcia por caminhar sempre lado a lado comigo. Tu és a mais bela 
expressão de amor que pode existir. O amor de irmão jamais será igualável por ser tão 
único e tão especial. Contigo partilho alegrias, tristezas, contigo partilho tudo. És o meu 
porto abrigo, a minha esperança, o meu eu.  
 
A ti Zé porque és simplesmente o meu Zé. Contigo partilho alegrias, tristezas e todos os 
momentos da minha vida. És o meu sorriso quando mais preciso, a minha alegria quando 
nada faz sentido. És aquele que escolhi para percorrer uma vida e sem o qual tudo seria 
mais dificil. Agradeço-te por seres como és e por fazeres de mim a pessoa que sou. Sei que 
foram duros estes 4 anos mas tu estiveste sempre lá e com muito carinho deste-me força 
para ultrapassar todos os obstáculos que foram aparecendo no meu caminho.   
 
À minha tia Mimi agradeço todos os conselhos, todo o carinho e todas as partilhas que me 
fizeram crescer. É, sem dúvida a minha inspiração, a minha força quando me sinto 
derrotada, e a minha esperança quando tudo parece impossível. Obrigada pelas longas 
conversas que me fizeram sempre sentir especial. Tenho em si o maior orgulho do mundo, 
por ser a pessoa admirável que é, e por ser minha tiínha. Obrigada por existir minha tia 
com sabor a chocolate, e por fazer parte da minha vida.  
 
À minha tia São que sempre se prontificou a ajudar-me. Obrigada tia por todos os 
ensinamentos, todos os conselhos e todos os momentos que temos partilhados juntas. 
Tenho o maior orgulho em que faças parte desta fase da minha vida e por poder contar 
contigo todos os dias.  
 
À restante família, tio Jorge, tio Armando e primos Hugo e Fábio agradeço todo o carinho 
e amizade. 
 
A minha arianinha por existir e por fazeres dos meus dias, dias melhores.  
 
Finalmente, e não menos importante ao meu Deus porque és a luz que ilumina o meu 
caminho.  
  
  xvii 
Finalmente agradeço às seguintes instituições: 
 
Fundação para a Ciência e a Tecnologia_FCT pela bolsa de doutoramento 
(SFRH/BD/74979/2010) e o suporte financeiro para esta dissertação.  
 
 
 
 
 
Ao “REQUIMTE” pelo suporte financeiro para o trabalho laboratorial decorrido durante 
esta tese. 
 
Ao Laboratório de Toxicologia da Faculdade de Farmácia da Universidade do Porto, ao 
Departamento de Bioquimíca da Faculdade de Ciências da Universidade do Porto, e à 
Faculdade de Desporto da Universidade do Porto pelo apoio logístico prestado para a 
realização desta dissertação. 
 
 
 
 
 xix 
 
PUBLICATIONS 
The author states to have afforded a major contribution to the conceptual design, technical 
execution of the work, interpretation of the results and manuscript preparation of the 
published or submitted articles included in this dissertation.  
 
Articles in international peer-reviewed journals  
Theoretical background  
1. Garcia J, Costa VM, Carvalho ATP, Baptista P, Guedes P, Bastos LM, Carvalho F. 
Amanita phalloides poisoning: mechanisms of toxicity and treatment. Submitted 
for publication 
Original Research  
1. Garcia J, Oliveira A, Guedes P, Freitas V, Carvalho ATP, Baptista P, Pereira E, Bastos 
ML, Carvalho F. Determination of Amatoxins and Phallotoxins in Amanita phalloides 
mushrooms from Northeast Portugal by HPLC-DAD-MS. Accepted in Mycologia. 
2. Garcia J, Carvalho AT, Dourado DF, Baptista P, de Lourdes Bastos M, Carvalho F. 
2014. New in silico insights into the inhibition of RNAP II by α-amanitin and the 
protective effect mediated by effective antidotes J Mol Graph Model 51:120-7.  
3. Garcia J, Costa VM, Baptista P, Bastos LM, Carvalho F. Quantification of alpha-
amanitin in biological samples by HPLC using simultaneous UV-diode array and 
electrochemical detection. Submitted for publication. 
4. Garcia J, Costa VM, Guedes P, Baptista P, Lourdes Bastos M, Carvalho F. Mushroom 
poisoning with Amatoxin and isoxazoles-containing mushrooms: A case report. Submitted 
for publication. 
5. Garcia J, Costa VM, Carvalho ATP, Dourado D, Silvestre R, Dinis R, Arbo M, Baltazar 
T, Baptista P, Bastos LM, Carvalho F. Discovery of an effective antidote for Amanita 
phalloides poisoning: a precious extension of polymyxin B pharmacotherapy. Under 
preparation. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
ABSTRACT
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxiii 
ABSTRACT 
The present dissertation reports a series of studies performed towards a better knowledge 
on the chemical composition of Amanita phalloides and its biological effects, and the 
successful endeavor of discovering an antidote for intoxications with this poisonous 
mushroom.  
The poisonous Amanita mushroom species, particularly A. phalloides (Death Cap), are 
responsible for 90-95% of the fatalities occurring after mushrooms ingestion. Toxins 
contained in A. phalloides include  a group of toxic bicyclic octapeptides known as 
amatoxins. The most relevant amatoxin regarding human intoxications is α-amanitin, for 
which there is no effective antidote available. Therefore, at present, the greatest clinical 
interest in this field resumes to the discovery of a new and effective antidote against A. 
phalloides poisoning.  
A significant variability in the amount of amatoxins contained in the mushrooms collected 
at different geographical areas has been described, being the Portuguese data very scarce. 
In this dissertation, the main composition of amatoxins and phallotoxins in A. phalloides 
collected at two different Portuguese sites were analyzed by liquid chromatography (LC)–
diode array (DAD) and mass spectrometry (MS) detection. The results showed that the 
concentration and distribution of toxins in the fruiting body are variable and influenced by 
site-specific environmental conditions, in particular the amount of phallotoxins. In 
sequence, a new high-performance liquid chromatography (HPLC) method was developed 
to allow simultaneous DAD and electrochemical (EC) quantification of α-amanitin in liver 
and kidney samples. Most importantly, this developed HPLC method was applied to 
human samples (urine and gastric juice) in a real case of amatoxins-containing 
mushrooms poisoning, which assisted in the diagnosis of that mushrooms intoxication. 
α-Amanitin is a powerful inhibitor of RNA polymerase II (RNAP II) and this effect is 
thought to be the main responsible for the hepatic and renal failure that occurs after 
A. phalloides poisoning. As a starting point to achieve our purpose of developing an 
effective antidote, an in silico model using docking and molecular dynamics simulation 
coupled to molecular mechanics-generalized born surface area method energy 
decomposition was applied to characterize the in silico interactions between the complex 
formed between RNAP II and α-amanitin. The in silico results obtained in this 
dissertation showed that α-amanitin directly interacts with bridge helix and trigger loop 
residues, and these interactions possibly contribute to the inhibition of RNAP II. 
Moreover, the interactions between RNAP II and the classically used A. phalloides 
poisoning antidotes, namely benzylpenicillin, silybin and ceftazidime, were also explored 
in silico. These antidotes show poor efficacy in clinical practice since mortality rate after A. 
phalloides intoxication still remains at 20-30%. In silico, benzylpenicillin, ceftazidime and 
  xxiv 
silybin were able to bind to the same site as α-amanitin, although not replicating the 
unique α-amanitin binding mode. Our RNAP II α-amanitin binding model provided a 
reliable platform for the discovery of novel antidotes against α-amanitin poisoning and 
that model was used in the subsequent study of this dissertation. In silico studies were 
applied to drugs that simultaneously were already in use on the clinical practice, (although 
with other therapeutic indications not related to mushroom poisonings) and that share 
structural similarities with α-amanitin. The results obtained in silico demonstrate that 
polymyxin B binds to the same interface as α-amanitin, potentially preventing the toxin 
from binding to RNAP II. Most importantly, polymyxin B does not interfere with the 
structures involved in messenger ribonucleic acid (mRNA) synthesis. Subsequent in vivo 
studies in Charles-River CD-1 mice were done as a proof of concept of the in silico data. It 
became demonstrated that a competition between α-amanitin and polymyxin B and/or 
displacement of α-amanitin from its RNAP II binding site by polymyxin B occurred, since 
polymyxin B significantly reverted the α-amanitin-induced transcription inhibition of 
renal specific genes, and decreased the α-amanitin induced liver and renal damage, and 
also hepatic oxidative stress. The effectiveness of polymyxin B, given 4 hours α-amanitin 
post-administration was also assessed by a survival rate study. The multiple 
administration of polymyxin B (at 4, 8 and 12 hours after α-amanitin) guaranteed a 50% 
of survival of the α-amanitin-treated mice (until 30th day), whereas all animals exposed 
only to α-amanitin died within 5 days. Moreover, a single dose of polymyxin B 
administered concomitantly with α-amanitin was able to assure a 100% survival until the 
30th day post exposure. Taken together, these results show that polymyxin B potentially 
acts on RNAP II, preventing α-amanitin from binding, and hence protecting RNAP II from 
inactivation. These promising results with polymyxin B insured an increase in survival of 
α-amanitin-treated animals, in clinical realistic human doses (2.5 mg/kg). 
In conclusion, the results of this dissertation allowed the full achievement of the 
established objectives: (i) it is provided an update of the state of the art concerning the 
toxicity of A. phalloides, (ii) new methodologies for measurement of α-amanitin were 
developed and applied in the analysis of amatoxins and phallotoxins in A. phalloides 
collected at two different Portuguese sites, as well as for clinical purposes and, (iii) 
polymyxin B is suggested to be the first effective amatoxin’s antidote, by acting upon 
RNAP II. As polymyxin B is already used in the clinical practice for other health issues, it 
has a great potential to be applied in humans immediately. The addition of polymyxin B to 
the present standard protocol of A. phalloides will improve the overall survival of 
intoxicated patients and prevent death and/costly treatments.  
Keywords: Amanita phalloides; α-amanitin; RNA polymerase II; polymyxin B.
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RESUMO 
A presente dissertação reporta estudos realizados com os objectivos de aumentar o 
conhecimento sobre a composição química da Amanita phalloides e os seus efeitos 
biológicos, e de desenvolver um antídoto eficaz para as intoxicações resultantes do 
consumo deste cogumelo tóxico. O género Amanita, e particularmente a espécie A. 
phalloides (chapéu da morte), são responsáveis  por cerca de 90-95% das fatalidades que 
resultam da ingestão de cogumelos. As toxinas presentes em A. phalloides incluem um 
grupo de octapéptidos bicíclicos tóxicos denominados genericamente de amatoxinas. 
Destas, a α-amanitina é considerada a mais relevante no contexto de intoxicações 
humanas por cogumelos do género Amanita, para a qual não existe antídoto eficaz. Deste 
modo, actualmente, o maior interesse clínico nesta área centra-se na descoberta de um 
antídoto eficaz para envenenamento por A. phalloides. 
A variabilidade da concentração de amatoxinas nos cogumelos colhidos em diferentes 
áreas geográficas tem sido amplamente descrita na literatura, embora dados relativos aos 
cogumelos colhidos em Portugal sejam praticamente inexistentes. Deste modo, nesta 
dissertação a composição das principais amatoxinas e falotoxinas presentes nos 
cogumelos A. phalloides colhidos em dois locais diferentes de Portugal foi analisada por 
cromatografia líquida de alta eficiência com recurso à detecção por um sistema de díodos e 
espectrometria de massa. Os resultados mostram que a quantidade e distribuição das 
toxinas no corpo frutífero dos cogumelos, em particular das falotoxinas, são variáveis e 
influenciadas sobretudo pelas condições ambientais especificas do local de colheita. No 
seguimentos deste estudo, um novo método de cromatografia líquida de alta eficiência foi 
desenvolvido com o objectivo de permitir a detecção e quantificação de α-amanitina em 
amostras de fígado e rim com recurso a dois detectores: um sistema de díodos e um 
detector electroquímico. O método desenvolvido revestiu-se de grande importância, pois o 
mesmo permitiu a análise de amostras humanas (urina e suco gástrico) provenientes de 
um caso clínico de intoxicação por amatoxinas, possibilitando, deste modo, a confirmação 
do diagnóstico.  
A α-amanitina é um inibidor potente da polimerase II do ácido ribonucleico (ARNP II) 
sendo este efeito apontado como o principal responsável pela falência hepática e renal que 
ocorre após a intoxicação por A. phalloides. Como ponto de partida para alcançar o 
primordial objectivo desta dissertação, o desenvolvimento de um antídoto eficaz na 
intoxicação por A. phalloides, o complexo formado entre a ARNP II e α-amanitina foi 
caracterizado in silico com recurso a técnicas de docking e dinâmicas moleculares 
acopladas a um método de decomposição de energia (em inglês designado de molecular 
mechanics-generalized born surface area method energy decomposition). Nesta 
dissertação, os resultados in silico demonstram que a α-amanitina interage directamente 
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com resíduos da hélice-ponte e de uma estrutura designada de trigger loop o que, 
possivelmente, contribui para a inibição da ARNP II. Além disso, as interacções entre a 
ARNP II e os fármacos actualmente usados na intoxicação por A. phalloides, 
nomeadamente a benzilpenicilina, silibina e ceftazidima, foram também exploradas in 
silico. Estes fármacos têm demonstrado pouca eficácia clínica, uma vez que a mortalidade 
associada à intoxicação por A. phalloides permanece ainda em cerca de 20-30%. In silico, 
a benzilpenicilina, ceftazidima e silibina mostram-se capazes de se ligar no mesmo local 
que a α-amanitina, sem no entanto reproduzirem o modo de ligação peculiar e único da α-
amanitina. O nosso modelo de ligação ARNP II/α-amanitina forneceu uma plataforma 
ideal para a descoberta de novos antídotos para a intoxicação por α-amanitina, e este 
mesmo modelo foi usado nos estudos subsequentes desta dissertação. Estudos in silico 
foram aplicados a fármacos que são simultaneamente usados na prática clínica (embora 
com outras indicações não relacionadas com intoxicação por cogumelos) e que partilham 
semelhanças estruturais com a α-amanitina. Os resultados obtidos in silico demonstram 
que a polimixina B se liga na mesma interface que a α-amanitina, prevenindo, deste modo, 
a ligação da toxina à ARNP II. A polimixina B não interfere com as estruturas envolvidas 
na síntese do ARN mensageiro. Subsequentemente, e com o objectivo de validar os 
estudos in silico, foram conduzidos estudos in vivo usando ratinhos. Esses estudos 
demonstraram que a polimixina B pode competir com a α-amanitina e/ou deslocar a α-
amanitina do seu local de ligação à ARNP II, uma vez que a polimixina B reverteu 
significativamente a inibição da transcrição de genes renais, reduziu os danos hepáticos e 
renais, assim como o stress oxidativo hepático causado pela α-amanitina. A eficácia da 
polimixina B, administrada 4 horas após a α-amanitina,  foi também avaliada através da 
realização de um estudo de sobrevivência. A administração múltipla de polimixina B (4, 8 
e 12 horas) resultou em 50% de sobrevivência dos ratinhos tratados com α-amanitina (até 
ao dia 30), enquanto todos os animais expostos apenas com à α-amanitina morreram em 5 
dias. Além disso, a administração concomitante de uma dose única de polimixina B com 
α-amanitina garantiu 100 % de sobrevivência num período de estudo de 30 dias. No seu 
conjunto, estes resultados mostram que a polimixina B se liga, potencialmente, à ARNP II, 
prevenindo por isso a ligação da α-amanitina, e deste modo impedindo a inactivação da 
ARNP II. Estes resultados promissores da polimixina B asseguram uma maior taxa de  
sobrevivência dos animais tratados com α-amanitina, em doses clinicamente realistas (2.5 
mg/kg). 
Em conclusão, os resultados desta dissertação permitiram atingir com êxito os objectivos 
propostos. Foi realizada a actualização do estado de arte no que concerne à toxicidade da 
A. phalloides, e desenvolvidas novas metodologias para a quantificação da α-amanitina, 
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aplicadas na análise de amatoxinas e falotoxinas de cogumelos A. phalloides colhidos em 
dois locais portugueses diferentes, e também para fins clínicos. Finalmente, descobriu-se o 
papel antidotal da polimixina B para as intoxicações por amatoxinas, pela sua acção na 
ARNP II. 
Dado que a polimixina B é usada actualmente na prática clínica para outros fins 
terapêuticos, tem grande potencial de ser aplicada imediatamente em humanos. É nossa 
convicção que a adição da polimixina B ao actual protocolo hospitalar para a intoxicação 
por A. phalloides vai melhorar a taxa de sobrevivência dos pacientes intoxicados 
prevenindo mortes, assim como reduzindo os custos dos tratamentos. 
Palavras-chave: Amanita phalloides; α-amanitin; ARN polimerase II; polimixina B. 
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OUTLINE OF THE THESIS  
 
The thesis is organized in 5 chapters.  
 
Chapter I is the general introduction to contextualize the actual state of art of the key 
topics within the thesis. The general introduction section has a focused approach covering 
aspects of the clinical features of amatoxins poisoning, mechanisms of toxicity, putative 
treatments and their relevance to the treatment of human poisonings. 
Chapter II comprises the aims of the thesis and explains how these articulate with the 
subsequent experimental results presented. 
Chapter III contains the main studies performed, including materials, methods, results 
and discussion, which are presented in the form of published manuscripts or manuscripts 
under submission in peer-reviewed journals. For each study, information concerning the 
journal (upon acceptance or publication) and co-authors is provided. 
Chapter IV includes a general discussion and main conclusions of the thesis, highlighting 
the most relevant achievements and also the future work perspectives in the field.  
Chapter V includes the references used in chapter I and IV. 
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1. GENERAL ASPECTS 
 In the past few decades, mushrooms have become popular in the human diet as a 
result of its exquisite taste and texture, protein content, and an expanding body of 
scientific research supporting their health benefits (1). The increased public demand for 
wild edible mushrooms contributes to an increasing interest in their picking and 
consumption (2), which enhanced the risk of intoxications by toxic mushrooms (3). 
Despite warnings on the risks, collectors may confuse edible with toxic mushrooms, due to 
misidentification based on morphological characteristics. Toxic mushrooms can be 
grouped based on their toxic components: cyclopeptides, gyromitrin, muscarine coprine, 
isoxazoles, orellanine, psilocybin and gastrointestinal irritants (4). From these, 
cyclopeptides-containing mushrooms are the most toxic species throughout the world, 
being responsible for 90-95% of human fatalities (4). The main toxic agents are amatoxins 
that are present in three genera: Amanita (mainly A. phalloides, A.virosa and A.verna); 
Lepiota (the most frequently reported is L. brunneoincarnata) and Galerina (the most 
common being G. marginata) (Table I) (5). Among these species, A. phalloides is 
responsible for the majority of fatal cases due to mushroom poisoning (6-9). Amatoxin 
poisoning usually has a bad prognosis due to the risk of death from liver failure. It was 
estimated that the mortality incidence after A. phalloides poisoning ranges at about 10-
30% (5, 10, 11). Survival depends on the degree of hepatic destruction, the ability of the 
remaining liver cells to regenerate, and the management of complications that may 
develop during the intoxication course (12). Liver transplantation has significantly 
improved the survival in A. phalloides poisoned patients and remains the cornerstone of 
treatment in selected patients with fulminant hepatic failure (13, 14). However, organ 
transplant services totally depend on available organ donation, which is not always easy 
and is a costly and risky procedure.  
 Accurate estimates of worldwide poison by amatoxins-containing mushrooms are 
difficult to establish due to lack of case reporting in hospital emergency rooms. In Portugal 
there is only one retrospective analysis of 93 cases of mushroom poisonings admitted in 
ten Portuguese hospitals between 1990 and 2008. Of those poisonings 63.4% were 
attributed to amatoxins-containing mushrooms, 11.8% having a fatal outcome (15). In 
USA, a total of 6600 mushroom intoxications were reported to the national poison data 
system of the American association of poison control centers in 2012 (16). Among these 
cases, 82.7% were attributed to unknown mushroom types while cyclopeptides-containing 
mushrooms represented 44 cases (4 patients died) (16). A retrospective case study 
concerning the prevalence and the circumstances of exposure to mushrooms reported to 
the Swiss toxicological information centre between January 1995 and December 2009 
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reported a total of 32 confirmed cases of amatoxins poisoning, 5 with a fatal outcome (17). 
A retrospective study of all amatoxin poisoning cases recorded over 15 years (1988 to 
2002) in the Toxicological Unit of Careggi General Hospital (Florence University), 
reported 111 intoxications by amatoxins-containing mushrooms (2 patients died) (18), 
while available clinical French data reports 45 patients treated (1984–1989) with an 
overall mortality of 17.8% (19).  
 From the above information it is clear that amatoxins poisoning has emerged as a 
serious public health problem worldwide.  
 This introduction aims to provide the state of the art concerning the mechanisms 
of toxicity, patterns of clinical presentation and management of amatoxins poisoning, 
focusing on the efficacy and limitations of antidotes most commonly used. 
 
Table 1. Amatoxin-containing mushroom species from the genera Amanita, Galerina and 
Lepiota  
Amanita sp. Galerina sp. Lepiota sp. 
A. phalloides G. badipes L. brunneoincarnata 
A. bisporigera G. beinrothii L. brunneolilacea 
A. decipiens G. fasciculata L. castanea 
A. hygroscopica G. helvoliceps L. clypeolaria 
A. ocreata G. marginata L. clypeolarioides 
A. suballiacea G. sulciceps L. felina 
A. tenuifolia G. unicolor L. fulvella 
A. verna G. venenata L. fuscovinacea 
A. virosa  L. griseovirens 
  L. heimii 
  L. helveoloides 
  L. kuehneri 
  L. langei 
  L. lilacea 
  L. locanensis 
 
  
INTRODUCTION 
 
5 
2. AMANITA PHALLOIDES 
2.1. Biology  
 Amatoxins are present in several Basidiomycota species belonging to three genera, 
i.e. Amanita, Galerina, and Lepiota (20-22). Table I lists the main amatoxin-containing 
species (5). As case reports of fatalities following consumption of amatoxin-containing 
mushrooms are mainly associated with A. phalloides (20), this species will be the main 
focus of the present paper. 
 The smooth moist cap of A. phalloides is greenish yellow, darker in the center and 
faintly streaked radially. The cap is 6-12.5 cm across and easily peeled. The stalk is 
smooth, white and 6-12.5 cm high. There is an irregular ring near the top of the stalk and a 
bulbous cup at the base. The fruiting body emanates a sweetish and not unpleasant smell. 
Its taste is pleasant, according to the survivors after intoxication (7). A. phalloides is 
distinguished from other species like Volvariella volvacea by their irregular ring near the 
top of the stalk, the bulbous cup at the base and white gills under the cap that are not 
attached to the stem. The morphology of the bulbous cup has been an important feature to 
distinguish Amanita from other resembling genera. However, inexperienced collectors 
break the specimen off at the stem destroying or neglecting some of these characteristics, 
which puts the consumers in danger of intoxication (23). Moreover, the above-mentioned 
characteristics do not exclude the possibility of amatoxins ingestion because other non-
Amanita containing-amatoxins species exist (23). In fact, mushroom species have variable 
appearances at different times of year and at different locations, depending on weather, 
soil, and time of harvest, which makes more challenging the correct mushroom 
identification. 
 
2.2. Habitat and distribution 
Amanita phalloides is the predominant European poisonous mushroom, 
particularly in Central and Occidental Europe (20). Several cases of A. phalloides 
poisoning have also been reported in northeastern United States (24), Central and South 
America, Asia (4), Australia (25) and Africa (26). This species is an ectomycorrhizal fungus 
that forms symbiotic relationships with a variety of tree species, such as beech, oak, 
chestnut and pine. The best seasons of the year for A. phalloides fructification are spring, 
late summer, and autumn (7), and therefore the majority of intoxication cases appear in 
those seasons. 
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2.3. Main toxins and most poisonous parts of Amanita phalloides 
 Amanita phalloides contains three classes of cyclic peptide toxins, which can be 
grouped into amatoxins, phallotoxins and virotoxins. All groups of toxins contain a 
tryptophan residue substituted at position 2 of the indol ring by a sulfur atom (9) (Figure 
1,2 and 3). They have distinct toxicological profile: amatoxins are highly toxic 
[intraperitoneal lethal dose, 50% (LD50) 0.4-0.8 mg/kg, in the white mouse] causing death 
within 2-8 days, whereas phallotoxins and virotoxins are less toxic (intraperitoneal LD50 1-
20 mg/kg, in the white mouse) but act quickly, causing death within 2-5 hours (9).   
 Several studies investigated the content and distribution of the main toxins in 
different carpophore tissues and in several development stages of A. phalloides (27-29). 
There is an unequal distribution of the toxins throughout the carpophore. The highest 
amatoxins content was found in the ring, gills and cap, while the volva was the richest in 
phallotoxins levels (29). The collection site and the age of the collected species affect the 
toxin composition of the carpophore elements (27, 29). The collection site (mainly soil 
characteristics) determines toxins’ composition of each mushroom, mostly the 
predominance of either acidic or neutral phallotoxins (27). Regarding the maturation 
state, the content of amatoxins is relatively high during the early development stages 
(button, button with broken outer veil, and pileus revealed from outer veil) and decreases 
in the mature (completely developed fruit body with convex cap) and old (wilted fruit body 
with reflexed cap) stages (30). 
 
2.4. Phallotoxins  
 Phallotoxins are bicyclic heptapeptides, first isolated from A. phalloides (31) and 
formed by at least seven different compounds: phalloidin, phalloin, prophallin, phallisin, 
phallacin, phallacidin, and phallisacin (Figure 1) (9). The in vitro action of phallotoxins 
has been thoroughly characterized (32-35). Phallotoxins bind to F-actin, which stabilizes 
the actin filaments and prevents microfilaments depolymerization, disturbing the correct 
function of the cytoskeleton (35). They are only toxic to mammals if parentally 
administered since phallotoxins are not absorbed through the gastrointestinal tract (36). 
The LD50 values of phallotoxins for white mouse are listed in Table II. All phallotoxins 
have similar intraperitoneal LD50 (ranging from 1.5 to 4.5 mg/kg), except prophalloin, 
which appears to be less toxic (>20 mg/kg). The major in vivo toxic effect produced by 
intraperitoneal administration of phallotoxin occurs in the liver (35).  
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 Since phallotoxins are not orally absorbed the overall human intoxication features 
by A. phalloides are not attributed to this class of toxins. 
 
 
 
Figure 1. Chemical structure of phallotoxins 
 
 
 
 
 R1 R2 R3 R4 R5 
Phalloidin OH H CH3 CH3 OH 
Phalloin H H CH3 CH3 OH 
Prophallin H H CH3 CH3 H 
Phallisin OH OH CH3 CH3 OH 
Phallacin H H CH(CH3)2 COOH OH 
Phallacidin OH H CH(CH3)2 COOH OH 
Phallisacin OH OH CH(CH3)2 COOH OH 
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2.5. Virotoxins  
 Virotoxins are monocyclic peptides formed by at least five different compounds: 
alaviroidin, viroisin, deoxoviroisin, viroidin, and deoxoviroidin (Figure 2) (9). The 
structure and biological activity of virotoxins are similar to that of phallotoxins, thus 
suggesting that virotoxins are biosynthetically derived from phallotoxins or share common 
precursor pathways (37, 38). As with phallotoxins, virotoxins are not considered to have 
significant toxic effects after oral exposure. At molecular level, like phallotoxins, they 
interact with actin, stabilizing the bonds between actin monomers, which prevent 
microfilaments depolymerization. However, the ultraviolet-spectra of interaction between 
actin and virotoxins is different from that of actin-phallotoxins, suggesting a different 
molecular interaction (39).  
 
 
 
 
 
 
 
 
Figure 2. Chemical structure of virotoxins 
 
 X R1 R2 
Viroidin SO2 CH3 CH(CH3)2 
Deoxoviroidin SO CH3 CH(CH3)2 
Alaviroidin SO2 CH3 CH3 
Viroisin SO2 CH2OH CH(CH3)2 
Deoxoviroisin SO CH2OH CH(CH3)2 
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Virotoxins have a more flexible structure as compared with phallotoxins and the 
presence of two additional hydroxyl groups may provide different reactivity (Figure 2) (40, 
41). The intraperitoneal LD50 of virotoxins in mice ranges from 1.0 to 5.1 mg/kg (Table II) 
and their main toxicological feature is hemorrhagic hepatic necrosis caused by an 
interaction of the virotoxins with outer surface of the hepatocyte through unknown 
mechanism (42). At this point, the role of virotoxins in human toxicity remains unclear, 
although due to its poor oral absorption, little clinical importance is given to this class of 
toxins. 
 
2.6. Amatoxins 
 Amatoxins have been identified as bicyclic octapeptides with molecular weight of 
around 900 g/mol, formed by at least nine different compounds: α-amanitin, β-amanitin, 
γ-amanitin, ε-amanitin, amanin, amaninamide, amanullin, amanullinic acid and 
proamanullin (Figure 3) (9). The intraperitoneal LD50 of amatoxins in mice ranges from 
0.3 to 20 mg/kg (Table II). Amatoxins only differ by the number of hydroxyl groups and 
by an amide carboxyl exchange (Figure 3) (9). These toxins have great heat stability and 
this property combined with their solubility in water make them exceptionally toxic as 
they are not destroyed by cooking or drying (36). In addition, amatoxins are resistant to 
enzyme and acid degradation, and therefore when ingested they will not be inactivated in 
the gastrointestinal tract (36). A fatal case was reported after consuming A. phalloides 
frozen during 7-8 months, thus demonstrating that these compounds also resist to 
freeze/thawing processes (43). Additionally, amatoxins decompose very slowly when 
stored in open, aqueous solutions or following prolonged exposure to sun or neon light 
(20). 
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Figure 3. Chemical structure of amatoxins 
 
 
 
 R1 R2 R3 R4 R5 
α-amanitin CH2OH OH NH2 OH OH 
β-amanitin CH2OH OH OH OH OH 
γ-amanitin CH3 OH NH2 OH OH 
ε-amanitin CH3 OH OH OH OH 
Amanin CH2OH OH OH H OH 
Amanin 
amide 
CH2OH OH NH2 H OH 
Amanullin CH3 H NH2 OH OH 
Amanullic 
acid 
CH3 H OH OH OH 
Proamanullin CH3 H NH2 OH H 
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Table 2. LD50 values for amatoxins, phallotoxins, and virotoxins in different species and 
administration routes 
 
 
 
Toxin 
 
Micea 
 
Rata 
 
Doga 
 
Humana 
Administration 
route 
 
Ref. 
Amatoxins       
 0.3-0.6 4.0   Intraperitoneal (36) 
α-amanitin 0.002 0.01   Intracerebroventricular (36) 
   0.1  Intravenous (36) 
    0.1 Oral (9) 
β-amanitin 0.5    Intraperitoneal (44) 
γ-amanitin 0.2-0.5    Intraperitoneal (44) 
ε-amanitin 0.3-0.6    Intraperitoneal (44) 
Amanin 0.5    Intraperitoneal (44) 
Amanin amide 0.5    Intraperitoneal (44) 
Amanullin > 20    Intraperitoneal (44) 
Amanullinic 
acid 
> 20    Intraperitoneal (44) 
Proamanullin > 20    Intraperitoneal (44) 
Phallotoxins       
Phalloin 1.5    Intraperitoneal (44) 
Phalloidin 2    Intraperitoneal (44) 
Phallisin 2    Intraperitoneal (44) 
Prophalloin > 20    Intraperitoneal (44) 
Phallacin 1.5    Intraperitoneal (44) 
Phallacidin 1.5    Intraperitoneal (44) 
Phallisacin 4.5    Intraperitoneal (44) 
Virotoxins       
Alaviroidin 3.7    Intraperitoneal (42) 
Viroisin 1.68    Intraperitoneal (42) 
Deoxoviroisin 3.35    Intraperitoneal (42) 
Viroidin 1.0    Intraperitoneal (42) 
Deoxoviroisin 5.1    Intraperitoneal (42) 
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2.6.1. Toxicokinetics of amatoxins 
 The toxicokinetics of α-amanitin has been studied in animals and through data 
obtained in reports of human poisoning by amatoxins (19, 45). Amatoxins are readily 
absorbed from the human gastrointestinal tract and can be detected radioimmunologically 
in the urine as early as 90-120 minutes after ingestion (46). Amatoxins do not bind to 
albumin (45) being rapidly eliminated from the blood and distributed to liver and kidney 
within 48 hours (19). After intravenous administration in dogs, the plasma half-life of 
amatoxins was shown to be short, ranging from 26.7 to 49.6 minutes and were not 
detectable in plasma after 4-6 hours. The total body clearance was between 2.7 and 6.2 
ml/min/kg (45).  
 The liver is the primary target organ of toxicity of amatoxins, and hepatocellular 
effects represent the most lethal and the least treatable manifestation of toxicity (4). 
Amatoxins accumulate in the liver upon uptake via OATP located in the sinusoidal 
membrane of hepatocytes (Figure 4). Letschert et al. (2006) identified OATP1B3 as the 
main human uptake transporter for amatoxins. Amatoxins were analyzed in the liver 
following 2 fatal intoxications and in the liver of 2 patients who underwent liver 
transplantation, showing that high levels of amatoxins levels (α-amanitin ranged from 0 
to19 ng/g; β-amanitin ranged from 0 to 3298 ng/g) may be found up to 9 to 22 days post 
ingestion (19). 
 Amatoxins do not undergo metabolism and they are excreted in large quantities in 
the urine during the first days following ingestion, with maximal excretion occurring in 
the first 72 hours (19). A very small amount can be eliminated in bile and may be 
reabsorbed via the enteropatic circulation, which prolongs the body burden of these toxins 
(45). Intestinal elimination also seems to occur. In a human intoxication report (19) 6.3 
mg of α-amanitin was eliminated in the faces over a period of 24 hours; this quantity is 
believed to be lethal in an adult.  
 Possibly due to the preferential elimination route through the kidney, 
nephrotoxicity has also been reported (47). The concentration found in the kidney has 
been shown to be 6 to 90 times higher than in the liver (19). Therefore, although 
classically amatoxins are considered hepatic toxins, putative renal failure has to be 
evaluated. 
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Figure 4. Simplified model of α-amanitin transport and main toxic mechanism in 
hepatocytes. α-Amanitin accumulation occurs in the liver upon uptake via an organic 
anion-transporting octapeptide (OATP1B3) located in the sinusoidal membrane of 
hepatocytes. Once in the hepatocyte, α-amanitin binds to RNA polymerase II causing 
inhibition of its activity. The α-amanitin binding site is located in the interface of Rpb1and 
Rpb2 subunits. 
 
2.6.2. Clinical toxicology 
 The symptomatology of amatoxins poisoning can extend from a simple 
gastroenterological disorder to death. Signs and symptoms of α-amanitin poisoning are 
mainly attributable to the accumulation of α-amanitin in the liver and kidney (47). 
 Three distinct phases of the A. phalloides toxic syndrome have been established in 
the literature: 1) gastrointestinal phase, 2) latent period and 3) the hepatorenal phase (4). 
 The first stage of A. phalloides syndrome occurs abruptly, 6 to 24 hours after 
ingestion, and is characterized by nausea, vomiting, diarrhea (occasionally bloody), 
abdominal pain, and hematuria (48). This phase usually lasts about 12-36 hours. Fever, 
tachycardia, metabolic disorders like hypoglycemia, dehydration, and electrolyte 
imbalance may occur during this phase (20). 
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 The latent period is characterized by absence of symptoms, whilst progressive 
deterioration of hepatic and renal function is occurring (48). Hepatic lesions are 
accompanied by increased serum concentration of aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) (49). The blood 
coagulation is also severely disturbed, which may give rise to internal bleeding (50). 
 The pathological hallmark of amatoxin poisoning is the development of liver 
necrosis and this characterizes the hepatorenal phase. The patients progressively lose 
kidney and liver functions and may develop jaundice, hypoglycemia, oliguria, delirium and 
confusion (48). This phase culminates in rapid deterioration of central nervous system, 
severe hemorrhagic manifestations, renal and hepatic failure, which corresponds to a bad 
prognosis (7). About 20-79% of the intoxicated patients develop chronic liver disease (51). 
 
2.6.3. Mechanism of toxicity induced by amatoxins 
 There are significant inter and intraspecies variations, concerning the 
concentration of amatoxins in mushrooms. Therefore, an accurate prediction of toxicity 
based on the amount of mushrooms consumed is difficult (20). The lethal dose of 
amatoxins in humans has been estimated (from accidental intoxications) to be about 0.1 
mg/kg body weight (Table II), or even lower, and this amount may be present in a single 
mushroom (4). 
 Several toxicity mechanisms have been attributed to amatoxins. The main 
mechanism seems to be their known ability to non-covalently bind and inhibit RNA 
polymerase II (RNAP II) in the nucleus (52) (Figure 5). Many experimental studies have 
been conducted to get a better understanding of the interaction with RNAP II (53-55). 
Cochet-Meilhac and Chambon carried out a kinetic study to evaluate the interaction of 
amatoxins with RNAP II (53). The authors used purified calf thymus RNAP II and 
observed that the equilibrium association constant is high, in the order of 108-1010 (53). 
Bushnell et al. obtained the first X-ray elucidating the RNAP II/ α-amanitin interactions. 
In this structure, the α-amanitin binding site was located in the interface of subunits Rpb1 
and Rpb2 (56). Moreover, the X-ray structure allowed to partially elucidate the key 
molecular contacts that contribute to RNAP II inhibition. RNAP II residues interacting 
with α-amanitin are located entirely in the bridge helix (56). In particular, α-amanitin 
binds directly to the bridge helix residue Glu822, through a hydrogen bond, and indirectly 
to the bridge helix residue His816 (Figure 5) (56). 
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Figure 5. Crystal structure of 10 subunit RNA polymerase II in complex with α-amanitin. 
Crystal structure elucidates some of the key atomic contacts that contribute to RNA 
polymerase II inhibition. RNA polymerase II residues interacting with α-amanitin are 
located entirely in the bridge helix (magenta). α-Amanitin binds directly through a 
hydrogen bond with bridge helix residue Glu822 and indirectly with bridge helix residue 
His816. The α-amanitin and residues Glu822 and His816 are in licorice representation. 
 
 However, it has been also proposed that α-amanitin inhibits RNAP II by direct 
interference with the trigger loop (structural element that makes direct substrate contacts 
and promotes nucleotide addition) (57) therefore preventing the conformational change of 
RNAP II, inhibiting the deoxyribonucleic acid (DNA) elongation process (58).  
 The decline of levels mRNA leads to the decrease of protein synthesis and, 
ultimately, to cell death (52). Moreover, Nguyen et al. (1996) suggested that the binding of 
α-amanitin to RNAP II results in degradation of Rpb1 subunit. The authors have found, in 
mice fibroblasts, that α-amanitin promotes the degradation of the Rpb1 subunit, resulting 
in its irreversible inhibition (54). The characterization of this mechanism needs further 
investigation.  
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 In vitro studies have shown that apoptosis may play an important role in α-
amanitin-induced severe liver injury as observed in dog primary hepatocytes (59) and in 
human hepatocyte cultures (60, 61). The exposure of hepatocytes to α-amanitin (2 µM) 
resulted in p53- and caspase-3-dependent apoptosis (Figure 6) (Magdalan et al. 2011). In 
normal neonatal human diploid fibroblasts, α-amanitin (2 µg/mL) treatment for 24 hours 
resulted in a marked induction of p53. The concentration required for induction of p53 
was correlated with the concentration required to inhibit mRNA synthesis, suggesting a 
link between these two effects (62). To further evaluate the role of p53 in transcription 
inhibition-mediated cell death, p53 knock-out HTC116 cells and wild-type cells were 
treated with α-amanitin (10 µg/ml) for 24 hours and the extent of apoptosis was evaluated. 
The results showed that the knock-out p53 cells were less sensitive to death induced by α-
amanitin, corroborating that p53 plays an important role in α-amanitin-induced toxicity. 
A stress signal is elicited by α-amanitin, which leads to the translocation of cytoplasmic 
p53 to mitochondria resulting in alteration of mitochondrial membrane permeability 
through formation of p53 complexes with protective proteins (Bcl-xL and Bcl-2) (Figure 6). 
The complexes formation results in the release of cytochrome c into the cytosol and the 
prosecution of the intrinsic apoptotic pathway (Figure 6) (63).These results were further 
corroborated in in vivo assays.  Knockout p53/BAK mice showed marked resistance 
towards α-amanitin (5 µg/g)-induced liver damage, while wild-type mice in the same 
conditions undergo organ destruction (64). An interaction between p53 and mitochondrial 
BAK seems to be important for p53’s mitochondrial role in the induction of apoptosis (64). 
Other mechanisms might be involved in α-amanitin-induced toxicity. It has been 
suggested that TNF-α exacerbates α-amanitin-induced hepatotoxicity in vivo (Figure 6) 
(65). After in vivo administration of a high dose of α-amanitin, hepatic TNF-mRNA was 
increased and hepatocytes underwent apoptosis, whereas in mice treated with anti-TNF 
antibodies, liver injury caused by α-amanitin was prevented (65). In addition, transgenic 
mice lacking the 55 kDA TNF-α receptor seem to be relatively resistant to α-amanitin 
toxicity (65). Therefore hepatocyte apoptosis may result from a synergistic action of α-
amanitin with TNF-α (Figure 6) (65). However, the mechanism of such synergistic effects 
remains unclear at this point and the dependence of α-amanitin toxicity on the presence of 
TNF-α was not confirmed in another study using rat hepatocyte cultures (66). Thus, TNF-
α may not be indispensable for the development of cytotoxicity by α-amanitin but 
exacerbates it. Actually, TNF-α co-treatment significantly increased lipid peroxidation 
caused by α-amanitin and this effect was prevented by silybin, indicating the possible 
involvement of reactive oxygen species (ROS) (66). These results suggest that TNF-toxicity 
is associated with ROS production (66). In fact, oxidative stress has also been postulated 
to be important in the development of severe hepatotoxicity in other studies (Figure 6) 
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(67, 68). In vivo, hepatic accumulation of α-amanitin leads to increase of superoxide 
dismutase (SOD) activity and malondialdehyde products, and also results in the decrease 
of catalase activity (Figure 6) (68). Lipid peroxidation may contribute to severe 
hepatotoxicity with massive necrosis (68). Zheleva (2013), using the electron 
paramagnetic resonance spin trapping technique, studied the in vitro and in vivo 
oxidation of α-amanitin. During in vitro oxidation, α-amanitin can form unstable 
phenoxyl radicals by itself. Using the same technique, these authors detected the 
production of reactive species in mice kidney subjected to an intraperitoneal 
administration of 1 mg/kg of α-amanitin. Thus, α-amanitin is able to form phenoxyl free 
radicals that might be involved in generation of ROS (Figure 6) (67). More investigations 
are needed to completely clarify the pathophysiology of ROS in the α-amanitin-induced 
toxicity, as it has been a scarcely studied subject. 
 
Figure 6. Signaling pathways involved in α-amanitin-induced toxicity. The main toxicity 
mechanism of α-amanitin is inhibition of RNA polymerase II. Other mechanisms have 
been suggested and include the formation of reactive oxygen species (ROS) leading to 
oxidative stress related damage. Generation of ROS may also be induced by increase of 
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superoxide dismutase (SOD) activity and inhibition of catalase activity. Amatoxins may act 
synergistically with tumor necrosis factor (TNF), to induce apoptosis, though the 
underlying mechanisms are not yet known. Amatoxins-induced apoptosis may also be 
caused by the translocation  of p53 to the mitochondria causing alteration of 
mitochondrial membrane permeability through formation of complexes with protective 
proteins (Bcl-xL and Bcl-2). These changes result in the release of cytochrome c into the 
cytosol and activation of the intrisic pathway of  apoptosis. Question marks indicate that 
the mechanism remains unknown. 
 
2.6.4. Pathophysiology of intoxications by amatoxins 
 
2.6.4.1. Liver  
 As previously referred, the main pathophysiologic feature of intoxication by 
amatoxins is liver failure. Histopathological findings in liver biopsy specimens have shown 
massive centrilobular hepatic necrosis (24). Acute toxic hepatitis may develop rapidly, 
then reaching the state of liver insufficiency and coma (47). Five autopsies were performed 
on patients fatally poisoned with A. phalloides (69). Pathological autopsies revealed 
intensely yellow liver of creamy consistency and diffuse subcapsular hemorrhaging. The 
histological examination confirmed stasis in all organs, including liver with diffuse 
hemorrhagic foci. The liver showed typical features of massive centrilobular necrosis and 
vacuolar degeneration of hepatocytes (69). Pathological examinations were also 
performed in two explanted liver after amatoxins poisoning. The cut surface of the 
explanted livers was hemorrhagic and had a nutmeg appearance. Centrilobular massive 
hemorrhagic necrosis and fatty degeneration areas were also observed (70).  
 Liver failure can lead to disseminated intravascular coagulation due to reduced 
clearance of activated clotting factors, release of pro-coagulants from damaged 
hepatocytes and reduced synthesis of coagulation inhibitors, contributing to multi-organ 
failure (71, 72). Consumption and subsequent exhaustion of coagulation proteins and 
platelets (from ongoing activation of coagulation) may culminate in severe bleeding (71, 
72). 
 
2.6.4.2. Kidney 
 Nephrotoxicity after A. phalloides poisoning is also frequent. Patients can develop 
acute tubular necrosis with kidney failure (47). Post-mortem examinations of patients 
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dying from amatoxin poisoning revealed dark red kidneys with extravasation of blood, 
especially in the cortical region. Stasis with diffuse hemorrhagic foci, acute tubular 
necrosis, and massive quantities of hyaline casts in the tubules were also found in patients 
that died after A. phalloides intoxication (69). Fanconi-type renal tubular acidosis 
associated with A. phalloides ingestion has also been reported (20). 
 
2.6.4.3.  Central nervous system 
 Neurologic manifestations, either primarily due to accumulation of ammonia or 
secondary to multi-organ failure combined with hypotension, may develop in response to 
abnormal liver and kidney functions (20). Ammonia, a by-product of protein metabolism, 
is neurotoxic at high concentrations (73). The liver transforms ammonia to urea, which is 
excreted through the kidneys. Amatoxin-intoxicated patients with continued loss of 
hepatocellular function are not able to transform ammonia to urea. Blood ammonia levels 
rise and is delivered to the brain causing encephalopathy, disorientation, confusion, 
lethargy, somnolence, vertigo, convulsions, and coma (7).  
 
2.6.5. Treatment and management of intoxications by amatoxins 
 General treatment measures applied to amatoxins’ poisoned patients include: 
stabilization of vital functions, intensive and supportive measures, prevention of the 
poison absorption, use of putative antidotes, enhanced elimination of the poison and 
prevention of complications (8). Some of these measures have shown some degree of 
success, while others show negligible efficacy (Table III). At this point, it can be said that a 
lot of research work still needs to be done to achieve a satisfactory therapeutic efficacy 
against amatoxin intoxications. 
 
2.6.5.1. Dealing with intoxication cases 
 On a putative case of amatoxins intoxication the initial step is to take the clinical 
history of the patient and perform stabilizing measures, if required. Fluid and electrolyte 
imbalance may occur in the gastrointestinal phase or result from measures undertaken to 
eliminate the amatoxins. Intravenous fluids may have to be given for extra-fluid and 
electrolyte replacement with careful clinical chemistry monitoring (49). The effects of 
amatoxins on protein synthesis and the damage on liver cells will cause alteration on 
coagulation factors (49), therefore optimal treatment includes intravenous vitamin K and 
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fresh-frozen plasma (6). Liver damage should be assessed promptly as it allows 
determining how far is the damage caused and the best clinical actions to take. Laboratory 
evaluation should include liver and kidney function, testing aminotransferases, 
prothrombin time, blood urea nitrogen, creatinine, ammonia, fibrinogen, bilirubin, 
complete blood count, electrolyte analysis, amylase, lipase, and urinalysis (74).  
 All basic information, such as the amount, type (a sample of the ingested 
mushroom is of outmost importance), time of mushrooms ingested, the first evidence of 
symptoms, and the symptoms present at the moment of hospitalization are of great value 
in the first contact with the possible amatoxins’ poisoned patient. The time between 
ingestion and onset of symptoms is critical. Sudden onset of intense gastrointestinal 
symptoms after a delay of 6-24 hours, following a mushrooms meal, should raise the 
suspicion of amatoxin poisoning. 
 
2.6.5.1.1. Identification of amatoxins and phallotoxins 
 If A. phalloides-type mushrooms is suspected, gastric content, mushroom samples, 
and stool specimens, if available, should be analyzed to verify the presence of amatoxins 
and phallotoxins (48). Several methods can be used for identification and quantification of 
amatoxins and phallotoxins in specimens of A. phalloides. Evaluation of these toxins in 
mushrooms has been performed using reversed-phase high-performance liquid 
chromatography (RP-HPLC) (27, 29, 30, 66, 75, 76), capillary electrophoresis coupled to 
mass spectrometry (MS) (77), liquid chromatography (LC) coupled to MS or to tandem 
MS (78, 79), and LC electrospray ionization time-of-flight-MS (LC/ESI-TOF-MS) (80). 
RP-HPLC is the most commonly used method, although the LC-MS method appears to 
provide the most reliable and sensitive results.  
 The Meixner test can also be used if a specimen of the ingested mushroom is 
available for analysis (81). The test is based on an acid-catalyzed (using concentrated 
hydrochloric acid) reaction of amatoxins with the complex biopolymer lignin to form a 
blue product. As described by Meixner, the test is run by squeezing the juice from a piece 
of fresh mushroom tissue onto a piece of newsprint, which contains lignin, allowing the 
spot to dry, and then applying one drop of concentrated hydrochloric acid. Formation of a 
blue color indicates a positive test (81). Nevertheless, the efficacy of this test is limited by 
false positive results. Mushrooms containing hydroxyl-substituted tryptamine compounds 
such as psilocin or serotonin may also produce a positive Meixner reaction (82), and 
therefore a positive test result requires further confirmation of the mushroom identity. 
 A rapid and sensitive method that can be performed in the patient bed side, or 
within minutes in the hospital structures, would be of outmost value for a better clinical 
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assessment but it is not available presently. Urine analysis is a vital tool for amatoxin 
poisoning surveillance, contributing to the management of suspected mushroom 
poisoning (83). If analysis is performed within 36 hours of ingestion, α-amanitin can be 
detected in urine. After 36 hours the analysis is unreliable in that a negative result cannot 
rule out poisoning.(4). There are different methods for urine analysis: radioimmunoassay, 
Enzyme Linked Immunosorbent Assay (ELISA) and HPLC (20).  
 
2.6.5.1.2. Minimizing absorption, and inactivation in the gastrointestinal 
tract 
 After careful consideration of the risks to the intoxicated patient, gastrointestinal 
(GI) decontamination should be considered based upon the time elapsed from ingestion to 
time of presentation at the hospital. Several methods of GI decontamination that can be 
used alone or in combination, include gastric lavage, whole bowel irrigation, 
administration of activated charcoal, and endoscopic or surgical removal of the ingested 
poison (84). Whole bowel irrigation has a very limited impact in the treatment of human 
poisoning, and therefore should not be used routinely in the management of the poisoned 
patient (84-86). Gastric lavage is most useful if attempted within 1 hour after ingestion of 
a potentially life threatening poison (87), while it is contraindicated in patients with loss of 
airway protective reflexes, such as in a patient with a depressed state of consciousness, 
and in patients who are at risk of hemorrhage or gastrointestinal perforation, as well as in 
patients that underwent recent surgery or have other medical conditions such as 
coagulopathy (88). Clinical toxicology database of the United Kingdom national poisons 
information service (TOXBASE) recommends gastric lavage up to 1 hour after A. 
phalloides ingestion (89). 
 Activated charcoal effectiveness decreases with increased time elapsed after 
ingestion, while greatest benefit can be observed within 1 hour after ingestion of the 
poison (84). The efficacy of activated charcoal was not yet proven in controlled clinical 
settings towards amatoxins ingestion, but activated charcoal (20-40 g every 3-4 hours) has 
been administered routinely because it may interrupt the enterohepatic circulation of 
amatoxins and potentially reduce their toxicity (20). The centre of anti-poisoning 
information (CIAV) in Portugal and TOXBASE recommend a dose of 50 g every 4 hours 
(89, 90). If vomiting is troublesome the dose can be reduced to 12.5 g charcoal hourly or 
25 g every 2 hours (89). As most patients reach the hospital emergency hours after 
ingesting the mushrooms, these clinical measures have limited efficacy, although they are 
undertaken to insure the best clinical treatment available in a life risk situation, even 
before confirmation of amatoxins poisoning. 
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2.6.5.1.3. Elimination of absorbed amatoxins 
 As stated, excretion of amatoxins is mainly urinary; therefore diuresis would 
potentially increase the renal clearance and could be a potential good therapy for this 
intoxication. Forced diuresis is recommended, with urine output of 100-200 ml/h for 4-5 
days (91). This procedure is also recommended by CIAV and national poisons centre of 
New Zealand, especially in the first 48 hours after ingestion (90, 92). 
 Amatoxins are only detected in the plasma at the early phase of poisoning and only 
for a short period of time. For that reason, removing amatoxins by extracorporal 
elimination, particularly hemodialysis, hemoperfusion or plasmapheresis was previously 
considered to have no impact on patient survival (19, 93). Some studies present some 
evidence demonstrating benefits of molecular adsorbent recirculating system (MARS) in 
management of A. phalloides poisonings (94, 95). However, these findings have not been 
adequately corroborated, since only few case reports have been published and further 
evidence is needed.  In a recent study, the effectiveness and safety of combined 
extracorporeal techniques using the fractionated plasma separation and adsorption 
system, FPSA, Prometheus® 4008H, Fresenius Medical Care, Germany, in poisoned 
patients with A. phalloides was investigated (96). This technique consists on the 
elimination of protein-bound and water-soluble toxin. Prometheus® seemed to be a 
promising treatment for A. phalloides poisoning preventing the need for liver 
transplantation. However, such treatment was administered associated to other therapies 
(silybin and N-acetylcysteine). MARS and Prometheus® are based in the same principle, 
the extracorporeal elimination of toxins. As α-amanitin is rapidly eliminated from plasma, 
these techniques may be especially useful if patients are presented to the hospital when 
the first symptoms appear. 
 
2.6.5.2. Drug therapy 
 Based on pre-clinical findings, several treatments have been applied in 
intoxications by amatoxin, namely using hormones (insulin, growth hormone, glucagon), 
steroids, vitamin C, vitamin E, cimetidine, α-lipoic acid, antibiotics (benzylpenicillin, 
ceftazidime), N-acetylcystein, and silybin (5). From these, only benzylpenicillin, 
ceftazidime, N-acetylcystein, and silybin were proven to have some degree of therapeutic 
efficacy, although the death rate remains extremely high (97) (Table III). Some of the most 
used procedures that showed some clinical effectiveness are addressed below. 
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2.6.5.2.1. β-Lactam antibiotics 
 The most widely used drug in the management of amatoxins poisoning, as a 
monotherapy or in combination with other agents is benzylpenicillin. One study involving 
47 patients poisoned with A. phalloides demonstrated that benzylpenicillin combined with 
supportive measures was an effective treatment in 43 cases (Table III) (98). The 
effectiveness of benzylpenicillin was, also, evaluated in a retrospective study including 111 
patients treated from 1988 to 2002 in the Toxicological Unit of Careggi General Hospital 
for amatoxins poisoning (18). The administration of benzylpenicillin combined with 
intensive fluid and supportive therapy, restitution of the altered coagulation factors, 
multiple-dose activated charcoal, mannitol, dexamethasone and glutathione, resulted in 
complete recovery of all patients treated within 36 hours after mushroom ingestion (Table 
III) (18). Two patients admitted to the hospital more than 60 hours after mushroom 
ingestion died (Table III) (18). On the other hand, benzylpenicillin monotherapy 
administered to 103 intoxicated patients resulted in an overall mortality of 7.8 % (Table 
III). Higher overall mortality (22.2 %) was observed in Croatia in a study including 18 
patients treated in 1988 (Table III) (5). Taken together, these results evidence that 
benzylpenicillin has some therapeutic effectiveness, although the high mortality rate 
(Table III) indicates that this antidote is far from ideal. 
 In vitro studies using human hepatocytes provided some evidence to support the 
effectiveness of benzylpenicillin in limiting the cytotoxicity of amatoxins (61, 99). In vivo 
studies, dogs (beagles, weighing 8-15 kg) were given an oral dose of lyophilized A. 
phalloides, which contained 0.14 mg/g of acid phallotoxins, 0.04 mg/g of acid amatoxins, 
0.04 mg/g of neutral phallotoxins, and 1.1 mg/g of neutral amatoxins. Benzylpenicillin 
(1000 mg/kg) was intravenously given at 5 hours after poisoning and silymarin (50 
mg/kg) was intravenously given at 5 hours followed by a dose of 30 mg/kg at 24 hours 
after poisoning. The results showed that benzylpenicillin combined with silymarin may 
help prevent and treat liver damage, since they reverted the increases of 
aminotransferases (ALT and AST) and also alkaline phosphates induced by A. phalloides 
(100). However, the effectiveness of benzylpenicillin (intraperitoneal dose of 1 million 
units/kg/day administered at 4 hours after poisoning) may be species dependent, as it was 
not found to be effective in limiting hepatic injury in mice  (weighed an average of 42.4 g) 
induced by a single intraperitoneal dose of α-amanitin (0.6 mg/kg) (101). Dog seem to be 
the model that is closest to human concerning intoxications by amatoxins, since the 
clinical course and symptoms are almost identical to those seen in humans (45). 
Moreover, dogs and humans share a great oral bioavailability for amatoxins (45). Despite 
the scarce oral bioavailability in rodents, the toxic effects of amatoxins are similar to those 
in humans (102). Most in mice studies use intraperitoneal administration that could 
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intensify the amatoxins-induced organ damage. In fact, that can explain the lack of 
efficacy of the antidotes in mice injected with high doses of amatoxins. 
 Several hypothesis have been proposed to explain the mechanism of 
benzylpenicillin in amatoxins poisoning. It was previously thought that benzylpenicillin 
could displace α-amanitin from albumin, allowing better renal elimination, but such 
hypothesis was later refuted by evidences demonstrating that α-amanitin does not bind to 
serum albumin (103). The influence of benzylpenicillin on the hepatic uptake of amatoxins 
has also been studied but remains unclear. Kroncke et al. studied amatoxins hepatic 
transport in membrane vesicles from rat liver using radiolabeled α- and γ-amanitins (104). 
It was observed that amatoxin membrane transport was not inhibited by benzylpenicillin. 
However, recent in vitro findings, using human hepatocytes, suggest that benzylpenicillin 
blocks α-amanitin uptake, being a potent inhibitor of OATP1B3 transporter (Letschert et 
al. 2006). Such putative protective effect requires further experimental in vivo 
confirmation. 
 Despite the reported efficacy of benzylpenicillin, this antidote has safety issues. 
The administration of benzylpenicillin may result in high sodium salt concentration in the 
body, which can disrupt electrolyte balance. In addition, it may cause allergic reactions, 
granulocytopenia and evoke neurotoxic symptoms in patients with nervous system disease 
and renal insufficiency (5). 
 Another β-lactam antibiotic used in the management of A. phalloides poisoning is 
ceftazidime. However, the number of amatoxins poisoning cases treated with ceftazidime 
was limited (97) and this antidote was always administered in combination with silybin 
(5), which causes bias to  its putative protective effect. Further investigations are needed to 
better understand the underlying protective mechanism of action of ceftazidime. 
 The Portuguese poisoning information center recommends a dose of 
benzylpenicillin of 1 million units/kg/day, by continuous intravenous infusion (90) in 
amatoxins poisoning. This treatment should be maintained until clinical and laboratory 
improvement is achieved as observed by serum transaminases levels and prothrombin 
time. TOXBASE recommends a dose of 0.5 million units/kg/day as a continuous infusion 
for 2-3 days from the day of ingestion, with close monitoring of renal function (89). 
However the national poisons centre of New Zealand does not recommend the 
benzylpenicillin administration (92). 
 
2.6.5.2.2. Silymarin 
 Silybum marianum (‘milk thistle’) is currently the most well researched plant used 
in the treatment of liver diseases. The active constituents of milk thistle are flavonolignans 
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including silybin, silydianin, and silychristine, collectively known as silymarin. Silybin is 
the component with the highest antioxidant activity, and ‘milk thistle’ extracts are usually 
standardized to contain 70-80% silybin (105). Due to its antioxidant activity, silybin has 
been applied in the management of amatoxin poisoning and evidence on the effectiveness 
of silybin in poisoned patients has been reported. Forty-six cases of amatoxins poisoning 
treated with silybin as monotherapy showed that all patients survived (Table III) 
(Enjalbert et al, 2002). These results indicate that silybin has some effectiveness in the 
management of amatoxin poisoning exhibiting low mortality rates (Table III). Silybin 
seems to be more effective as monotherapy than when combined with benzylpenicillin. In 
fact, in a recent study based on 1500 documented cases, it was concluded that the overall 
mortality in intoxicated patients with A. phalloides treated with silybin, as Legalon® SIL 
(silibinin-C-2’,3-dihydrogen succinate, disodium salt), is less than 10% in comparison to 
more than 20% when using benzylpenicillin or a combination of silybin and 
benzylpenicillin (106).  
 Cytotoxicity evaluation of cultured human hepatocyte using MTT reduction and 
LDH leakage was performed at 12, 24 and 48 hours of exposure to α-amanitin (2 µM) 
and/or silybin. The treatment with silybin showed a strong protective effect against cell 
damage in α-amanitin-induced toxicity (61). 
 The protective effects of silymarin on amatoxin poisoning have also been studied in 
different animal models. Again, species differences were found, as a significant 
hepatoprotective effect was observed for silybin in α-amanitin-induced liver damage in 
dogs (107), while no protective effect was observed in mice (101). In both species, the α-
amanitin LD50 was administered, however different routes of administrations were used. 
α-Amanitin was administered orally to dogs while in mice it was administered 
intraperitoneally. It is reasonable to consider that α-amanitin-induced toxicity in mice 
could be enhanced by intraperitoneal administration and the overall protection induced by 
silybin failed. Moreover inter-species differences may also exist.  
 As mentioned above, the postulated protective mechanism of action mediated by 
silybin is associated to its strong antioxidant activity, which could explain its action 
against hepatotoxic agents that act through oxidative stress. Silybin and silymarin reduce 
the free radical load, stimulate the activity of SOD and increase reduced glutathione (GSH) 
levels (108). Moreover, Pradhan and Girish (2006) suggest that silymarin is able to enter 
the nucleus and specifically stimulate RNA polymerase I. This increased transcription of 
ribosomal RNA may counterbalance the inhibition of RNAP II induced by amatoxins 
(109). Nevertheless, this hypothesis needs further confirmation. 
 Based on animal studies and limited human data, it seems that silybin has been the 
most promising molecule to prevent pathophysiological events after amatoxin 
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intoxications, with a good safety profile. Therefore CIAV and the national poisons centre of 
New Zealand recommend a intravenously dose of 20-50 mg/kg/day in four divided doses. 
Treatment should be continued for 48 to 96 hours after mushroom ingestion (90, 92). 
TOXBASE recommendations for A. phalloides poisoning treatment do not include silybin 
administration (89). 
 
2.6.5.2.3. N-acetylcysteine 
 N-acetylcysteine has been in medical use for more than 50 years as a mucolytic 
agent. It is also a well-known treatment for acetaminophen overdose, and related liver 
damage (110). Due to the clinical similarity between acetaminophen overdose and 
amatoxins poisoning, leading to hepatic and renal necrosis, N-acetylcysteine has been 
applied in the management of amatoxins poisoning. This compound is a precursor of GSH 
and due to its antioxidant and liver protecting effects it is postulated to play a protective 
role in patients poisoned with A. phalloides. N-acetylcysteine, administered to 86 
amatoxins poisoned patients showed overall survival of 93.0 % (5) (Table III). A 
retrospective multidimensional multivariate statistical analysis of 2110 clinical cases of 
amatoxin poisoning was performed in order to optimize therapeutic decision-making (97). 
The results of this study showed that N-acetylcysteine has a statistically positive impact on 
amatoxin poisoning (97). A retrospective study including 40 amatoxins-intoxicated 
patients was performed in order to investigate the benefits of N-acetylcysteine treatment 
in addition to the standard treatment that included benzylpenicillin in patients with A. 
phalloides intoxication (111). The mortality rate was lower when N-acetylcysteine was co-
administered (4.4% vs 18.7 % in the group that received only benzylpenicillin). Thus, the 
authors concluded that A. phalloides intoxication could be successfully treated with N-
acetylcysteine in addition with benzylpenicillin (111). N-acetylcysteine can act at two 
levels: by direct ROS scavenging and/or restoring hepatic GSH (97). In accordance, a 
recent in vitro study showed that treatment of human hepatocyte cultures with N-
acetylcysteine, conferred a strong protective effect against subsequent α-amanitin 
cytotoxicity (61). 
 On the other hand, research previously conducted by Schneider et al. and Tong et 
al. failed to show any relevant clinical efficacy of N-acetylcysteine in the treatment of A. 
phalloides intoxication in mice (101, 112). Both studies used 1.2 g/kg of N-acetylcysteine 
administered 4 hours after intraperitoneal administration of α-amanitin (0.6 mg/kg). 
Efficacy data of N-acetylcysteine administration in α-amanitin-intoxicated dogs are 
lacking. However it is reasonable to consider that there is no reason to not include N-
acetylcysteine in the treatment regimen.  
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 CIAV and TOXBASE protocols for A. phalloides poisoning do not include 
administration of N-acetylcysteine (89, 90), whereas the national poisons centre of New 
Zealand recommends to administer 150 mg/kg in 200 mL vehicle (5 % dextrose in water) 
intravenously over 15 minutes followed by 50 mg/kg in 500 mL vehicle over 4 hours 
followed by 100 mg/kg in 1000 mL vehicle over 16 hours (92). 
 
 
Table 3. Summary of clinical therapy in amatoxins poisoning 
 
   
Cases Years Country 
Drug 
therapy 
Prevention 
of 
amatoxins 
absorption 
Elimination 
of absorbed 
amatoxins 
Liver 
transplantation 
Mortality 
rate (%) Ref. 
47 
1971-
1975 
Italy BPC    4.0 (98) 
205 
1971-
1980 
6 
European 
countries 
BPC+S
LB 
   22.4 (113) 
2 
1980-
1981 
Austria SLB    0.0 (114) 
16 
1980-
1981 
Austria 
BPC + 
SLB 
   6.25 (114) 
44 1981 Italy BPC AC   9.1 (115) 
43 
1984-
1989 
France 
BPC+ 
SLB 
  2 17.8 (19) 
4 1994 New York BPC AC   25 (116) 
21 
1984-
1993 
Germany 
BPC + 
SLB 
 PL  4.8 (117) 
2 2000 Portugal 
BPC+S
LB 
AC   0.0 (6) 
2 2000 Portugal 
BPC+S
LB 
AC PL 2 0.0 (6) 
103 
1971-
1995 
Slovak 
Republic 
BPC  HP, HD  7.8 (5) 
18 1988 Croatia BPC  
FD, HD, 
PL 
 22.2 (5)  
86 
1987-
1993 
Italy NAC    7.0 (5) 
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Cases Years Country 
Drug 
therapy 
Prevention of 
amatoxins 
absorption 
Elimination 
of absorbed 
amatoxins 
Liver 
transplantation 
Mortality 
rate (%) 
Ref. 
25 
1980-
1986 
Europe SLB  
FD, HP, 
HD 
 4.0 (5) 
20 
1991-
1999 
Slovak 
Republic 
SLB  
FD, HP, 
HD 
 0.0 (5) 
26 1993 Germany SLB    0.0 (5) 
1 
2000
-2004 
Czech 
Republic 
BPC + 
SLB 
AC HD  0.0 (118) 
2 
2000
-2004 
Czech 
Republic 
BPC + 
SLB 
AC, GL HP  0.0 (118) 
1 
2000
-2004 
Czech 
Republic 
BPC + 
SLB 
AC, GL, FD  1 100 (118) 
2 
2000
-2004 
Czech 
Republic 
BPC FD   0.0 (118) 
2 
2000
-2004 
Czech 
Republic 
BPC GL, AC   0.0 (118) 
2 
2000
-2004 
Czech 
Republic 
BPC GL, AC HP  0.0 (118) 
1 
200-
2004 
Czech 
Republic 
BPC GL   100 (118) 
111 
1988-
2002 
Italy BPC AC   1.8 (18) 
28 
1983-
1992 
NS SLB    4.0 (106) 
126 
1983-
1992 
NS 
SLB + 
BPC 
   11.0 (106) 
118 
1957-
2005 
NS SLB    5.1 (106) 
77 2008 Turkey 
BPC + 
SLB + 
NAC 
AC, GL HF 1 2.5 (119) 
2 2009 Massachus
etts  
BPC + 
SLB + 
NAC 
AC   0.0 (120) 
2 
1999-
2012 
Australia 
BPC + 
SLB + 
NAC 
AC   0.0 (121) 
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PS: plasmapheresis; HD: hemodialysis, HF: hemofiltration; HP: hemoperfusion, FD: forced diuresis; 
GL: gastric lavage; AC: activated charcoal; BPC: benzylpenicillin; SLB: silybin; NAC: N-
acetylcysteine; NS: not specified.  
 
2.6.5.3. Transplantation  
 In some cases of A. phalloides poisoning, acute liver failure can be developed and a 
consequent liver transplant is needed to guarantee patients’ survival. Acute liver failure is 
a devastating effect characterized by sudden and severe liver cell dysfunction. This 
catastrophic illness can rapidly progress to coma and death due to cerebral edema and 
multi-organ system failure (122). Several criteria to decide the timing of liver 
transplantation have been proposed, although they are not universally accepted. The most 
widely used criteria for liver transplantation were developed by The Liver Unit at King’s 
College Hospital, (123). Their prognostic model was based on prothrombin time, age, 
etiology, time passing between appearance of jaundice and onset of encephalopathy, and 
bilirubin concentration. These criteria differentiate acetaminophen and non-
acetaminophen induced acute liver failure. The King’s College Hospital prognostic criteria 
for non-paracetamol-induced fulminant hepatic failure includes: prothrombin time > 100 
s; and any three of the following: age <10 or >40 years; jaundice >7 days before onset of 
encephalopathy, prothrombin time >50 s and bilirubin >300 µmol/l (123). However the 
application of King’s college criteria for non-acetaminophen induced acute hepatic failure 
on A. phalloides poisoning is limited (O’Grady 2012). Not all variables included in these 
criteria are useful in predicting a fatal outcome. In a distinct rationale, liver 
transplantation based on the Clichy criteria complies the combination of decrease in factor 
V below 30% of normal patients over 30 years or below 20% of normal patients below 30 
years and grade 3-4 encephalopathy (124). On the other hand, a retrospective study of 198 
amatoxin intoxicated patients showed that prothrombin index < 25% in combination with 
serum creatinine > 106 µmol/L from day 3 to 10 after A. phalloides ingestion is a strong 
predictor of fatal outcome (11). Ganzert’s criteria do not include the evaluation of hepatic 
Cases Years Country 
Drug 
therapy 
Prevention of 
amatoxins 
absorption 
Elimination 
of absorbed 
amatoxins 
Liver 
transplantation 
Mortality 
rate (%) 
Ref. 
2 
1999-
2012 
Australia 
BPC + 
SLB 
   50 (121) 
5 
1999-
2012 
Australia 
SLB 
+NAC 
AC   40 (121) 
24 
2001-
2006 
Turkey 
 
BPC+NA
C 
AC, GL HP  4.4 (111) 
16 
2001-
2006 
Turkey 
 
BPC AC, GL HP  18.7 (111) 
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encephalopathy due to imprecise data in the patients’ records (11). In order to re-assess 
the transplantation criteria, Escudie et al. (2007) studied 27 A. phalloides poisoned 
patients and the above criteria were compared. Encephalopathy, an absolute prerequisite 
in Clichy criteria for deciding emergency transplantation, was not fully observed in this 
study (10). Not all patients with a fatal outcome developed encephalopathy and in those 
who developed, the mean interval between the onset of encephalopathy and death was 
very short (10). Regarding to Ganzert’s criteria, the prothrombin index below or equal to 
25% of normal values, between day 3 and day 10 after ingestion, was refuted by Escudie et 
al. (2007). Their findings showed that 52% of patients that had a decrease in prothrombin 
index recovered without the need of transplantation. The authors concluded that such 
prothrombin index should be lowered in order to avoid unnecessary transplantation (10). 
Moreover, it was also shown that the value of serum creatinine has some limitations. 
Escudie et al. (2007) found that not all patients with fatal outcome had a creatinine level 
over 106 µmol/L 3 days or more after ingestion. The authors suggested that serum 
creatinine should not be an absolute requirement for emergency transplantation. They 
also pointed out that liver transplantation should be strongly recommended in patients 
with an interval between ingestion of mushrooms and the onset diarrhea less than 8 hours 
(10). In addition to this interval, female sex was also a significant risk factor for a fatal 
outcome than males. Lastly the decrease in prothrombin index below 10% of normal 
(international normalized ratio > 6) 4 days or more after ingestion, should lead to 
consider an emergency transplantation (10). 
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Taking into consideration the above-mentioned regarding the burden of amatoxins 
poisoning, the potential lethality, and the current inexistence of an effective antidote, the 
global aim of this thesis was to develop an efficient strategy for the treatment of amatoxins 
poisoning. The strategy pursued to achieve the proposed main objective comprised the 
following original studies:  
 
Study I 
a) To analyze the contents and distribution of the major amatoxins and phallotoxins 
in different tissues of A. phalloides from two different sites of Portugal by HPLC-
DAD-MS. 
 
Study II 
a) To develop and validate a HPLC-DAD-EC analytical method for the determination 
of α-amanitin in biological samples. 
 
Study III 
a) Application of the developed HPLC-DAD-EC method in a clinical case of co-
ingestion of amatoxins and isoxazoles-containing mushrooms. 
 
Study IV 
a) To elucidate, in silico, the molecular mechanisms of RNAP II inhibition by α-
amanitin. 
b) To elucidate the molecular mechanisms underlying the therapeutic effects of 
current antidotes (benzylpenicillin, silybin, ceftazidime) in amatoxins’ poisoning. 
 
Study V 
a) To evaluate in silico peptides with similar composition and molecular weight to 
that amatoxins for putative competition and displacement from its binding site in 
RNAP II. 
b) To validate in vivo the antidotal effectiveness of polymyxin B through survival rate, 
biochemical, histological, toxicological and genetic studies. 
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Abstract: Amanita phalloides is a toxic mushroom responsible for the majority of deaths 
occurring after mushrooms ingestion, mainly due to its high levels of amatoxins. In the 
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present study the contents and distribution of the major amatoxins and phallotoxins in 
different tissues of A. phalloides from two different sites of Portugal were analyzed by 
liquid chromatography (LC)–diode array (DAD) and mass spectrometry (MS) detection. 
The main toxins were separated by LC and its chemical structures confirmed by MS. α-
Amanitin contents in caps, stipe and volva tissues were quantified by RP-HPLC. The 
results show that caps have the highest content of amatoxins, whereas the volva was 
richest in phallotoxins. Moreover, variability in the toxins composition from different 
geographic sites was also observed. This study provides, for the first time, the content of 
toxins in A. phalloides from Portugal. 
Key words: Amanita phalloides, α-amanitin, mass spectrometry, reversed phase 
high performance liquid chromatography, toxins. 
INTRODUCTION 
Amanita phalloides (death cap) is one of the most toxic mushrooms worldwide. Fatalities 
due to A. phalloides poisoning account to about 90% of deaths occurring after ingestion of 
mushrooms (Karlson-Stiber and Persson 2003). This mushroom species grows in 
symbiosis with arboreal trees, such as beech or oak in Europe and America. Amanita 
phalloides is characterized by greenish yellow cap, darker in the center and faintly 
streaked radially (FIG. 1). The stipe is smooth and white and it has a distinct ring. The base 
of the stipe is enclosed in a volva which is a distinctive and morphological diagnostic 
feature (Bonnet and Basson 2002). Poisoning from the consumption of this mushroom 
usually occurs as a result of confusion of A. phalloides with edible mushroom species, such 
as Amanita fulva, Agaricus spp., Macrolepiota procera and Tricholoma portentosum 
(Barceloux 2008). Cooking, freezing and drying do not eliminate the toxicity of A. 
phalloides (Vetter 1998). 
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FIG. 1. Basidiocarp of Amanita phalloides (Death Cap) from Vinhais, Portugal. 
 
This species contains two main groups of toxins, amatoxins and phallotoxins.  The 
amatoxins group is composed by α-amanitin (AA), β-amanitin (BA), γ-amanitin (GA), ε-
amanitin, amaninamide, amanin, amanullin, amanullic acid and proamanullin (FIG. 2).  
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FIG. 2. Chemical structure of amatoxins The backbone structure is the same in all the 
amatoxins and five variable groups determine the specific compound. 
 
The phallotoxin group consists of phalloidin (PHD), phalloin, prophallin, phallisin 
(PHS), phallacin, phallacidin (PCD) and phallisacin (FIG. 3) (Vetter 1998).  
 
 
 
FIG. 3. Chemical structure of phallotoxins. The backbone structure is the same in all the 
phallotoxins and five variable groups determine the specific compound. 
 
 
Amatoxins are the main toxins responsible for the toxicity and the human fatalities 
following intoxication with A. phalloides. The mechanism of action of amatoxins is not 
completely understood but it is known that the main target of AA is hepatic RNA 
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polymerase II enzyme. Following uptake by organic anion-transporting octapeptide 
(OATP) located in the sinusoidal membrane of hepatocytes, AA inhibits RNA polymerase 
II, reducing the mRNA synthesis and, consequently, provoking a decrease of protein 
contents and, ultimately, liver cell death (Mas 2005). The mechanisms of toxicity of AA 
has been studied by our group and we have focused our efforts on understanding the 
molecular mechanism of RNA polymerase II inhibition (Garcia et al. 2014). 
Several methods for isolation and analysis of amatoxins and phalotoxins have been 
published, the reversed-phase high performance liquid chromatography (RP-HPLC) being 
the most common used method (Enjalbert et al. 1996; Enjalbert et al. 1999; Enjalbert et al. 
1993; Enjalbert et al. 1992; Enjalbert et al. 2002; Hu et al. 2012). Enjalbert et al. have been 
analyzed the content of main toxins in A. phalloides showing that the amount of toxins 
depends on climate, topography and soil characteristics (Enjalbert et al. 1996; Enjalbert et 
al. 1999). In addition, significant differences in amounts of toxins in different tissues of 
the fruiting body and in different growth phases have also been noted (Enjalbert et al. 
1996). The quantification of A. phalloides toxins in different part of the globe is important 
to get the greatest information possible, to ascertain its relative morbidity and lethal 
potential. To our knowledge, there is no study on the toxin content of A. phalloides from 
Portugal. 
In this work A. phalloides collected in north of Portugal were investigated for 
amatoxins and phallotoxins by using liquid chromatography–diode array and mass 
spectrometry detection (LC-DAD-MS). AA was quantified from caps, stipe and volva by 
RP-HPLC and DAD. 
MATERIAL AND METHODS 
Chemicals —α-amanitin (>90% pure) was purchased from Sigma-Aldrich. Acetonitrile 
(hypergrade) was brought from Fisher Chemicals. Water was purified with a Milli-Q Plus 
ultra-pure water purification system (Millipore, Bedford, Ma, USA). 
Description of the study area ––Considering the geographic differences, the northeast of 
Portugal province of Trás-os-Montes can be grouped into two areas: the ’’Terra Fria’’ (Cold 
Land) located in the northern area, with higher altitudes, and the ‘‘Terra Quente’’ (Hot 
Lands) located in the southern areas, marked by the valleys of the Douro River (Dias et al. 
2012). These two areas have significant climatic differences. Cold Land is characterized by 
cold and prolonged winter, and a brief hot summer with annual mean precipitation of 800 
mm and mean temperature of 12.5 C. On the other hand, Hot Land has a warm and dry 
summer and mild winter with annual mean temperature of 14.0 C and annual 
precipitation of 1200 mm (Evelpidou et al. 2010). The Vinhais region is located in Cold 
Land, whereas Mogadouro is in the Hot Land. The varieties of topographic and climatic 
conditions have a great impact on the type of soil. In fact, according to the Soil Map of 
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Northeast Portugal, 1: 1 00000 (Agroconcultores and Coba 1991), which follows the FAO 
system of classification (FAO/UNESCO 1987), leptosols are largely dominant in 
Mogadouro, whereas cambisols are the most representative soils of Vinhais. 
Amanita phalloides and soil sampling —Amanita phalloides fruiting body were collected 
in the Trás-os-Montes region during October and November of 2012 from two different 
sites named Vinhais and Mogadouro. The set consisted of 25 mature fruiting body. The 
mushrooms were identified by using morphological features and appropriate keys and 
monographs including Courtecuisse and Courtecuisse & Duhem (Courtecuisse 1999; 
Courtecuisse and Duhem 2005). Immediately after harvesting, the mushrooms were dried 
during three days at 60º C. Each specimen was divided into three parts namely the cap, 
stipe and volva. Representative voucher specimens (number 447) were deposited at the 
herbarium of School of Agriculture of the Polytechnic Institute of Bragança (Portugal). 
Soils samples from different sites of Vinhais and Mogadorouro regions were collected and 
represent different soil types (leptosol and cambisol). Bulk soil samples (6 replicates per 
soil; 0.5 kg per replicate) were collected in plastic bags and thoroughly homogenized 
before further processing. The soil pH was determined according to ISO 10390:2005 
method. The solid samples (weight 10 g) were treated with 50 mL 1M KCl, under stirring 
for 30 min. After, 1 hour, the pH for the each sample was measured at room temperature. 
Extraction of toxins —Several methods have been described in the past few years for the 
extration of phallotoxins from fungi (Enjalbert et al. 1992; Enjalbert et al. 1996; Kaya et al. 
2013). These methods are often laborious and time consuming. This is usually because 
most of the available protocols include multiple steps of solid/liquid extraction followed 
by incubation overnight. In addition to being lengthy, these methods also involve large 
amount of sample (2 g), which is a limitation when the amount of mushrooms available is 
scarce. Thus, in the present it was used a simpler but fully effective extraction method 
previously described by Jansson et al. (2012) with minor modifications. Briefly, cap, stipe 
or volva were ground to a powder in a mortar, after 0.5 g (dry weight) of  were extracted 
during 1 h with 1 ml of milli-Q water and 6 ml acetonitrile. After centrifugation at 3000 
rpm for 30 min, the supernatant was used for LC/MS analysis. The same supernatant was 
used for AA quantification by reversed-phase HPLC. 
Identification of A. phalloides toxins by liquid chromatography–diode array and mass 
spectrometry detection —A Finnigan Surveyor series LC, equipped with Lichrocart 
Purospher® Star reversed-phase column (150 mm x 4.6mm, C18, 5 mm) was used. The 
mobile phases’ flow rate was 0.5 ml.min-1, consisted of (A) 0.02 M aqueous ammonium 
acetate adjusted to pH 5.0 with glacial acetic acid and (B) acetonitrile (Zhao et al. 2006). 
The gradient profile was: 0→15 min, 0%→2.3% solvent B; 15→35 min, 2.3%→37.9% 
solvent B; 35→40, 37.9%→37.9% solvent B; 40→45 min, 37.9% →100% solvent B; 
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45→50 min, 100%→100% solvent B; 50→55 min, 100%→0% solvent B; 55→65, 0%→0% 
solvent. The sample injection volume was 20 µL. The chromatographic column was 
stabilized with the initial conditions for 10 min. Double-online detection was done by a 
DAD and MS detectors. The MS detector was a Finnigan LCQ DECA XP MAX (Finnigan 
Corp., San Jose, CA) quadrupole ion trap equipped with atmospheric pressure ionization 
source, using ESI. The vaporizer and the capillary voltages were 5kV and 4V, respectively. 
The capillary temperature was set at 325 ºC. Nitrogen was used as both sheath and 
auxiliary gas at flow rates of 90 and 35, respectively (in arbitrary units). 
Quantification of amatoxins by high-pressure liquid chromatography with diode array 
detection —Analyses were performed using a reversed-phase HPLC method (Enjalbert et 
al. 1992). An HPLC system (Waters model 2690) equipped with a photodiode array 
detector (Waters model 996) and C-18 column from Waters (150 mm x 4.6mm, C18, 5 µm) 
was used. The mobile phases’ flow rate was 1 ml.min-1 and consisted of (A) 0.02 M 
aqueous ammonium acetate adjusted to pH 5.0 with glacial acetic acid and (B) acetonitrile 
(Zhao et al. 2006). The gradient was: 0→15 min, 0%→2.3% solvent B; 15→45 min, 
2.3%→37.9% solvent B; 45→50, 37.9%→37.9% solvent B; 50→55 min, 37.9% →100% 
solvent B; 55→60 min, 100%→100% solvent B; 60→65 min, 100%→0% solvent B; 
65→70, 0%→0% solvent. The sample injection volume was 20 µL. All analyses were 
carried out in triplicate and at laboratory temperature. The absorbance was monitored by 
diode-array detector from wavelength 200 to 400 nm. The amounts of AA in the samples 
were determined by using a standard curve. 
Preparation of calibration curve and quality control samples —A standard sample of AA 
was dissolved in milliQ distilled water to a concentration of 1 mg.mL-1. A six-point curve 
was obtained with injections of 20 µL of 1, 5, 10, 25, 50, 100 µg.mL-1 and the linear 
regression equation and correlation coefficients were calculated. AA in the samples was 
identified by comparison of retention times and co-injection with standards. 
Concentrations were calculated using peak areas of reference compound. 
Quality control samples (10, 50 and 100 µg.mL-1) were independently and daily 
prepared in the extraction medium (acetonitrile/water). 
Validation procedure —The limit of detection was defined as the concentration where the 
signal-to-noise value exceeded 3.0. Intra- and inter-assay precision was also evaluated by 
considering three concentrations (10, 50 and 100 µg.mL-1) prepared in triplicate and 
analysed in the same day (intra-day) and in different days (inter-day).  The results are 
expressed as the coefficient of variation (CV %) of the experimental values at each 
concentration. 
Principal components analysis —Principal components analysis (PCA) was performed 
using the Matlab software version 7.9.0 (Mathworks, Natick, MA) with PLS Toolbox 
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version 5.5 (Eigenvector Research Inc., Wenatchee, WA). It was applied as an 
unsupervised technique for reducing the number of variables (6 variables corresponding 
to AA, BA, GA, PHD, PHS and PCD) to a smaller number of new derived variables 
(principal component or factors) that adequately summarize the original information. 
Moreover it allowed recognizing patterns in the data by plotting them in a 
multidimensional space, using the new derived variables as dimensions (factor scores). 
The aim of the PCA is to produce components suitable to be used as predictors or response 
variables in subsequent analysis (Rencher 1995). 
RESULTS 
Species identification and pH soil —A. phalloides specimens were identified by using 
morphological features and appropriate keys and monographs including Courtecuisse 
(1999) and Courtecuisse & Duhem (2005). Morphological features that were important for 
species level identification of A. phalloides include: cap convex or subplanar with a 
variance of olive-green to brown color; gills free and white to cream; stipe white to pale 
yellow with fine radial striations; ring in upper part of the stipe, white to pale yellow, with 
radial striations; and volva globose and white. 
The pH of all examined soil samples was strong to moderate acid. The result 
showed that the means pH for Vinhais and Mogadouro were between 5.170 ± 0.119 (strong 
acid) and 5.960 ± 0.211 (moderate acid), respectively. 
Extraction of toxins ––In order to ensure complete toxins extraction we performed the 
extraction at different time-points (1, 2 and 3 hours). As the α-amanitin content was the 
same at different times, we performed a second extraction of the same mushroom sample 
and an additional rinse under the same conditions. The LC-MS analysis did not recover 
detectable amounts of residual toxins. The extraction method enabled us to obtain 
complete toxins extraction, dispensing with the laborious and time-consuming steps. The 
extraction process involves one solid/liquid extraction step followed by centrifugation. 
Another advantage of this method is that it only requires a small amount of mushroom 
sample (0.5 g). 
Identification of α-amanitin, β-amanitin, γ-amanitin, phalloidin, phallisin and 
phallacidin —LC/DAD/MS analyses were performed in order to identify the main 
amatoxins and phallotoxins present in the mushroom tissues extract. FIG(S). 2 and 3 show 
the chemical structures of the main amatoxins and phallotoxins. The supposed 
identification of AA, BA, GA, PHD, PHS and PCD peaks detected under UV were based on 
their production spectra. Based on TABLE I the base peaks of the mass spectra were m/z 
919.20 (C39H54N10O14S) for AA, m/z 920.13 (C39H53N9O15S) for BA, m/z 903.20 
(C39H54N10O13S) for GA, m/z 789.27 (C35H48N8O11S) for PHD, m/z 805.27 (C35H48N8O12S) 
for PHS and m/z 847.20 (C37H50N8O13S) for PCD. The chromatographic ion peak [M+H]+ 
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at m/z 903.20 (C39H54N10O13S) could correspond to either GA or amaninamide. As 
amaninamide is specific to Amanita virosa (Buku et al. 1980), we identified this 
chromatographic peak as being the GA. The protonated molecular peaks with a NH4+ ion 
[M+NH4]+ peaks; m/z 935.67 for AA, m/z 936.67 for BA, m/z 919.67 for GA, m/z 805.60 
for PHD, m/z 821.47 for PHS and m/z 863.47 for PCD. A representative chromatogram 
recorded at 295 nm of A. phalloides cap extract is given in FIG. 4. 
 
 
FIG. 4. Representative chromatogram recorded at 295 nm of A. phalloides cap from 
Vinhais. Peaks: A= β-amanitin; B= α-amanitin; C= γ-amanitin; D= phallacidin; E= 
phallisin; F= phalloidin. 
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TABLE I. Identified toxins in A. phalloides extract 
 
 
Calibration and validation —The representative regression equation for the calibration 
curve was y = 10266x + 40831 over range of 1.00-100.00 µg.mL-1 with a coefficient of 
0.991. The lower limits of identification were 0.03µg.mL-1. The intra- and inter-assay 
precision and accuracy determined using the blank mushroom extract that had been 
spiked with AA is indicated in TABLE II. The CV for the intra- and inter-assay was between 
0.65 and 2.03% for the three concentrations studied. 
 
 
 
 
 
 
Compound name 
Theoretical 
monoisotopic 
Elemental 
composition 
Experimental 
[M+H]+ 
α-amanitin 918.35 C39H54N10O14S 919.20 
β-amanitin 919.34 C39H53N9O15S 920.13 
γ-amanitin 902.36 C39H54N10O13S 903.20 
Phalloidin 788.32 C35H48N8O11S 789.32 
Phallisin 804.31 C35H48N8O12S 805.27 
Phallacidin 846.32 C37H50N8O13S 847.20 
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TABLE II. Analytical accuracy and precision evaluated using standard spiked blank 
mushrooms 
 
Contents and distribution of α-amanitin in cap, stipe and volva —The retention time for 
AA was 12.65 min. The concentrations in the samples are shown in TABLE III. The amount 
of AA in caps of A. phalloides from Vinhais and Mogadouro, were 783.94 ± 2.66 µg.g-1 and 
666.00 ± 1.45 µg.g-1 respectively (TABLE III). The stipes from Vinhais and Mogadouro 
contained 323.48 ±4.03 µg.g-1 and 302.53 ± 2.78 µg.g-1respectively (TABLE III). Finally, the 
lowest concentrations were found in volva from Vinhais and Mogadouro which contained 
103.87 ± 1.84 µg.g-1 and 73.16 ± 1.66 µg.g-1, respectively (TABLE III). 
 
TABLE III. Content of α-amanitin in different tissues of A. phalloides 
 
a Content (µg g-1 dry weight). Values are mean ± standard deviation (n=3).  
 
Amatoxin and phallotoxin composition in the different tissues —Principal components 
analysis showed that 96.35% of the total variance of the data is explained using only three 
principal components. FIG. 5 shows the representation of the two principal components 
factor scores obtained from the mushrooms harvest in two different geographical sites and 
the loadings of the variables. The first principal component, accounting for 54.84% of total 
Concentration known 
(µg.mL-1) 
 
Concentration found CV (%) 
Intra-assay (n=3)   
1.00 0.90±0.03 3.38 
10.00 11.92±0.09 0.76 
100.00 101,15±1.27  1.26 
Inter-assay (n=3)   
1.00 0.87±0.02 2.02 
10.00 11.90±0.24 2.02 
100.00 106.58±0.84  0.79 
Tissue Vinhais  Mogadouro 
caps 783.94 ± 2.66a 666.00 ± 1.45a 
stipes 323.48  ± 4.03a 302.53 ± 2.78a 
volvas 103.87 ± 1.84a 73.16 ± 1.66a 
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variance and was strongly related to the tissue type. On the other hand the third principal 
component (13.58% of total variance) was related to the collection site. FIG. 5A illustrates 
the contrast between the two groups: the first group, projected in negative PC3 space 
composed by CV, SV and VV while the second group (projected in positive PC3 space) is 
represented by CM, SM and VM. The discrimination between these two groups is 
associated with the content in PHD and PHS which is correlated with the third PCA axis 
(FIG. 5B). FIG. 5A shows also a differentiation along PC1 among different tissues, cap, stipe 
and volva. Volva samples are projected on PC1 negative while caps are projected on PC1 
positive and stipe between these two groups. 
The separation among these three groups is associated with the content in AA, BA 
and GA which is very well correlated with the first PCA axis. 
 
 
FIG. 5. A. Principal components scores plots of the data from the mushrooms HPLC-DAD 
spectra. B. Principal components analysis loading plots of the variables α-amanitin (AA), 
β-amanitin (BA), γ-amanitin (GA), phalloidin (PHD), phallacidin (PCD) and phallisin 
(PHS). Key: Cap from Vinhais (CV); Stipe from Vinhais (SV); volva from Vinhais (VV); 
Cap from Mogadouro (CM); Stipe from Mogadouro (SM) and Volva from Mogadouro 
(VM). 
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DISCUSSION 
As ingestion of A. phalloides mushrooms is responsible for several accidental or 
premeditated fatal intoxications, it is of great importance to have data concerning A. 
phalloides toxin total composition, its distribution in mushroom fruiting body tissues 
(cap, stipe, and volva) and also its geographic preponderance. Few works are available in 
literature, and they come from researches performed in Poland, where several cases are 
reported (Lapinski and Prokopowicz 1998), France (Garrouste et al. 2009) and Czech 
Republic (Krenova et al. 2007). Portugal is a country where mushrooms take part of eating 
habits and every year several cases of mushroom intoxications are reported in media. 
However, no scientific works are available regarding toxins’ composition of A. phalloides 
growing in Portugal. Hence, this work aimed at determining the quantitative differences in 
the toxins amount of the fruiting body tissues from A. phalloides mushrooms collected at 
different sites as at present there is no data for the amount of toxins present in the 
Portuguese A. phalloides. These species exist throughout the Portuguese territory but with 
higher incidence in the northern part of the country. New cases of A. phalloides poisoning 
have been reported every year, however, it is difficult to estimate the exact number of 
cases of amatoxin poisoning that occur each year due to under-reporting procedures at 
hospital emergencies. As described before, this species contains two groups of toxins, 
amatoxins and phallotoxins. The less-harmful phallotoxins are poorly absorbed through 
the intestine, although they may contribute to the early gastrointestinal symptoms (Karimi 
and Razavi 2014). The group of amatoxins is mainly composed of AA. Our results showed 
that the content of this toxin and its distribution in tissues of A. phalloides varied 
significantly. The highest amounts were found in the cap and stipe and the lowest amount 
in the volva of the A. phalloides. The cap AA content was twice that in the stipe and four 
times higher than in the volva. The content and distribution of toxins in different tissues of 
A. phalloides were also previously investigated by Enjalbert et al. (1993). Their data 
revealed significant variations in the amounts of toxins present in the various tissues of A. 
phalloides, which is consistent with our findings, though they found higher amounts. This 
apparent discrepancy may be explained by environmental factors and genetic differences. 
The amount of toxin present may also be dependent on the age of the collected species, 
which may also be reflected in the variation of our values. The collected A. phalloides 
specimens were in mature stage, which explains the lower values that are consistent with 
results presented by Hu et al. (2012). 
 Concerning the environmental conditions of the collection area (temperature, 
microclimate, soil, and pH values) it seems play a determinant role in amatoxin and 
phallotoxin profile. In accordance, Enjalbert et al. (1996) reported that the geographical 
local significantly influences toxin composition of the fruiting body tissues, a finding that 
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is also corroborated in the present study. In fact, the geographic, topographic, climatic, 
and soil pH differences between the two areas analyzed seems to have an impact on toxin 
profile. Our findings pointed out that the site-specific environmental conditions have a 
greater influence on phallotoxin than on amatoxin composition, which is in agreement 
with Enjalbert et al. (1996). The greatest variations in the toxin concentration were 
recorded for PHD and PHS in the stipes from Vinhais and Mogadouro. The highest PHD 
concentration was found in the stipe from Mogadouro. On the other hand the highest PHS 
concentration was found in the stipe from Vinhais. A. phalloides belongs to a category 
called ectomycorrhizal-symbiotic fungi. These fungi are known to have an intimate 
relationship (symbiotic) with their host plants. In this context, an ectomycorrhizal fungus 
gains carbon supply and other essential organic substances from the tree and in return, 
the plant benefits from receiving water and nutrient resources to grow. Therefore, the 
close ties between ectomycorrhizal fungi and their plant hosts would lead us to expect 
greater host influence on chemical composition of ectomycorrhizal mushrooms species. 
The A. phalloides specimens from Vinhais were in a symbiotic association with chestnut 
tree and specimens from Mogadouro were in a symbiotic association with oak tree. Thus, 
we strongly believe that host tree and the surrounding flora involved in the symbiotic 
relationship could influence the chemical composition of mushrooms. 
 The multivariate techniques of data analysis was used to obtain more information on 
the variables that mainly influence the sample similarities and/or diﬀerences. The same 
technique has been recently applied by our group to discover molecules that can be used to 
assist in identifying mushroom species (Carvalho et al. 2014) in which 6 molecules that 
can be species-or-genus specific were successfully identified. In the present study, we are 
able to discriminate the different tissues that composed fruiting body mushroom based on 
toxin composition. Therefore the cap tends to contain more amatoxins (AA, BA and GA) 
than stipe and volva (FIG. 6). In contrast, volva exhibited the lowest concentration of 
amatoxins. On the other hand, volva contains more PCD than caps and stipes  
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FIG. 6. Principal components scores and loadings plots. 
 
Taken together, these results based on statistical evaluation of HPLC-DAD data 
revealed that amatoxins and phallotoxins are not equally distributed in the fruiting body 
tissues and vary from one area to another. Furthermore, findings from this study support 
the hypothesis that environmental conditions play a significant role in the content of 
toxins. 
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Abstract 
α-Amanitin is a natural bicyclic octapeptide, from the family of amatoxins, present in the 
deadly mushroom species Amanita phalloides. The toxicological and clinical interests 
raised around this toxin, require highly sensitive, accurate and reproducible quantification 
methods for the respective pharmacokinetic and toxicokinetic studies. In the present 
work, a high-performance liquid chromatographic (HPLC) method with in-line connected 
diode-array (DAD) and electrochemical detection was developed and validated to quantify 
α-amanitin in biological samples (namely plasma, liver and kidney) following intoxication. 
Sample pre-treatment consisted of a simple and unique deproteinization step with 5% 
perchloric acid followed by centrifugation at 16000g, 4ºC, for 20 min. The high recovery 
found for α-amanitin (≥ 96.8%) makes this procedure suitable for adequately extracting α-
amanitin from liver and kidney homogenates. The resulting supernatant was collected and 
injected into the HPLC, using a commercially pre-packed reverse phase cartridge, Waters 
Spherisorb RP 18 (5 µm) ODS2 column. Mobile phase was composed by 20% methanol in 
50 mM citric acid, and 0.46 mM octanessulfonic acid, adjusted to pH 5.5. The 
chromatographic runs took less than 22 min and no significant endogenous interferences 
were observed at the α-amanitin retention time. Calibration curves were linear with 
regression coefficients higher than 0.994. The overall inter- and intra-assay precision did 
not exceed 15.3%.  
This present method has low interferences and has a simple and fast processing step, 
being a suitable procedure to support in vivo toxicokinetic studies involving α-amanitin. 
In fact, the validated method was successfully applied to quantify α-amanitin in biological 
samples following intraperitoneal α-amanitin administration to rats. The results clearly 
indicate that the proposed method is suitable to investigate the pharmacokinetic and 
tissue distribution of α-amanitin.  
In the present work, human plasma was also used as matrix and the purposed method was 
adequate for detection of α-amanitin in that matrix. Moreover, the method will be very 
useful in the development of novel and potent antidotes for amatoxin’s poisoning and to 
improve the knowledge of α-amanitin toxicity. 
 
Keywords: High-performance liquid chromatographic; diode-array; electrochemical; α-
amanitin 
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Abbreviations 
 
 
  
HPLC High-performance liquid chromatography  
DAD Diode-array 
EC Electrochemical  
DNA Deoxyribonucleic acid 
LOD Limit of detection 
LOQ Limit of quantification 
LC Liquid chromatography 
MS Mass spectrometry 
RNA Ribonucleic acid 
RNAP II RNA polymerase II  
RSD Relative standard deviation  
SPE  Solid phase extraction 
UV Ultraviolet 
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1. Introduction 
 
The main toxin of the amatoxins, α-amanitin (Figure 1) is a toxic bicyclic octapeptide 
present in the deadly mushroom species Amanita phalloides. It accounts up to 40% of the 
amatoxins present in this mushroom and is the main responsible for its toxic effects [1]. α-
Amanitin produces hepatic and kidney failure, which result in a potentially fatal outcome 
in most of the human intoxication cases [2]. The mechanisms underlying the toxicity of α-
amanitin are not completely understood, but it is accepted that the inhibition of RNA 
polymerase II (RNAP II) leads to its the main effects [3]. Other mechanisms also appear to 
be involved, including oxidative stress [4].  
 
 
Figure 1. Chemical structure of α-amanitin 
 
So far, there is no specific and totally effective antidote for Amanita phalloides poisoning. 
Benzylpenicillin, ceftazidime, N-acetylcystein, and silybin are the most extensively used 
antidotes, however mortality remains high [5]. Currently, in vivo and in silico studies are 
ongoing in search of effective antidotes, either directed to the toxicokinetics or to the 
toxicodynamics of amatoxins [6-9]. In both approaches, it is expected that the 
development of more insightful analytical and physiological methodologies, will provide 
essential tools for achieving this purpose. From the analytical stand-point, however, 
sensitive methodologies for α-amanitin to be applied in biological samples are lacking. 
Besides the toxicological interest in α-amanitin, recent findings indicate that α-amanitin is 
emerging as an attractive new class of potent anticancer drug [10]. For this clinical  
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application, adequate analytical methodologies are also required for the evaluation of α-
amanitin pharmacokinetics, both in pre-clinical and clinical studies. 
The comprehensive characterization of antidotes in Amanita phalloides poisoning and the 
pharmacokinetics and toxicokinetic studies of α-amanitin require highly sensitive, 
accurate and reproducible quantification assays. Currently, there are several high-
performance liquid chromatography (HPLC)–ultraviolet (UV) [11-17] and HPLC–mass 
spectrometry (MS) [18-20] methods to determine α-amanitin in mushrooms, liver and 
fluids. HPLC-MS methods for α-amanitin detection are accurate, sensitive, and specific; 
nevertheless HPLC-MS is an expensive technique and is not available in many 
laboratories. To date there are no published HPLC with electrochemical detection 
methods for the analysis of α-amanitin in biological tissues. Hence, in this paper, we 
describe a simple acidic extraction and HPLC methodology with in-line connected 
photodiode array detection (DAD) and EC detection to quantify α-amanitin in rat liver and 
kidney. Moreover, we applied the validated method to identify α-amanitin in human 
plasma. The validated method was successfully applied to quantify α-amanitin in plasma, 
liver and kidney tissues following intraperitoneal administration to rats. The new method 
provides the required high analytical sensitivity and reproducibility, with a simple and fast 
pretreatment, as it is required for advanced pharmacokinetic and toxicokinetic research. 
 
2. Material and methods 
  
2.1. Reagents and Chemicals 
α-Amanitin (>99%), bovine serum albumin, and 1-octanesulfonic acid sodium salt were 
purchased from Sigma-Aldrich (St. Louis, Mo, USA). Analytical HPLC grade methanol was 
obtained from Fisher Scientific (Waltham, Massachusetts, USA). Sodium chloride (NaCl), 
potassium chloride (KCl), sodium hydrogen phosphate (Na2HPO4), potassium dihydrogen 
phosphate (KH2PO4) and perchloric acid were purchased from Merck (Darmstadt, 
Germany). Water was purified with a Milli-Q Plus ultra-pure water purification system 
(Millipore, Bedford, Massachusetts, USA).  
 
2.2. Chromatographic conditions  
HPLC analysis was performed using a Waters 2690 separation module (Waters, Milford, 
MA, USA), and a commercially pre-packed reverse phase cartridge of 250mm x 4.6mm, 
Waters Spherisorb RP-18 (5 µm) ODS2 column. The mobile phase (20% methanol in 
50mM citric acid, 0.46mM octanessulfonic acid, adjusted to pH 5.5) was filtered through a 
0.45 µm membrane (Millipore, Madrid, Spain) and degassed. An isocratic elution was 
performed at a flow rate of 1.0mL/min, at room temperature. Sample aliquots of 20 µL 
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were injected. A Compaq computer fitted with Millenium32 software (Waters) processed 
the chromatographic and spectral data. 
For the spectroscopic and coulochemical analysis, a photodiode array detector (Waters 
model 996) and/or a Colouchem II (ESA, Chelmsford, USA) equipped with a guard cell 
(ESA 5020) and analytical cell (ESA 5011A) electrochemical detector were used. In all the 
studies, both detectors were used, with the analytical cell of the coulochemical detector 
placed after the photodiode array detector. The electrochemical potential settings of 
Coulochem II detector were: guard cell, -550 mV, and analytical detector + 500 mV, 
following a previous reported procedure [21]. A current of 5 µA full-scale was used. 
Ultraviolet-visible spectra was collected for all samples between from 230 to 400 nm. For 
quantitative analyses chromatograms were integrated at 305 nm [15]. 
 
2.3. Stock solution and calibration standards  
A stock solution of α-amanitin was prepared in water Milli-Q and diluted to a final 
concentration of 1 mg.mL-1. All stock solutions were stored of -20 ºC. A set of eleven 
standards ranging from 0.025 µg.mL-1 to 10 µg.mL-1 were prepared at the moment of use 
by spiking the rat liver and kidney samples with appropriate amounts of α-amanitin. All 
calibration standards were prepared in triplicate. 
 
2.4. Animals and sample preparation 
The liver and kidney tissues were obtained from adult male Wistar rats. These animals 
were used as healthy controls in other experiments, in which liver and kidney were not 
used. A minimum number of animals was used in order to obtain valid results. All 
experiments were approved by local ethical committee. All rats were between 5 and 6 
months of age and weighting about 150 to 200 g. Rats were sacrificed by guillotine 
decapitation by an experienced veterinarian and liver and kidney tissues were immediately 
collected and kept frozen at -20ºC until homogenization. One gram of each organ was 
homogenized using an Ultra-Turrax homogenizer in 4 mL of 0.1M phosphate buffer, pH 
7.4. The homogenate was placed in perchloric acid (5% final concentration) for protein 
denaturation, and centrifugated at 16000 g, 4ºC for 20 min. The resulting supernatant 
was collected and injected into the HPLC before or after spiking with α-amanitin, 
depending on the condition to be tested. 
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2.5. Method Validation 
The HPLC method with simultaneous DAD and EC detection for the determination of α-
amanitin in 5% perchloric acid, and in liver and kidney samples was validated by the 
evaluation of the following parameters: specificity, linearity, recovery, precision, 
sensitivity, matrix effect and analyte stability. 
 
2.5.1. Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of components 
that may be expected to be present [22] . Specificity of the method was tested by analysis 
of three different blanks: 5% perchloric acid, rat liver and kidney extracts and compared to 
samples spiked with 5 µg.mL -1 of α-amanitin to ensure the absence of compounds with 
similar retention times. The purity of the peak of α-amanitin was investigated by 
determining the ultraviolet and visible spectrum with maximum absorbance using the 
DAD and by comparing the retention times between spiked samples and pure controls. 
 
2.5.2. Linearity  
The linearity of an analytical procedure is its ability to obtain test results that are directly  
proportional to the concentration of analyte in the sample within a given range [22]. The 
linearity response for α-amanitin was initially studied using eleven standards in 5% 
perchloric acid injected three times, covering the range of 0.025-10µg.mL-1. Subsequently, 
linearity was studied in biological samples spiked with a series of α-amanitin standards 
covering the mentioned range. The linearity was evaluated by linear regression analysis. 
 
2.5.3. Recovery 
Typically, the accuracy of the analytical methods is determined by recovery studies done 
by spiking the blank matrix with the analyte prior to sample treatment [23]. Therefore, 
recovery was used to further evaluate the accuracy of the method in our study. To 
determine method accuracy, different concentrations of α-amanitin (low, medium and 
high) were used to spike blank liver and kidney samples (n=3). After homogenization, 
known concentrations of α-amanitin were added to three different rat liver and kidney 
preparations placed in 0.1M phosphate buffer. The final hepatic homogenate 
concentrations used to assess low, medium and high concentrations were: 0.5, 5, and 7.5 
µg.mL-1. The final renal homogenate concentrations used to assess low, medium and high 
concentrations were: 0.82, 5, and 7.5 µg.mL-1. After vortexing for 1 min, the homogenates 
were placed in perchloric acid (5% final concentration). Centrifugation followed for 10 min 
at 16000×g, the supernatants being collected and injected into the HPLC. The recoveries 
were assessed by comparing the peak area of the α-amanitin extracted from liver and 
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kidney homogenates to those of blank deproteinized liver and kidney samples spiked with 
similar concentrations and injected in the same day and HPLC conditions. 
 
2.5.4. Precision 
Precision expresses the degree of scatter between a series of measurements obtained from 
multiple sampling of the same homogeneous sample. Precision may be considered at three 
levels: repeatability, intermediate precision, and reproducibility [22]. In this work, 
method precision (intra-assay repeatability), instrument precision (injection 
repeatability), and intermediate precision were investigated. To determine method 
precision (intra-assay), different concentrations of α-amanitin (low, middle and high) 
were used by spiking blank hepatic and renal samples and performing several replicates 
(n=6). Known concentrations of α-amanitin were added to biological matrices to obtain 
final liver matrix concentrations of 0.5 [24], 5 (medium) and 7.5 µg.mL-1 (high) and kidney 
matrix concentrations of 0.82 [24], 5 (medium) and 7.5 µg.mL-1 (high). The samples were 
analyzed by the same analyst and in the same day. Intermediate precision was also studied 
in order to determine the agreement of the measurements when the method was used on 
different days. The inter-assay precision was determined by the analysis of the same 
concentrations of α-amanitin used in the intra-assay study through the injection of six 
replicates on three different days over a period of three weeks. The precision was reported 
as the relative standard deviation (% RSD). The % RSD of the proposed method was 
calculated using the following equation: %RSD =S/x where S is the standard deviation and 
x is the mean of response. 
 
2.5.5. Sensitivity 
The limit of detection (LOD) of an analytical procedure is the lowest concentration of an 
analyte in a sample, which can be detected but not necessarily quantitated as an exact 
value. The limit of quantification (LOQ) is the lowest amount of analyte in a sample that 
can be quantitatively determined with suitable precision and accuracy [22]. The LOD and 
LOQ were calculated by using standard solutions prepared in 5% perchloric acid, liver and 
kidney samples. Two different criteria were applied. Firstly, the LOD and LOQ were 
measured based on visual evaluation according to International Conference on 
Harmonization Q2 (ICH Q2) guidelines [25], by successively diluting a stock solution 
containing 1 µg.mL-1. The minimum concentrations of α-amanitin that were reliably 
detected and quantified with acceptable accuracy and precision were considered the LOD 
and LOQ of our method respectively. Additionally, the LOD and LOQ were determined 
using the calibration curve method described in the same guidelines [25]. The LOD 
(!=3.3) and LOQ (!=10) were calculated using the following equation: !=!!/S, where ! is 
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LOD or LOQ, σ is the standard deviation of the response, and ! is the slope of the 
calibration curve. 
 
2.5.6. Evaluation of the matrix effect 
The matrix effect was evaluated by comparing the calibration graphs obtained by spiking 
liver and kidney samples with known amounts of α-amanitin, and the calibration graph 
was obtained from standard α-amanitin 5% perchloric acid solutions.  
 
2.5.7. Analyte stability 
A stability study was performed in order to assess the stability of the analyte, in different 
storage and analysis conditions. α-Amanitin stability experiments’ were evaluated in 5% 
perchloric acid, and in deproteinized liver and kidney samples. Perchloric acid (5%) and 
blank liver and kidney samples were divided into four aliquots, and each aliquot was 
spiked with α-amanitin at 2.5 µg.mL-1. Final concentration of each sample was analyzed 
immediately, while the remaining samples were stored at room temperature, 4ºC, -20ºC 
and -80ºC and thereafter analyzed after 24h, 7, 14 days without any other freeze-thaw 
cycles.  
Stability was also studied after several freeze–thaw cycles. Perchloric acid (5%), blank liver 
and kidney samples were divided into two aliquots, each aliquot was spiked with α-
amanitin at 2.5 µg.mL-1 and stored at -20 ºC and -80 ºC.  These samples were analyzed 
after three freeze–thaw cycles at room temperature. All samples used for stability testing 
were tested in triplicate. A standard curve was constructed during each analytical 
evaluation and injected in the same day and conditions. 
 
2.7. Method application 
The described analytical method was applied to four different human plasma samples. 
Aliquots of these plasmas were spiking with α-amanitin to a final concentration of 5 
µg.mL-1 followed by deproteinization using perchloric acid (5% final concentration). The 
dispersion was vortexed for 1 min and then the samples were centrifugated at 16000 g for 
10 min at 4ºC. The supernatants were then collected and injected into the developed 
HPLC system. 
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2.8. Proof of concept 
2.8.1. Experimental procedures on animals 
Female Wistar rats were used as the animal model for in vivo experiments. Animals were 
obtained from vivarium of Institute of Biomedical Sciences - ICBAS, University of Porto 
and were between 120-150 g at the time of experiment. The protocol was approved by the 
local committee for the welfare of experimental animals and was performed in accordance 
with national legislation. Rats received α-amanitin (dissolved in saline solution) 
intraperitoneally at a dose of 10 mg/kg and 21.4 mg/kg for different time-points. After two 
or four hours, the animals were anesthetized with isoflurane and sacrificed by 
exsanguination, collecting the blood in the inferior vena cava into EDTA-containing tubes. 
Plasma was isolated from blood by centrifugation at 920 g for 10 min at 4 ºC. Livers and 
kidneys were removed, weighed, and homogenized in ice-cold 0.1M phosphate buffer, pH 
7.4. An aliquot of the homogenate was stored (-20°C) for posterior protein quantification. 
An aliquot of the homogenate was placed in perchloric acid (5% final concentration) for 
protein denaturation, and centrifugated at 13000 g, 4 ºC for 20 min. The supernatant was 
then collected and injected into the HPLC system. A set of eleven standards ranging from 
0.025 µg.mL-1 to 10 µg.mL-1 were prepared at the moment of use by spiking rat liver and 
kidney samples with appropriate amounts of α-amanitin. The α-amanitin levels in plasma, 
liver and kidney that had accumulated at 2 and 4 hours after administration were 
calculated. As to confirm the identity of the α-amanitin peak, samples were spiked with a 
standard solution of 5 µg.mL -1 of α-amanitin. 
 
2.8.2. Protein determination 
Protein content was determined by the method described by Lowry [24]. Bovine serum 
albumin was used as protein standard. Fifty µL of samples, standards or blank were added 
in triplicate to a 96-well microtiter plate, followed by addition 100 µL of 
extemporaneously prepared Reagent A [9.8 mL of 2% sodium carbonate ), 100 µL of 2% 
sodium potassium tartrate and 100 µL of 1% sulfate cupper II ]. After 10 min under light 
protection, 100 µL of extemporaneously prepared Reagent B (Folin–Ciocalteu reagent and 
H2O, 1:14) was added. The microtiter plate was kept protected from the light for 20 min, 
after which the absorbance was measured at 750 nm.  
 
2.9. Statistical analysis  
The linearity was evaluated by the linear regression test. Evaluation of the matrix effect 
was performed by one-way analysis of variance to determine the statistical significance 
between the slopes of the 5% perchloric acid, liver and kidney standard calibration curves. 
Statistical significance was set at p ≤ 0.05. The Tukey multiple comparisons test was used 
Study II: Quantification of alpha-amanitin in biological samples by HPLC using simultaneous UV-diode array and 
electrochemical detection  
 
 69 
once a significant p was achieved. In the evaluation of stability, different conditions were 
assessed in different time-points, thus a two-way analysis of variance was performed. If a 
statistical significant effect was found (p ≤0.05) the Tukey multiple comparisons test was 
performed. All statistical tests were performed using GraphPad Prism version 6 (San 
Diego, California, USA). 
 
3. Results  
 
3.1. Optimization of the chromatographic conditions 
In order to obtain low background noise in the biological matrices, citric acid/methanol 
was used as mobile phase, as citrate can be used in a wide range of pH (2.1 <pH <6.4) and 
provides low background noise [23,26]. It was observed that the ratio of citric acid and 
methanol (80:20) was key to a good separation and resolution of the peaks. The pH value 
also studied as it has an important role in the α-amanitin ionization: α-amanitin has an 
amine (-NH2) group (Figure 1), and therefore the pH of the mobile phase influences both 
HPLC retention and ionization efficiency. The amine group will be ionized at pH below its 
pKa (9.72)[27], in which α-amanitin behaves as an extremely polar molecule. For this 
purpose, a pH of 5.5 was chosen. Taken together, the optimization of the mobile phase and 
pH led to a optimal chromatographic resolution of the sample components and a low 
chromatographical run (22 min) (Figure 2).  
 
3.2. Sample preparation 
The main goal of the sample preparation was to create a simple method that allowed the 
elimination of interferences and good stability of the analyte, α-amanitin. Liver and kidney 
are quite complex matrices, with high level of proteins, thus, a good deproteinizing step 
was required. For this purpose, we used perchloric acid (5% final concentration). After 
centrifugation, the resulting supernatant can be directly injected into HPLC, therefore 
resulting in a simple procedure that can be performed in all laboratory settings.  
 
3.3 Method validation 
 
3.2.1 Specificity 
The specificity of the assay was examined using the described chromatographic conditions 
on section 2. Representative chromatograms recorded at 305 nm of blank 5% perchloric 
acid and a 5% perchloric acid spiked to contain 5 µg.mL-1 of α-amanitin (Figures 2A), 
blank liver sample and a liver sample spiked to contain 5 µg.mL-1 of α-amanitin (Figures 
2C) and a blank kidney sample and a kidney sample spiked to contain 5 µg.mL-1 of α-
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amanitin (Figures 2E) are shown in Figure 2. Representative electrochemical 
chromatograms of blank 5% perchloric acid and a perchloric acid spiked to contain 5 
µg.mL-1 of α-amanitin (Figures 2B), blank liver sample and a liver sample spiked to 
contain 5 µg.mL-1 of α-amanitin (Figures 2D) and a blank kidney sample and a kidney 
sample spiked to contain 5 µg.mL-1 of α-amanitin (Figures 2F) are also shown. There were 
no endogenous interfering substances in the samples. 
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Figure 2. Representative chromatograms recorded at 305nm (A) of blank 5% perchloric 
acid and 5% perchloric acid spiked to contain 5 µg.mL-1 of α-amanitin; (B) blank liver, and 
liver sample spiked to contain 5 µg.mL-1 of α-amanitin and (C) blank kidney, and kidney 
sample spiked to contain 5 µg.mL-1 of α-amanitin. Representative electrochemical 
chromatograms of (D) blank 5% perchloric acid and 5% perchloric acid spiked to contain 
5 µg.mL-1 of α-amanitin; (E) blank liver, and liver sample spiked to contain 5 µg.mL-1 of 
α-amanitin and (F) blank kidney, and kidney sample spiked to contain 5 µg.mL-1 of α-
amanitin. 
 
3.2.2. Linearity 
The linear least squares regression equation (1/c2) correlation coefficients of the standard 
curves for α-amanitin in 5% perchloric acid, and for liver and kidney extracts were all 
above 0.994. The linear equations and corresponding coefficient of determination (r2) 
values for solutions of α-amanitin in 5% perchloric acid, liver and kidney matrices are 
represented in Table 1. All the linearity, range parameters, and their related validation 
data are shown in Table 1. The regression data for calibration curve shows good linear 
relationship with r2 > 0.990. 
 
 
 
 
 
 
 
 
E F 
5 10 15 20 25
-0.0004
0.0011
Time (min)
A
b
s
o
rb
a
n
c
e
 (
A
U
)
Kidney spiked with 5µg/mL 
α-amanitin
Blank lkidney  
5 10 15 20 25
-5
0
5
Time (min)
C
u
rr
e
n
t 
(m
V
)
Kidney spiked with 
5µg/mL α-amanitin
Blank lkidney  
Study II: Quantification of alpha-amanitin in biological samples by HPLC using simultaneous UV-diode array and 
electrochemical detection  
 
 72 
Table 1. Linearity data of α-amanitin analysis in 5% perchloric acid and tissue samples. 
 
 
3.2.3. Recovery 
Recovery from the spiked samples was determined as described in section 2.5.3. Results 
show an overall mean percent recovery of above 96 % (Table 2). 
 
3.2.4. Precision 
The repeatability and the intermediate precision (intra- and inter-assay precision) were 
calculated as the RSD of replicate samples at three concentration levels of α-amanitin, as 
described in section 2.5.4. 
The intra- and inter-assay precision for detection of α-amanitin in 5% perchloric acid, and 
rat liver and kidney matrices are presented in Table 2. As shown in Table 2, intra-assay 
precision for 5% perchloric acid matrix ranged from 1.15% to 2.75% (DAD) and 1.64% to 
2.64% [25] whereas the inter-assay precision ranged from 5.57% and 6.10% (DAD) and 
3.91% to 10.70% [25]. Intra-assay precision for liver matrix ranged from 0.61% to 8.65% 
(DAD) and 0.55% to 2.27% [25] whereas the inter-assay precision ranged from 3.54% to 
15.30% (DAD) and 6.36% to 9.72% [25]. Finally, intra-assay precision for kidney matrix 
ranged from 1.73% to 8.16% (DAD) and 2.43% to 3.87% [25] whereas the inter-assay 
precision ranged from 2.63% to 11.59% (DAD) and 6.64% to 10.94% [25]. Acceptable RSD 
values (lower than 20%) were obtained for all concentration and for both detectors (DAD 
and EC), thus the developed method was sufficiently precise.  
 
Linear 
equation 
Slope (±SD) 
Intercept 
(±SD) 
Determination 
coeficiente (r2) 
Linear 
range 
(µg.mL-1) 
305 nm      
      
Perchloric acid 5% 
 
 
y = 9677x– 910.8 9677 ± 121.1 -910.8 ± 556.9 0.9964 0.45-10 
Liver 
 
 
 
y = 9279x+ 432.2 9279 ± 87.21 432.2 ± 381.8 0.9983 0.33-10 
Kidney  y = 6858x + 2404 6858 ± 54.21 2404 ± 256.3 0.9990 0.5-10 
      
Electrochemical 
detection 
 
     
      
Perchloric acid 5% 
 
y = 54113x - 4772 53759 ± 931.4 -4772 ± 3814 0.9935 0.19-10 
Liver 
 
 
 
y = 54260x + 
77.95 
54260 ± 
674.8 
77.95 ± 2763 0.9966 0.21-10 
Kidney y = 42409x + 
951.0 
42409 ± 
426.4 
951 ± 1646 0.9975  0.11-10 
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Table 2. Precision and accuracy results 
  
α-amanitin (µg.mL-1) Intra-assay 
precision 
RSDa (%) (n=6) 
Inter-assay 
precision 
RSDa (%) (n=18) 
Recovery (%) RSD (%)  
(n=3) 
305 nm 
 
    
     
Perchloric acid 5%     
     
0.84 
 
2.75 6.10   
5 
 
1.15 5.57   
7.5 1.65 5.66   
     
     
Liver     
     
0.5 
 
8.65 15.30 99.99 2.49 
5 
 
3.97 4.27 98.48 2.00 
7.5 0.61 3.54 99.89 0.21 
     
     
Kidney     
     
0.82 
 
8.16 11.59 101.06 2.13 
5 
 
2.18 6.30 99.42 1.05 
7.5 1.73 2.63 99.69 0.90 
     
Electrochemical 
detection 
  
    
     
Perchloric acid 5%     
     
0.84 
 
2.13 3.91   
5 
 
2.64 5.22   
7.5 1.64 10.70   
     
     
Liver     
     
0.5 
 
2.27 7.49 99.87 3.41 
5 
 
1.65 6.36 99.80 1.03 
7.5 0.55 9.72 96.87 3.21 
     
     
Kidney     
     
0.82 
 
3.87 10.94 99.49 1.99 
5 
 
3.60 8.99 98.19 2.16 
7.5 2.43 6.64 101.45 2.62 
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3.2.5. Sensitivity  
LOD and LOQ were evaluated and the obtained data are shown in Table 3. Based on visual 
evaluation, the LOD and LOQ values for 5% perchloric acid were 0.050 and 0.250 µg.mL-1 
(DAD), and 0.025 and 0.025 µg.mL-1 [25], respectively.  For liver matrix, the LOD and 
LOQ values were 0.050 and 0.250 µg.mL-1 (DAD) and 0.025 and 0.025 µg.mL-1 [25], 
respectively. For kidney matrix the LOD and LOQ values were 0.125 and 0.250 µg.mL-1 
(DAD) and 0.05 and 0.100 µg.mL-1 [25], respectively. Based on the calibration curve, for 
5% perchloric acid matrix, the LOD and LOQ values were 0.150 and 0.450 µg.mL-1 (DAD) 
and 0.060 and 0.190µg.mL-1 [25], respectively; for liver matrix the LOD and LOQ values 
were 0.100 and 0.330 µg.mL-1 (DAD) and 0.070 and 0.210 µg.mL-1 [25], respectively. 
Lastly, for kidney matrix, the LOD and LOQ values were 0.160 and 0.500 µg.mL-1 (DAD) 
and 0.040 and 0.110 µg.mL-1 [25], respectively. 
 
Table 3. LOD and LOQ values (expressed as µg.mL-1) computed according to different 
criteria   
  
 
 
Perchloric acid 
5% 
Liver Kidney 
305nm    
LOD 
 
   
Calibration Curve 0.150 0.110 0.160 
Based on visual 
evaluation 
0.050 0.050 0.125 
    
LOQ 
 
   
Calibration Curve 0.450 0.330 0.500 
Based on visual 
evaluation 
0.250 0.250 0.250 
    
Electrochemical    
LOD 
 
   
Calibration Curve 0.060 0.070 0.040 
Based on visual 
evaluation 
0.025 0.025 0.050 
    
LOQ 
 
   
Calibration Curve 0.190 0.210 0.100 
Based on visual 
evaluation 
0.025 0.025 0.100 
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3.2.6. Matrix effect 
The matrix effect was evaluated by comparing the slopes of the calibration curves obtained 
when processing standard 5% perchloric acid solutions and deproteinized liver and kidney 
samples spiked with standards in the same concentrations. No significant difference was 
found by comparing 5% perchloric acid and liver. On the other hand, there is a statistically 
significant difference (p < 0.0001) between the 5% perchloric acid standards and the α-
amanitin renal spiked samples. 
 
3.2.7. Stability 
Stability of α-amanitin was investigated using 5% perchloric acid, liver and kidney 
matrices. α-Amanitin in all matrices was stable at room temperature and 4ºC over a 
period of 24h, with no significant degradation observed (Figure 3). On the other hand, in 
samples kept at room temperature, a degradation of α-amanitin was observed over the 
period of 14 days. Significant degradation was already observed at 7 days being more 
pronounced at 14 days. Values of α-amanitin declined to non-detectable concentrations at 
the 7th day at room temperature.  In contrast, a slow degradation was observed in the case 
of α-amanitin samples stored at 4 ºC. However, a significant degradation was observed at 
7 days being more pronounced at 14 days. Excellent stability was obtained either at -20 
and -80 ºC as it can be seen in Figure 3. No significant degradation of α-amanitin in 5% 
perchloric acid, liver and kidney matrices was detected after storing the samples 14 days at 
-20 and -80 ◦ C. Moreover three freeze-thaw cycles did not cause significant degradation 
in 5% perchloric acid and in both biological matrices analyzed. Overall the results indicate 
that α-amanitin in tissue samples is stable during storage, extraction and chromatographic 
analysis. Moreover, we concluded that the samples can be safely stored at -20 ºC and can 
be subjected to at least three cycles of freeze-thaw without significant degradation of the 
analyte. 
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Figure 3. Stability study of α-amanitin on several matrices, temperatures, and time-
points. Values of α-amanitin are represented as mean ± standard deviation (SD) of three  
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independent samples. Each matrix was analyzed by diode array (DAD) and 
electrochemical [25] after storage at different temperatures [room temperature (RT), 4ºC, 
-20ºC and, -80ºC] over 1, 7 and 14 days. Stability of α-amanitin was evaluated in (A,B) 
5% perchloric acid, (C,D) liver and (E,F) kidney matrices. Statistical analysis was 
performed using two-way ANOVA. If a statistical significance was achieved (p <0.05), the 
Tukey’s multiple comparisons test was performed. Significant differences (two-way 
ANOVA, followed by the Turkey’s multiple comparisons test post-hoc test): ****p < 0.0001 
vs. RT, time=0min; ####p< 0.0001 vs. 4ºC, time=0; $$$$p< 0.0001 vs. 4ºC, time=7 days; 
$$$p< 0.001 vs. 4ºC, time=7 days; $$p < 0.01 vs. 4ºC, time=7 days; &&&&p< 0.0001 4ºC vs -
80ºC, time= 7 days; &&&&p< 0.0001 4ºC vs -20ºC, time=7 days;  &&p< 0.01 4ºC vs -20ºC, 
time=7 days; ++++p< 0.0001 4ºC vs -80ºC, time= 14 days; ++++p< 0.0001 4ºC vs -20ºC, 
time=14 days. 
 
3.6. Method application  
The established HPLC method was applied to human plasma. Figure 4 shows an EC 
chromatogram (A) and a chromatogram recorded at 305 nm (B) of blank plasma and 
plasma spiked to contain 5 µg.mL-1 of α-amanitin. There were no endogenous interfering 
substances in the samples. 
 
 
 
 
 
A 
5 10 15 20 25
-70
-65
-60
-55
Time (min)
C
ur
re
nt
 (m
V)
Plasma spiked with 5µg/mL 
α-amanitin
Blank plasma  
Study II: Quantification of alpha-amanitin in biological samples by HPLC using simultaneous UV-diode array and 
electrochemical detection  
 
 78 
 
 
Figure 4. Representative EC chromatograms of (A) blank plasma and plasma spiked to 
contain 5 µg.mL-1 of α-amanitin. Representative chromatograms recorded at 305 nm of 
(B) blank plasma and plasma spiked to contain 5 µg.mL-1 of α-amanitin. 
 
3.7. α-Amanitin quantification in kidney, liver and plasma after administration of the toxin 
to rats 
The concentrations of α-amanitin in rat plasma and tissues were determined after 
administration of a single intraperitoneal (10 or 21.4 mg/kg) dose to Wistar rats. 
Representative EC chromatogram and chromatogram recorded at 305nm of kidney and 
their respective spiking with α-amanitin are show in Figure 5. Table 4 shows the values 
obtained by processing the plasma and tissues as indicated in section 2.4 and are 
expressed as ng of α-amanitin per mg of protein. The highest overall concentrations in the 
tissues examined were in the following order: kidneys> liver. No detectable values were 
found in plasma. Peak identity was confirmed by spiking samples with α-amanitin. 
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Figure 5. (A) Representative electrochemical chromatogram of rat kidney after an 
intraperitoneal administration of 21.4 mg. kg-1 of α-amanitin that was sacrificed 4 hours 
later. The same sample was spiked with α-amanitin. (B) Representative chromatogram 
recorded at 305 nm of rat kidney after an intraperitoneal administration of 21.4 mg. kg-1 of 
α-amanitin that was sacrificed 2 hours later. The same sample was spiked with α-amanitin.  
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Table 4. Quantification of α-amanitin in real samples (plasma, liver, and kidney) from 
rats injected with α-amanitin 
 
 
 
4. Discussion 
Several methods are available in the literature for the analysis and quantification of α-
amanitin and in different matrices mainly mushrooms [11-15], plasma [19,28] and urine 
[21] due to the toxicological importance of this amatoxin. Research studies have been 
focused on the detection of α-amanitin in body fluids for an early diagnosis of 
intoxications as to allow the rapid application of therapy [16,19,21]. However, presently 
the overall toxic mechanisms of α-amanitin remain unclear, hindering the development of 
new and more effective antidotes, and relevant forensic studies on α-amanitin are scarce. 
Improved knowledge of the toxicity mechanisms and the kinetics of this toxin will help the 
development of more efficient antidotes for A. phalloides poisoning. Moreover, recent 
findings suggest that α-amanitin is emerging as an attractive new potent anticancer drug 
[10]. Therefore the efficacy of α-amanitin as an anticancer agent must be scientifically 
validated, through animal experiments that include pre-clinical pharmacokinetic and 
pharmacodynamic studies. However, the lack of analytical methods to quantify α-amanitin 
in body compartments hinders the quantification of this drug in tissues. To 
comprehensively characterize the mechanisms of toxicity, pre-clinical pharmacokinetics 
and efficacy of α-amanitin as anticancer agent, a highly sensitive, accurate, and 
reproducible quantification assay is required. To date there are no published HPLC 
 Plasma (ng.mg-1) Liver (ng.mg-1) Kidney  (ng.mg -1) 
305nm    
Rat (10 mg.kg-1 4h) N.D. 0.97 1.40 
Rat (21.4 mg.kg-1 2h) N.D. N.D. 3.16 
Rat (21.4 mg.kg-1 4h) N.D. 0.71 26.58 
Electrochemical    
Rat (10mg.kg-1 4h) N.D. 1.00 1.66 
Rat (21.4 mg.kg-1 2h) N.D. N.D. 4.00 
Rat (21.4 mg.kg-1 4h) N.D. 0.80 33.74 
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methodologies equiped with EC detector for the analysis of α-amanitin in biological 
tissues. The presence of a 6-hydroxytryptophan residue in the molecule of α-amanitin 
suggested the possibility of detecting this compound through an EC detector operating in 
an oxidative mode [21,28]. Herein, an isocratic HPLC method using DAD and EC 
detectors was developed and validated for the quantitative measurement of α-amanitin in 
rat liver and kidney tissues. The extraction of α-amanitin from the tissue homogenates was 
achieved by a deproteinization step using 5% perchloric acid followed by centrifugation, 
thus resulting in a simple, convenient and rapid separation of the analyte. Previously 
described extraction procedures of α-amanitin in liver samples using methylene chloride 
and acetonitrile are time-consuming use organic solvents and the resulting 
chromatograms are quite complex showing several interferences [19]. Herein, our 
procedure was also efficient with plasma samples, which indicates that this simple 
deproteinization step can be applied to other biological matrices. Deproteinization using 
5% perchloric acid can be performed on any biological sample and can be routinely 
applied in many laboratories all over the world. Moreover, clean chromatograms were 
obtained, thus improving the analysis. In our method, the buffer of the mobile phase was 
also optimized. The buffer capacity, the type of detectors used (DAD and EC), the stability 
of the solution, the solubility and the column were taken into account. Defendenti et al 
(1998) developed and validated a HPLC method with EC detection to measure α-amanitin 
in urine. For this purpose the authors used a mobile phase composed of phosphate buffer 
and acetonitrile. One of the major problems with phosphate buffers is the precipitation of 
phosphates in the HPLC system. As an alternative, we used citrate as a buffer of the 
mobile phase. Citrate can be used in a wide range of pH (2.1 <pH <6.4) and provides low 
background noise, which is mainly important electrochemical analysis [23,26]. The ratio 
of citrate:methanol (80:20) and the pH 5.5 were key to obtain good separation and 
resolution of the α-amanitin peak. Moreover, the short run time of 22 min enables a large 
number of samples to be analyzed in a short period of time. Furthermore, the method was 
highly specific since liver, kidney and plasma samples analyzed did not exhibited 
chromatographic peaks corresponding to endogenous compounds co-eluting with the 
target analyte. Calibration curves over the entire ranges of concentrations were adequately 
described by 1/concentration weighted quadratic regression of the peak–area ratios of α-
amanitin, with regression coefficient r2 always greater than 0.994 in all analytical runs. 
This shows that our method was linear and a broad range of concentrations can be used. 
Extraction recovery at a concentrations ranging from 0.5-7.5 µg.mL-1, results in an overall 
mean percent recovery of above 96 %. This recovery gives a great deal of confidence as this 
method can be applied into intoxicated humans, in terms of forensic analysis as well as to 
post-mortem tissues and confirm the etiology of symptoms. 
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Considering that intra-assay variations (expressed as RSD), higher variability was found 
as the analyte levels were lower (Table 2) whereas inter-assay variations (expressed as 
RSD), higher variability was found in the higher analyte levels (Table 2). Results show an 
overall RSD of 15.30%, making the developed method precise. The LOD and LOQ values 
were obtained using two different criteria as to make it comparable to those found in the 
literature (Table 3) [25]. The values based on visual evaluation are slightly lower than the 
LOD and LOQ calculated from the linear regression parameters (Table 3). In previous 
reports, the LOD was about 10 ng.ml-1 (corresponding to a signal-to-noise ratio of 25) for 
urine by HPLC–UV [16], 2 ng.mL-1 (corresponding to a signal-to-noise ratio of 2) for 
plasma by HPLC-EC [28], although most of these methods are specific for a certain 
matrix. In other matrices our LOD values are comparable with the results by the above 
methods. To the best of our knowledge, there is only one published study using liver tissue 
to detect α-amanitin and was made using LC-MS/MS/MS [19]. In that study, liver was 
prepared by homogenization with aqueous acetonitrile and subsequent removal of 
acetonitrile using methylene chloride. The aqueous phase was then extracted using solid 
phase extraction cartridges and α-amanitin was detected with a LOD of about 0.50 ng.g-1. 
The LC-MS/MS/MS method offered the highest specificity and sensitivity, however 
HPLC–MS instruments are not available in many laboratories. The concentration of α-
amanitin in liver and kidney tissues poisoning cases analyzed by HPLC-UV show high 
variance (0-1719 ng.g-1) [29], which indicates that our method is sensitive enough for the 
quantification of α-amanitin in liver and kidney from suspected human intoxications.  
The comparison between the two detectors (DAD and EC) shows that the LOD and LOQ 
for α-amanitin could be improved through the use of an EC detector. Nevertheless, HPLC-
EC instruments are not available in many laboratories. For that reason, validation using 
UV detector was made since it is a more common instrument all over the world. Moreover 
does not require a long period of stabilization as it happens with EC detector. 
Evaluation of the matrix effect shows that there is a difference between the HPLC 
response for α-amanitin in 5% perchloric acid and the response for the α-amanitin in 
kidney matrix. This is probably due to residual components of the kidney matrix, thus 
demonstrating the importance of the study on equivalent matrices. On the other hand, no 
statistical difference was found between 5% perchloric acid and liver matrix.  
The results of all stability tests indicated that α-amanitin in 5% perchloric acid and tissue 
samples was stable during sample storage, extraction and chromatographic analysis. 
Evaluation of more than one freeze–thaw cycle was performed in case that samples 
require multiple analysis. Three freeze thaw cycles also did not cause any significant 
degradation in all matrices when stored in acidic matrix. The tissue collection can be done 
after acidification since our data show that α-amanitin was stable at room temperature 
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and 4 ºC over a 24 hour period. No liquid nitrogen or urgent freezing seems to be 
required, making this method very practical and reliable in all laboratories and clinical 
settings. 
As to prove the applicability of our method we performed an in vivo study with different α-
amanitin doses and sacrifice times. After the intraperitoneal administration of a single 
dose of α-amanitin (10 or 21.4 mg/kg) to Wistar rats, the validated analytical method was 
successfully applied. In rats, there are no α-amanitin pharmacokinetic data available at 
this point. Therefore based on in vivo studies [8,30], in murine models we selected the 2 
and 4 hours post-administration periods to perform sample collection. The toxicokinetic 
of α-amanitin has been studied in intoxicated humans and dogs and shows a short half-life 
(is totally eliminated from the blood after 41.02 minutes), being widely distributed to 
target tissues (liver and kidney). Our method was able to detect α-amanitin in several 
samples. The short half-time of α-amanitin was confirmed, as no analyte was found in 
plasma. Our results show higher levels of total α-amanitin in kidney than in liver. These 
differences may be explained by the fact that the kidney serves as an elimination organ of 
α-amanitin. 
Of interest, this method was also successfully applied to quantify α-amanitin in human 
plasma since there were no endogenous substances in the samples co-eluting with the 
peak of interest. Considering this, we suggest that this method can be used for early 
diagnosis of A. phalloides poisoning, tissues analysis and other pharmacokinetic studies. 
In fact, this method is a suitable tool to support in vivo toxicokinetic studies designed to 
elucidate the mechanisms of toxicity of α-amanitin, being able to assist in the development 
of novel and potent antidotes for amatoxin’s poisoning. 
 
5. Conclusion 
A selective and sensitive HPLC method using DAD and EC detectors has been developed 
and validated for the quantitative measurement of α-amanitin in 5% perchloric acid, rat 
liver and kidney. The extraction of α-amanitin from tissue homogenates was achieved by a 
simple deproteinization step with a high recovery of the analyte. Validation was carried 
out by the evaluation of the most relevant parameters for checking the quality of the 
method. The method proved to be linear in the concentration range studied as well as 
selective, accurate, precise and sensitive. All stability tests indicated that α-amanitin was 
stable during sample storage, extraction, and chromatographic analysis. Moreover this 
method was successfully applied to real samples, after α-amanitin administration to 
Wistar rats. Taken together, these characteristics combined with a short chromatographic 
run time of 22 min, allows this assay to be easily applied for the determination of α-
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amanitin in liver and kidney and other biological samples. This method provides a 
convenient tool for the future toxicological and clinical studies involving α-amanitin. 
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Table legends 
 
Table 1. Calibration data resulting from linear least squares regression analysis for the 
determination of α-amanitin in perchloric acid 5% and tissue samples. Slope of calibration curves, 
intercept, and the determination coefficients were calculated. 
 
Table 2. Method precision was evaluated by the intra-assay repeatability and intermediate 
precision (inter-assay). To determine intra-assay and inter-assay precision, different 
concentrations of α-amanitin (low, middle and high) were used  by spiking blank liver and kidney 
samples and performing several replicates (n=6). The precision was reported as the relative 
standard deviation (% RSD). Recovery was used to further evaluate the accuracy of the method. 
 
Table 3. Limits of detection (LOD) and quantification (LOQ) of α-amanitin in perchloric acid 5%, 
liver and kidney samples based on two criteria. The two criteria adopted were based on visual 
evaluation and on the standard deviation of the response and slope of the calibration curve. 
 
Table 4. Quantification of α-amanitin in real samples (plasma, liver, and kidney) obtained from 
Wistar rats exposed to α-amanitin. Two different concentrations of α-amanitin (10 mg/kg and 21.4 
mg/kg) and two different time points (2 and 4 hours) were used. 
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Abstract 
Mushrooms poisoning occurs when ingestion of wild mushrooms containing toxins takes 
place putting the consumers at life-threatening risk. In the present case report, an unusual 
multiple poisoning with isoxazoles- and amatoxins-containing mushrooms in a context of 
altered mental state and poorly controlled hypertension is presented. A 68-year-old 
female presented to São João hospital (Portugal) with complaints of extreme dizziness, 
hallucinations, vertigo and imbalance, 3 hour after consuming a stew of wild mushrooms. 
The first observations revealed altered mental state and elevated blood pressure. The 
examination of cooked mushroom fragments allowed a preliminary identification of A. 
pantherina. Gas chromatography–mass spectrometry (GC-MS) showed the presence of 
muscimol in urine. Moreover, through high-performance liquid chromatography-
ultraviolet detection (HPLC-UV) analysis of the gastric juice it was revealed the presence 
of α-amanitin, indicating that amatoxins-containing mushrooms were also included in the 
stew. After 4 days of supportive treatment, activated charcoal, silybin and N-
acetylcysteine, the patient recovered being discharged 10 days post-ingestion with no 
organ complications. The prompt and appropriate therapy protocol for life-threatening 
amatoxins toxicity probably saved the patient’s life as oral absorption was decreased and 
also supportive care was immediately started.  
 
Keywords: Wild mushrooms; Amanita pantherina; Amanita phalloides; isoxazoles, 
amatoxins, intoxication 
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Abbreviations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CNS Central Nervous System 
DAD Diode-array 
EC Electrochemical coulometric detection  
DNA Deoxyribonucleic acid 
GC-MS 
HPLC 
Gas chromatography-mass spectrometry 
High Performance Liquid Chromatography 
RNA Ribonucleic acid 
RNAP II 
TIC 
RNA polymerase II  
Total ion chromatogram 
UV Ultraviolet 
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1. Introduction 
An altered mental state is a very common occurence in the emergency room and the 
diagnosis/treatment is highly challenging (Xiao et al., 2012). In fact, two or more 
etiologies may coexist, including pathological disorders, (e.g. hypoglycemia; cranial 
trauma; alcohol; infection; psychoses; stroke; hypertensive, metabolic, hepatic, or uremic 
encephalopathies), consumption of psycho-active substances; and others (Schwartz et al., 
1992). Among these, possible accidental or intentional exposure to psycho-active 
substances present in some wild mushrooms species should not be neglected (Tsujikawa 
et al.). In fact, consumption of wild mushrooms has increased substantially in the last 
decades (Thimmel and Kluthe, 1998). Mushrooms are appreciated worldwide as a 
delicacy, due to their exquisite palatability and texture. Moreover, their chemical, 
nutritional, and functional properties make them exceptional in the human diet (Cheung, 
2010). Despite these benefits, the ingestion of wild mushrooms containing toxins 
frequently occurs, which can put the consumers at life-threatening risk. Mushroom 
poisoning is usually accidental, rarely suicidal, and frequently occurs as a result of 
misidentification of a toxic mushroom as an edible species (Barbato, 1993; Cochran, 
1987). The severity of mushroom poisoning depends on the species of mushroom, the 
amount of mushroom consumed, the prompt therapy and the health status of the 
individual (Broussard et al., 2001; Durukan et al., 2007). The main toxins associated to 
mushroom poisoning are: cyclopeptides, orellanine, gyromitrin, isoxazoles, muscarine, 
psilocybin and gastrointestinal specific irritants (Koppel, 1993). Of the mentioned toxins, 
the most dangerous and potentially fatal poisonings are caused by cyclopeptides (mainly 
amatoxins) (Karlson-Stiber and Persson, 2003), while orellanine, isoxazoles, muscarine, 
psilocybin, and gyromitrin can cause a serious illness but are rarely fatal (Koppel, 1993). 
Amatoxins are natural toxic bicyclic octapeptides present in mushroom species from three 
different genera: Amanita, Galerina, and Lepiota (Vetter, 1998). The species A. phalloides 
is involved in the majority of human fatal cases of mushroom poisoning (Karlson-Stiber 
and Persson, 2003). Its main toxin is α-amanitin, which causes hepatic and kidney 
damage, often fatal (Faulstich, 1979; Klein et al., 1989; Santi et al., 2012). The mechanisms 
of toxicity of α-amanitin are complex, but its most known mechanism is the inhibition of 
RNA polymerase II (RNAP II) (Vetter, 1998). 
Muscimol and ibotenic acid belong to the family of toxins known as isoxazoles. Amanita 
pantherina and A. muscaria are the most commonly known isoxazoles-containing 
mushrooms (Diaz, 2005). Data on the incidence of intoxication by isoxazoles-containing 
mushrooms are scarce. The severity of the symptoms is mild, thus intoxicated people often 
do not seek medical attention. In Portugal, only a few cases of isoxazoles-containing 
mushrooms intoxications have been reported (Morgado et al., 2006). The American 
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Association of Poison Control Centers annual report of 2012 presents 36 cases of 
isoxazoles-containing mushroom intoxications in the United States of America, with no 
death cases associated (Mowry et al., 2013). Ibotenic acid is an agonist of glutamic acid 
receptors; its decarboxylated derivative, muscimol, is an agonist at gamma-aminobutyric 
acid (GABA) receptors. The central effects of these toxins are generally attributed to these 
pharmacological properties (Krogsgaard-Larsen et al., 1980; Michelot and Melendez-
Howell, 2003; Snodgrass, 1978) and include hallucinations, confusion, dizziness, visual 
and auditory aesthesia (hypersensitivity), space distortion, and unawareness of time 
(Michelot and Melendez-Howell, 2003).  
In this work, we describe a case of a 68-years-old patient with poorly controlled 
hypertension and altered mental state after eating wild mushrooms, and the respective 
clinical management of the case. The suspicion of a hypertensive crisis and isoxazoles- and 
amatoxins-containing mushrooms poisoning were taken into consideration in the medical 
decisions. 
 
2. Case report 
A 68-years-old female with hypertension was admitted to the emergency room of São João 
Hospital (Porto, Portugal) after ingestion of mushrooms. After specific query, her son 
reported that the patient had ingested several wild mushrooms that where collected in a 
public yard by the patient. She stewed the mushrooms, and, immediately after ingestion,  
she started experiencing dizziness, vertigo and imbalance. She self-induced vomiting and 
had no symptoms of nausea, spontaneous vomiting or diarrhea. On admission, 3 hours 
post-ingestion, the examination revealed an altered mental status including confusion and 
repetitive speech, only responsive to severe painful stimuli, and mydriatic pupils. These 
symptoms resolved in a few hours after admission. Initial emergency room vital signs 
were: blood pressure 230/108 mmHg, normal pulse and respiratory rate, temperature 
96.8 degrees Fahrenheit, and oxygen saturation of 97.5 percent using an oxygen mask at 
10L/min. Physical exam demonstrated dry skin and dry mucous membranes. Additionally, 
she had clear breath and heart sounds, no abdominal tenderness, and no gross focal 
neurologic deficits. A brain computed tomography was immediately performed revealing 
no abnormalities. Additionally, electrocardiogram, funduscopy and urinary sediment were 
analyzed demonstrating no evidence of lesions. Her serial hematological parameters, 
coagulation profile, liver and renal function tests were normal and are in Table 1.  
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Table 1. Clinical parameters over three days post-ingestion 
a Clinical parameters three hours post-ingestion 
b Reference values adopted by São João Hospital  
  
Parameters 1st daya 3rd day Reference valuesb 
Hematological parameters     
White blood cell count ( x 109/L) 6.69  6.98 4-11 
Mean Corpuscular Volume (fL) 88.4 89.0 87-103 
Mean Corpuscular Hemoglobin (pg) 30.8 31.2 27-35 
Mean Corpuscular Hemoglobin Concentration 
(g/dL) 
34.8 35.1 28-36 
Platelet Count (x 109/L) 212 187 150-400 
Red Cell Distribution (%) 12.5 13.0 11-16  
(Width-coefficient of 
variation %) 
Red Cell Distribution (fL) 40.0 42.1 37-54  
( Width-standard 
deviation) 
Red Blood Cell Count (x1012/L)  4.84 4.29 12.0-16.0 
Hemoglobin (g/dL) 14.9 13.4 12.0-16.0 
Blood Chemistry Tests    
Lactate dehydrogenase (U/L) 273 182 135-225 
Albumin (g/L)  34.2 38-51 
Alanine aminotransferase (U/L) 38.0 24.0 10-31 
Aspartate aminotransferase (U/L) 31.0 34.2 10-31 
Alkaline phosphatase (U/L) 102 75.0 30-120 
Total bilirubin (mg/dL) 1.06 2.00 < 1.2 
Conjugated bilirubin (mg/dL) 0.50 0.52 <0.4 
Gamma-glutamyl transpeptidase (U/L) 74.0 53.0 7-32 
Creatine phosphokinase (U/L) 193 88.0 10-149 
Urea (mg/dL) 36.0 21.0 10-50 
Creatinine (mg/dL) 0.74 0.55 0.51-0.95 
Ammonia (µmol/L) 30.0 45.0  
Amylase (U/L) 38.0  22-80 
Lipase (U/L) 22.0 36.0 7-60 
Activated Partial Thromboplastin Time (s) 30.1 30.4 24.5-36.5 
Prothrombin Time (s) 12.5 11.5 9.5-13.8 
Fibrinogen (mg/dL) 506 557 190-400 
C-reactive protein (mg/L) 8.80 20.5 <3.0 
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As a standard procedure for intoxications with wild mushrooms, until species 
identification by laboratory, the general detoxification treatment with oral-activated 
charcoal was immediately instituted on admission, and it was followed by the specific 
treatment for A. phalloides poisoning, through the administration of silybin and N-
acetylcysteine. N-acetylcysteine and silybin were administered in a loading dose of 10.5 g 
(150 mg/kg) and 350 mg (5 mg/kg), respectively, followed by perfusion. The perfusion of 
silybin was maintained at a dosage of 58 mg/h (20 mg/kg/d) and N-acetylcysteine at 875 
mg/h (12.5 mg/kg/h) for the following 4 hours. Labetalol perfusion was also administered 
for blood pressure control. The patient was then transferred to intermediate care unit to 
continue with the treatment with continuous surveillance. A total of 300 mg/kg of N-
acetylcysteine was administered in the first 21 hours after admission. The perfusion of 
activated charcoal and silybin were kept until the fourth day in which day a normal 
coagulation profile and liver function were observed). Serum aminotransferases and 
coagulation profile were normal during all the time that surveillance was maintained, 
although an elevation of total bilirubin (twofold the normal value) was observed at day 2 
(conjugated bilirubin was normal at that time). Two days after, total bilirubin level started 
to decline, and it normalized within one week. After labetalol perfusion, the blood 
pressure control was achieved by administration of sublingual captopril until the fourth 
day.  
The patient kept some of the stew after ingestion, which was then provided for analysis. 
The identification of the mushrooms was firstly performey 2 experts based on the 
macroscopic features of the fruiting body (Courtecuisse, 1999; Courtecuisse and Duhem, 
2005). In the stewed mushrooms, the color of some of the cap fragments resembled A. 
pantherina, namely brown with whitish-brown warts (Figure 1). The gills were free and 
whitish-brown color and the stipe was cylindrical and seemed to be white.  
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Figure 1. Macroscopic identification of Amanita pantherina found in the stew, showing a 
mushroom fragment (left), with its characteristic features. The cap fragments are brown 
with whitish-brown warts (white arrow). The stipe is cylindrical.  
 
Therefore, to confirm the intoxication by A. pantherina, we looked for the presence of 
muscimol in the urine. Gas chromatography–mass spectrometry (GC-MS) analysis 
confirmed the presence of muscimol (Figure 2) in the patient’s urine. These data allowed 
to identify the putative responsible for the patient’s hallucinogenic effects, since she 
possibly ingested ibotenic acid and muscimol-containing mushrooms.  
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Figure 2. Zoomed views for the part of GC-MS total ion chromatograms corresponding to 
peak of muscimol after the derivatization. A) muscimol standard, B) blank urine, and C) 
patient’s urine. Mass spectrum of D) derivatized muscimol standard and E) patient’s 
urine. The molecular ion m/z 331 and chemical formula of derivatized muscimol are 
represented. 
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As a result of the severity of possible A. phalloides intoxication, the presence of the main 
toxin of this mushroom was investigated in the biological fluids (urine and gastric juice) 
and in the mushrooms collected. α-Amanitin was identified in the gastric fluid by high-
performance liquid chromatography with ultraviolet detection (Figure 3), as previously 
described (Garcia et al., 2014). The α-amanitin levels in the gastric fluid were 1.12 µg/mL, 
whereas no detectable levels of α-amanitin were found in the urine [the methods limit of 
detection is 0.05 µg/mL (Garcia et al., 2014)]. 
In the fifth day after mushroom ingestion, the patient was discharged from the 
intermediate care and transferred to the ward without evidence of liver abnormalities and 
with better blood pressure control. Ten days post-ingestion the patient was discharged 
home with no organ complications. 
 
 
 
Figure 3. Chromatogram of the patient’s gastric juice recorded at 305 nm superposed to 
the chromatograms of the same sample spiked with α-amanitin and standard solution of 
20 µg/mL of α-amanitin. 
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3. Discussion 
Altered mental status comprises clinical symptoms including cognitive disorders, 
attention disorders, arousal disorders, and decreased level of consciousness (Xiao et al., 
2012). It is a very common situation in the emergency room, and has many possible causes 
including pathological disorders and consumption of psycho-actives substances (Xiao et 
al., 2012). In the case presented herein, the high blood pressure in association with altered 
mental status lead to suspicion of a hypertensive crisis case. However, the clinical 
evaluation showed no lesion of target organs (normal brain computed tomography, 
electrocardiogram, funduscopy and urinary sediment), thus that hypothesis was 
discarded. At the same time, the history of wild mushroom consumption implied 
measures to counteract its putative life-threatening toxicity. Worldwide most cases of 
intoxications by wild mushrooms have been attributed to amatoxin-containing 
mushrooms (Brandão et al., 2011; Mowry et al., 2013), with only a very small percentage 
of cases attributed to ibotenic acid and muscimol-containing mushrooms (Morgado et al., 
2006; Mowry et al., 2013).  
In the case presented herein, the features of the clinical presentation are consistent with 
the diagnosis of intoxication by isoxazoles-containing mushrooms. Positive identification 
of A. pantherina mushroom, found in the patient’s home, was accomplished by 2 experts. 
This species contains the toxins ibotenic acid and muscimol (Michelot and Melendez-
Howell, 2003). Ibotenic acid is metabolized to muscimol (Michelot and Melendez-Howell, 
2003) and the presence of muscimol was confirmed in the patient´s urine sample. 
Muscimol and ibotenic acid cross the blood-brain barrier exerting their effects primarily 
on the Central Nervous System (CNS), where they act as neurotransmitter agonists 
(Michelot and Melendez-Howell, 2003). Ibotenic acid mimics the excitatory amino acid 
glutamic acid and acts on N-methyl-D-aspartic acid (NMDA) receptors. Muscimol is a 
potent agonist of GABAA receptors and also exerts CNS effects (Michelot and Melendez-
Howell, 2003). Nausea, hallucinations, delirium, and sleepiness are often described after 
isoxazoles-containing mushrooms ingestion (Diaz, 2005; Satora et al., 2006). The toxic 
threshold estimated for ibotenic acid and muscimol is 30-60 mg and 6 mg, respectively 
(Halpern, 2004) and these amounts can be found in a single mushroom (Rumack and 
Spoerke, 1994).  At this point, the toxicokinetics of muscimol and ibotenic acid remains 
largely unknown, but based on the rapid onset of symptoms after mushrooms ingestion, a 
fast absorption of toxins is presumed. Moreover, the toxins are readily excreted in urine, 
where they can be detected within 1 hour after ingestion (Stribrny et al., 2012). Clinical 
symptoms have been reported 30 min to 2 hours after ingestion and include nausea, 
hallucinations, delirium, muscular spasm, and sleepiness (Diaz, 2005; Satora et al., 2006). 
The CNS effects are usually short-lived, and fatalities rarely occur (Benjamin, 1992; Diaz, 
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2005), thus the recommended treatment after isoxazoles-containing mushrooms consists 
of eliminating the toxins from gastrointestinal tract, administration of activated charcoal, 
and supportive measures to alleviate CNS symptoms (Michelot and Melendez-Howell, 
2003). Even when the intoxication symptoms largely indicate a self-limited mushroom 
intoxication, if the patient’s meal contained wild mushrooms, the possible presence of 
amatoxins should be taken into consideration in the medical protocol to be followed. 
Amatoxins are a group of toxic bicyclic octapeptides present in the genus Amanita. α-
Amanitin is considered the main responsible for the human toxic effects. Upon ingestion, 
α-amanitin binds to the RNAP II enzyme, inhibits the transcription process and, 
ultimately, causes cell death. The main target organ seems to be the liver, as α-amanitin 
undergoes enterohepatic circulation (Letschert et al., 2006) but the kidneys can also be 
compromised (Amini et al., 2011). In the liver, α-amanitin causes broad necrosis that 
results in acute hepatic failure and further complications, such as hepatic coma, 
coagulation disorders, and renal failure (Enjalbert et al., 2002). The estimated lethal dose 
of amatoxins in humans is about 0.1 mg/kg body weight, or even lower, and this lethal 
amount may be present in a single mushroom (Faulstich, 1980). Upon ingestion, 
amatoxins seem to be gradually absorbed from the gastrointestinal tract. In the present 
case, the patient was taken to the hospital emergency room 3 hour after mushrooms 
ingestion and the presence of α-amanitin was confirmed in gastric juice but not in urine.  
We can presume that the fast CNS symptoms elicited the hospital attendance even before 
the amatoxins were fully absorbed. The gastric lavage undertaken in the hospital settings, 
as it was immediately performed, decreased or even abrogated the absorption of the 
toxins. The clinical course after amatoxins intoxication is initially characterized by a latent 
period followed by gastrointestinal symptoms, which include nausea, diarrhea and 
vomiting. However, no amatoxins toxicity signs or symptoms are usually found until 6-24 
hours after ingestion (Enjalbert et al., 2002). Presently, there is currently no specific and 
effective antidote for A. phalloides poisoning but several therapeutic drugs are used to 
protect the target organs of amatoxins poisoning. Intravenous silybin is the pharmacologic 
treatment of choice in Europe (Mengs et al., 2012) and USA (French et al., 2011). Other 
therapies have been suggested and includ benzylpenicillin, ceftazidime, or N-
acetylcysteine (Enjalbert et al., 2002). The administration of silybin used in amatoxin 
poisoning cases is based on its strong antioxidant activity and the ability of stimulate RNA 
polymerase I, counterbalancing the activity inhibition of RNAP II (Fraschini et al., 2002), 
whereas N-acetylcysteine’s potential therapeutic effect is due to its known antioxidant 
activity (Montanini et al., 1999). 
Since α-amanitin undergoes extensive enterohepatic recycling, repeated doses of activated 
charcoal were, also, administered, to enhance the elimination. The administration of 
 
Study III: Co-ingestion of amatoxins and isoxazoles-containing mushrooms and successful treatment: A case report 
 
 101 
activated charcoal had implications in the choice of the route of administration of the 
antihypertensive drug to be used. Activated charcoal may prevent the absorption of orally 
administered therapeutic agents; therefore sublingual captopril was administered.. 
In summary, in the present case, the treatment of a patient that suffered mushroom 
intoxication was immediately started after patient’s admission and consisted of gastric 
lavage, oral-activated charcoal, silybin and N-acetylcysteine, and anti-hypertensive 
therapy. It can be inferred that the early hospitalization, rapid diagnosis and aggressive 
management concurred for the successful of the therapy after A. phalloides lethal 
mushroom poisoning. Every effort should be made to identify the toxins present in the 
mushrooms ingested as to continue with supportive therapy or not, but clinical measures 
should not wait for the analytical results, as time is of the essence in these cases. In the 
present case, the simultaneous ingestion of isoxazoles toxins and amatoxins lead to the 
early application of the A. phalloides therapy protocol in hospital settings, since the 
former caused rapid hallucinogenic symptoms. The facilities for toxicological analysis are 
not commonly available in most Hospitals. The collaboration between hospitals and 
toxicological laboratories and the communication between physicians and toxicologists 
could be helpful in reducing the time of therapy implemented as well as the morbidity and 
mortality in cases of poisoning. The rapid hospitalization and the history of mushrooms 
ingestion lead to an early therapeutic intervention for amatoxins poisoning, which was key 
to prevent complications resulting from amatoxins intoxication. 
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Poisonous!-amanitin-containingmushrooms are responsible for themajor cases of fatalities aftermush-
room ingestion.!-Amanitin is known to inhibit the RNA polymerase II (RNAP II), although the underlying
mechanisms are not fully understood. Benzylpenicillin, ceftazidime and silybin have been the most fre-
quently used drugs in the management of !-amanitin poisoning, mostly based on empirical rationale.
The present study provides an in silico insight into the inhibition of RNAP II by !-amanitin and also on
the interaction of the antidotes on the active site of this enzyme.
Docking and molecular dynamics (MD) simulations combined with molecular mechanics-generalized
Born surface area method (MM-GBSA) were carried out to investigate the binding of !-amanitin and
three antidotes benzylpenicillin, ceftazidime and silybin to RNAP II.
Our results reveal that !-amanitin should affects RNAP II transcription by compromising trigger loop
(TL) function. The observed direct interactions between !-amanitin and TL residues Leu1081, Asn1082,
Thr1083, His1085 and Gly1088 alters the elongation process and thus contribute to the inhibition of
RNAP II. We also present evidences that !-amanitin can interact directly with the bridge helix residues
Gly819, Gly820 and Glu822, and indirectly with His816 and Phe815. This destabilizes the bridge helix,
possibly causing RNAP II activity loss.
We demonstrate that benzylpenicillin, ceftazidime and silybin are able to bind to the same site as !-
amanitin, although not replicating the unique!-amanitin bindingmode. They establish considerably less
intermolecular interactions and the ones existing are essential confine to the bridge helix and adjacent
residues. Therefore, the therapeutic effect of these antidotes does not seem to be directly related with
binding to RNAP II.
RNAP II !-amanitin binding site can be divided into specific zones with different proper-
ties providing a reliable platform for the structure-based drug design of novel antidotes for
!-amatoxin poisoning. An ideal drug candidate should be a competitive RNAP II binder that inter-
acts with Arg726, Ile756, Ala759, Gln760 and Gln767, but not with TL and bridge helix residues.
© 2014 Elsevier Inc. All rights reserved.
1. Introduction
The poisonous Amanita mushroom species Amanita phalloides
(Death Cap), Amanita verna (White Deadly Amanita) and Amanita
virosa (Destroying Angel) are responsible for 90–95% of the fatal-
∗ Corresponding authors. Tel.: +351 220428597; fax: +351 226093390.
E-mail addresses: jugarcia 18@hotmail.com, garciaju1987@gmail.com
(J. Garcia), felixdc@ff.up.pt (F. Carvalho).
ities occurring after mushroom ingestion [1]. Toxins contained
in these species include bicyclic octapeptides and consist of
nine defined members: !-amanitin, "-amanitin, #-amanitin, $-
amanitin, amanin, amanin amide, amanullin, amanullinic acid, and
proamanullin [2]. From these, !-amanitin accounts for about 40%
of the amatoxins [2].
Specific properties characterize these toxins. They are ther-
mostable and are not removed by boiling and discarding water or
by any form of cooking or drying, and belong to the most violent
http://dx.doi.org/10.1016/j.jmgm.2014.05.002
1093-3263/© 2014 Elsevier Inc. All rights reserved.
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Fig. 1. Structure of RNAP II/!-amanitin complex. Trigger loop, active site, DNA and
!-amanitin are colored red, blue, magenta and yellow, respectively. Active site is
represented by the Asp 481, Asp 483 and Asp 485 catalytic residues. (For interpre-
tation of the references to color in this figure legend, the reader is referred to the
web version of the article.)
poisons from higher fungi: only one medium-size amatoxin-
containing specimen contains from 10 to 12mg amatoxins, a
potential lethal dose for human adults (lethal dose: LD50 of
0.1–0.5mg/kg body weight) [3].
After ingestion poisonous Amanita mushrooms, amatoxins are
readily absorbed and accumulate in the liver upon uptake via an
organic anion-transporting octapeptide (OATP) located in the sinu-
soidal membrane of hepatocytes [4], which is the same transport
system for biliary acids. The main molecular mechanism of toxic-
ity is their strong inhibition of RNAP II [5] which is responsible for
the transcription of the precursor of messenger RNA. This in turn
causes inhibition of DNA and protein synthesis processes and leads
to cell death [6].
RNAP II consists of a 10-subunit core enzyme and a periph-
eral heterodimer of subunits Rpb4 and Rpb7 (Rpb4/7 subcomplex).
The core enzyme comprises subunits Rpb1, Rpb2, Rpb3, Rpb5,
Rpb6, Rpb8, Rpb9, Rpb10, Rpb11 and Rpb12 [7]. The active site
is located in the interface between the core subunits Rpb1 and
Rpb2. The catalytic process involves the nucleotide addition cycle
(NAC) and begins with binding of a nucleoside triphosphate (NTP)
substrate to the elongation complex (EC). Catalytic addition of the
nucleotide to the growing 3′-end of the RNA leads to formation
of a pyrophosphate ion. Pyrophosphate release leads to the pre-
translocation state, in which the newly added, 3′-terminal RNA
nucleotide remains in the substrate site. Finally, translocation of
DNA and RNA results in the post-translocation state, in which the
substrate site is free for binding the next NTP, and the NAC can be
repeated [8]. This process involve a structural element named trig-
ger loop (TL), whichmakes both direct and indirect contact with all
features of the nucleotide in the polymerase active center and the
bridge helix which guides the template DNA strand in the active
site and positions the DNA-RNA hybrid relative to the active site
[9]. TL has been hypothesized to have several conformations, but
two of them, the “open” (Fig. 1) and “closed” conformations were
observed in X-ray structures [9,10]. In the open TL structure the
substrate enters on the enzyme, and then the TL rotates (see arrow
in Fig. 1) to the active site (closed conformation) [9]. The flexibility
of the trigger loop on the catalysis is directly influenced by the con-
formation of the bridge helix [11]. Recently a crystal structure of
!-amanitinwith yeast RNAP II was published revealing several key
molecular interactions that may contribute to inhibition of RNAP II
[10].Multiple relevant interactionsbetween!-amanitinwithRNAP
II are located in the bridge helix (previously defined “cleft” region)
and in adjacent part of Rpb1 (previously defined funnel region).
Based on this !-amanitin may block translocation by interacting
with bridge helix and preventing the conformational change of the
TL and consequently transcriptional elongation (Fig. 1) [12].
No specific antidote for intoxications with amatoxins is
available. Based on pre-clinical findings several antidotes have
been used in amatoxin poisonings, including hormones (insulin,
growth hormone, glucagon), steroids, vitamin C, vitamin E, cime-
tidine, thioctic acid, antibiotics (benzylpenicillin, ceftazidime),
N-acetylcysteine, and silybin. From these, only benzylpenicillin,
ceftazidime, N-acetylcysteine and silybin been reported some suc-
cess in the pharmacologic management of amatoxin poisonings,
though with varying extent [1]. Furthermore, the precise phar-
macological mechanism of action for these drugs remains to be
elucidated.
In the current study we report the mode of interaction of !-
amanitin and three antidotes (benzylpenicillin, ceftazidime and
silybin) with RNAP II, using docking methods and molecular
dynamics simulations. To secure significant sampling, we per-
formed 3 molecular dynamic simulations (in a total of 34ns) in
explicit water of each one of the RNAP II/!-amanitin/antidotes
complexes. In order to provide a new insight into the inhibition
mechanism of RNAP II by !-amanitin, and the possible therapeutic
mechanism of action of benzylpenicillin, ceftazidime and silybin in
amatoxin poisoning, we used binding energy decomposition based
on the molecular mechanics generalized Born surface area (MM-
GBSA) approach.
2. Materials and methods
2.1. Molecular docking
Molecular Docking of several compounds is helpful in eluci-
dating key features of ligand–receptor interactions. This method
allows us to explore the interaction of the antidotes with RNAP II
and predict their preferred orientation, which would form a com-
plex with overall minimum energy. The crystal structure of RNAP
II complexed with !-amanitin (Protein Data Bank entry 3CQZ and
2VUM)was used to obtain the starting structures for themolecular
docking [8,11] and only subunits Rpb1 and Rpb2 were used.
The optimized Rpb1 and Rpb2 subunits were docked with !-
amanitin, benzylpenicillin, silybin and ceftazidime. The docking
procedure was made with the AutoDock 4 program [13,14]. This
automated docking program uses a grid based method for energy
calculation of the flexible ligand in complex with a rigid protein.
The program performs several runs in each docking experiment.
Each run provides one predicted binding mode. The Lamarckian
genetic algorithm (LGA) was used in all docking calculations. The
48×44×44gridpoints along the x,yand zaxeswas centeredon the
!-amanitin which was large enough to cover all possible rotations
of the toxin and antidotes. The distance between two connecting
grid points was 0.375 ´˚A. The docking process was performed in 250
LGA runs. The populationwas 150, themaximumnumber of gener-
ationswas 27,000 and themaximumnumber of energy evaluations
was 2.5×106. After complete execution of AutoDock ten confor-
mations of ligand in complex with the receptor were obtained,
which were finally ranked on the basis of binding energy [15]. The
resulting conformations were visualized in the Visual Molecular
Dynamics [16].
After analysis of all the solutions obtained, the best docking
solutions were chosen as starting structures for the subsequent
minimization and molecular dynamic studies.
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Fig. 2. Chemical structures: (a) !-amanitin; (b) benzylpenicillin; (c) ceftazidime; and (d) silybin.
2.2. Optimization of antidotes and ˛-amanitin
The structures of !-amanitin, benzylpenicillin, ceftazidime and
silybin (Fig. 2) were constructed and optimized in Gaussian at
the HF/6-31G* level of theory. For each antidote, we performed
two optimizations: one in vacuum and another in the condensed
phase. The partial charges were calculated resorting to the RESP
method.
2.3. Molecular dynamic simulations
The enzyme was first neutralized by adding Na+ ions and sol-
vated in a cubic box of TIP3 water molecules, such that there were
at least 10.0 ´˚A of water between the surface of the protein and the
edge of the simulation box. The initial geometry optimization of
the enzymewasminimized in two stages. In the first stage only the
hydrogen and water atoms were minimized; in the second stage
the entire system was minimized.
The parameters of the chosen models were validated with MD
simulations in explicit solvent. The MDs were performed with
ff99SB force field and the generalized amber force field (Gaff) [17].
An initial minimization was performed followed by an equilibra-
tion of 500ps. The equilibration was performed in a NVT ensemble
using Langevin dynamics with small restraints on the protein
(100kcalmo1−1). For each of the four systems an initial produc-
tion simulation of 10ns was performed followed by two random
initial velocities replica runs, totaling 34ns per substrate. This rep-
resented a substantial computational effort, since each system is
composed by ≈44,000 atoms containing protein, DNA and RNA.
Temperature was maintained at 300K in the NPT ensemble using
Langevin dynamics with a collision frequency of 1.0ps−1. The time
step was set to 2 fs. The trajectories were saved every 500 steps
for analysis. Constant pressure periodic boundary was used with
an average pressure of 1 atm. Isotropic position scaling was used
to maintain the pressure with a relaxation time of 2ps. SHAKE
constraints were applied to all bonds involving hydrogen. The par-
ticle mesh Ewald (PME) method was used to calculate electrostatic
interactions with a cutoff distance of 8.0 A˚.
2.4. Calculation of the binding energy
MM-GBSAwas applied to compute the binding energy between
the protein and each ligand and to decompose the interaction ener-
gies on a per residue basis by considering molecular mechanics
energies and solvation energies [18].
The energy decomposition was performed for gas-phase ener-
gies, desolvation free energies calculated by GB model [19] and
nonpolar contributions to desolvation using the linear combina-
tions of pairwise overlaps (LCPO) method [20].
Conformational entropy was not considered because our aim
was to identify important interactions between the !-amanitin
and the antidotes with RNAP II residues, rather than to obtain very
accurate absolute values for the binding free energy.
3. Results and discussion
The determination of the crystal structures with bound !-
amanitin it showed that this toxin binding site was quite far from
the RNAP II active site. Inhibition could only be explained if !-
amanitin binding could lead to some conformational change that
would affect the active site. The mystery was partially solved with
the determination of the complex RNAP II/DNA.RNA/substrate [9].
In this complex the TL is in the opposite direction and interacting
with the substrate. The TL is thus a highly flexible structural motif
within the enzyme capable of large conformational changes at each
catalytic cycle. Superposition of the pre-catalytic complexwith the
complex with !-amanitin shows that the large size of the toxin
could prevent the movement of the TL (Fig. 3).
Consequently, a description of the full TL movement is still
missing. Many TL conformations are still not described and the
crystal structures only give initial andfinal snapshots for thismove-
ment. To gain detailed insight about the most important residues
for the !-amanitin/antidotes dynamical interaction with RNAP II
we performed and analyzed MD simulations on docked complexes
of RNAP II/!-amanitin and with the antidotes. Moreover, we per-
formed detailed hydrogen bonds analyses (Table 1), measured the
most relevant distances between the protein residues and the
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Fig. 3. Interaction of!-amanitinwith RNAP II, demonstrated in silico. Superposition
of the lowest RMSD for the average structure of the simulation (gray), pre-catalytic
complex (magenta, pdb code 2E2H), complexwith!-amanitin. The!-amanitin is in
licorice representation and the substrate is in yellow licorice representation). (For
interpretation of the references to color in this figure legend, the reader is referred
to the web version of the article.)
toxin/antidotes. Finally, we performed energy decomposition. The
protein per residue energy values gives us a fast and relatively reli-
able estimation of the contribution of each residue to the binding
[21]. Our goal was provide a new insight into the inhibition mech-
anism of RNAP II by !-amanitin by identifying the critical residues
for RNAP II binding and subsequently understanding howantidotes
interact with RNAP II and if they can bind to the same position
without inhibiting the enzyme.
3.1. Identification of critical residues for ˛-amanitin binding
Superposition of the average simulation structure and the crys-
tal structure is shown in Fig. 4. The most noticeable differences
between the crystal structure and our simulation structure rely
in the displacement of TL (Fig. 4), which may be attributed to the
high flexibility and intrinsic mobility of the TL. In the our simula-
tion structure, Gly1088 residue interacts with !-amanitin oxygen
(O33), while in the crystal structure this residue is far away from
the !-amanitin. The demonstrated accuracy of the docked com-
plex validates our protocol and supports the results obtained for
the antidotes, for which there is no crystal structure (described in
Section 3.2).
In order to more easily and accurately grasp the interactions
between the protein and !-amanitin we performed an energy
decomposition analysis of the simulations.We resorted to theMM-
GBSAmethod. The calculated binding energies of each complex can
be seen in Table 2. Evennot considering the entropy, computational
studies using MM-GBSA calculations on different complexes of
protein-inhibitors showed good correlationswith respect to exper-
imental data [21]. Individual energy decomposition of all residues
in the complex was also calculated in order to qualitatively find
the key residues that play a more important role in the !-amanitin
binding (Figs. 5a and 6a). Values are expressed as mean± SD of the
3 replicates. Fig. 5a depicts the relative position of the inhibitor
and important residues in the binding complex by using the low-
est root-mean-square deviation RMSD structure in respect to the
average of the simulation. The toxin !-amanitin interacts with
residues Arg726, Ile756, Ala759, Gln760, Gln767, Gln768, Ser769,
Gly819, Gly820, Glu822, Leu1081, Asn1082, Thr1083, His1085 and
Gly1088 (Figs. 5a and 6a). The guanidinium group of Arg726 forms
cation–" interactions with!-amanitin phenyl group, which corre-
sponds to energy of−1.71±1.51kcalmo1−1. The binding energy of
residue Ile756 is −2.53±0.83kcalmol−1, agreeing with the CH–"
interaction of Ile756 alkyl group with !-amanitin phenyl ring.
At the same time, Ala759 alkyl group also forms CH–" inter-
actions with !-amanitin phenyl group (−0.67±0.04kcalmol−1).
The side-chain nitrogen atom of Gln760 forms a hydrogen bond
with !-amanitin O4 (Table 1), leading to a favorable binding
energy of −1.40±0.89kcalmol−1. Thus the indole portion of !-
amanitin inserts in the hydrophobic pocket created by Arg726,
Ile756, Ala759 and Gln760 (Fig. 5a). The side-chain oxygen of
Gln767 forms a hydrogen bond with !-amanitin N30, which
Table 1
Hydrogen bonds formed between the toxin/antidotes and RNA polymerase IIa.
Toxin/Antidote Donor AcceptorH Acceptor Distanceb( ´˚A) Angleb (◦) % per time frame
Gln767:OE1 !-amanitin:H77 !-amanitin:N30 1.81 166.53 60
!-amanitin:O4 Gln768:HE2 Gln768:NE2 2.87 157.06 80
!-amanitin !-amanitin:O4 Gln760:HE2 Gln760:NE2 2.11 148.55 26
!-amanitin:O59 Ser769:H Ser769:N 2.04 157.88 88
Glu822:OE1 !-amanitin:1H11 !-amanitin:O63 2.55 172.43 60
Benzylpenicillin Benzilpenicillin:O3 Hie816:HE2 Hie816:NE2 2.51 134.78 48
Benzilpenicillin:O1 Gln760:1HE2 Gln760:NE2 1.96 167.45 56
Silybin Silybin:O56 Gln760:1HE2 Gln760:NE2 2.17 142.68 75
Silybin:O4 Gly823:H Gly823:N 2.08 150.30 47
a Hydrogen bonds were analyzed in the average structures from MD simulation.
b The geometric criterion for the formation of H-bonds is common with an acceptor-donor distance less than 3.5 ´˚A and the donor-H-acceptor angle larger than 120.
Table 2
Binding energy calculation between the three antidotes and !-amanitin with Rpb1 and Rpb2 subunits (all energies are in kcalmol−1).
Complex !Gele !Gvdw !GInt !GGas !GGBSUR !GGB !GGBsol !GGBele !Gtot
Rpb1Rpb2/!-amanitin −60.97 −60.91 0.00 −121.88 −8.16 108.70 100.53 47.73 −21.34
Rpb1Rpb2/benzylpenicillin −19.78 −31.34 0.00 −51.12 −4.27 41.53 37.26 21.75 −13.87
Rpb1Rpb2/silybin −21.00 −42.58 0.00 −63.62 −5.87 47.96 42.09 26.95 −21.53
Rpb1Rpb2/ceftazidime −59.96 −38.20 0.00 −98.16 −5.31 89.94 84.63 29.98 −13.53
!Gele: electrostatic energy.!Gvdw: van derwaals energy;!Gint: internal energy;!GGas: total gas phase energy (sum!Gele,!Gvdw,!Gint);!GGBSUR: nonpolar contribution to
solvation;!GGB: the electrostatic contribution to the solvation free energy;!GGBSOL: sum of nonpolar and polar contributions to solvation;!GGBELE: sum of the electrostatic
solvation free energy and electrostatic energy;!GTOT: estimated total binding energy.
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Fig. 4. Superposition of the lowest RMSD for the average structure of RNAP II (cyan) with !-amanitin (green), crystal structure of RNAP II (magenta, pdb code 3CQZ) in
complex with !-amanitin (yellow).
Fig. 5. Geometries of key residues, which produce some favorable interactions with RNAP II, are plotted in the complexes according to the average structure from the
MD trajectory. (a) RNAP II/!-amanitin complex; (b) RNAP II/benzylpenicillin complex; (c) RNAP II/ceftazidime complex; and (d) RNAP II/silybin complex. The dashed lines
represent hydrogen bonds between the !-amanitin/antidotes and RNAP II.
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Fig. 6. !-Amanitin/antidotes-residues interaction spectrum of (a) RNAP II/!-amanitin complex; (b) RNAP II/benzylpenicillin complex; (c) RNAP II/ceftazidime complex and
(d) RNAP II/silybin complex. The residues with interaction energy than −0.5 kcalmol−1 are labeled. Values are expressed as mean± s.d. of the 3 replicates.
corresponds to interaction energy of −2.70±1.60kcalmol−1. The
nitrogen atom of Gln768 also forms a hydrogen bond with !-
amanitin O4 (Table 1), which is the strongest interaction among all
residues (−2.82±0.88kcalmol−1). The!-amanitin/Ser769 interac-
tion energy is −2.18±0.80kcalmol−1, which is due to a hydrogen
bond between Ser769 nitrogen atomand!-amanitinO59 (Table 1).
Hydrophobic interactions may be the main force between bridge
helix residuesGly819,Gly820and!-amanitin,whichcorrespond to
energies of −0.61±0.08 and −0.53±0.00kcalmol−1, respectively.
The interaction energy of the bridge helix residue Glu822 with
!-amanitin is −1.90±0.97kcalmol−1, corresponding to a hydro-
gen bond between the Glu822 side chain oxygen and !-amanitin
hydroxyproline OH (Table 1). The alkyls group of Leu1081 and
Asn1082 interact with !-amanitin alkyls by hydrophobic interac-
tions, which correspond to energies of−1.14 and−2.75kcalmol−1,
respectively. The interaction energy of Thr1083with !-amanitin is
−2.01kcalmol−1, mostly attributed to dipole–dipole interactions.
TL residues His1085 and Gly1088 form dipole–dipole interactions
with !-amanitin hydroxyproline and produce interaction energies
of −0.53±0.12 and −0.62kcalmol−1, respectively, which is sup-
porting by experimental data [22].
According to Figs. 5a and 6a and the above analysis, three
valuable findings can be observed: (1) Hydrogen bonds, CH–"
and hydrophobic interactions drive the bindings of !-amanitin
to RNAP II. (2) Our results indicate interactions with bridge helix
residues Gly819, Gly820 and Glu822. Moreover, indirect con-
tacts to the bridge helix were also observed. !-Amanitin binds
to residue Gln768, which in turn binds to His816 and Phe815
and forms a hydrogen bond with Ser769. Ser769 interacts with
the bridge helix residue Gly819. (3) !-Amanitin interacts with TL
residues Leu1081, Asn1082, Thr1083, His1085 and Gly1088. These
interactions can prevent TL movement and hence contributing to
inhibit transcription.
3.2. Binding mode predictions of antidotes to RNAP II
In order to provide a new insight into the mechanism of action
of benzylpenicillin, ceftazidime and silybin in amatoxin poisoning
we analyzed the antidotes binding to RNAP II.
According to Figs. 5b and 6b, several residues are involved
in the RNAP II/benzylpenicillin binding. The binding energy of
benzylpenicillin to Ile756 is −1.77±0.49kcalmol−1, agreeing
with CH–" interactions between Ile alkyls and benzylpenicillin
phenyl ring (Fig. 5b). Gln760 nitrogen atom binds to ben-
zylpenicillin O1 by a hydrogen bond, corresponding to energy of
−1.63±0.45kcalmol−1 (Table 1). At same time, other hydrogen
bond between His816 nitrogen and benzylpenicillin O3 con-
tributes with −0.69±0.14kcalmol−1 (Table 1). Val765 alkyl group
and benzylpenicillin alkyl group generate dispersive interactions
(−1.03±0.14kcalmol−1). Dipole–dipole interactions are observed
between Gly820 and benzylpenicillin (−1.54±0.00kcalmol−1).
Leu824 alkyls groups interact with benzylpenicillin alkyls groups
by hydrophobic interactions (−0.79±0.23kcalmol−1). Finally,
Gln2218 and Pro2220 form dipole–dipole interactions with
benzylpenicillin carboxyl group, corresponding to energies of
−1.65±0.45 and −0.79±0.20kcalmol−1, respectively. Based on
the above analysis, two valuable findings can be described:
(1) Residues Ile756, Gln760 and Gly820 are common sites for
!-amanitin and benzylpenicillin. (2) Our results indicate that
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benzylpenicillin interacts with bridge helix residues His816,
Gly820 and Leu824.
In the case of the RNAP II/ceftazidime complex the follow-
ing residues contribute for binding energy (Figs. 5c and 6c).
Ile756 alkyl group and ceftazidime dihydrothiazine ring gener-
ate CH–! interactions (Fig. 5c), corresponding to an interaction
energyof−4.28±1.70kcalmol−1. The interactionenergyofAsn757
is−0.80±0.10kcalmol−1,which canbeattributed todipole–dipole
interactions with ceftazidime carboxylic acid group. Dipole–dipole
interactions between Val765 and ceftazidime propylcarboxy
moiety are responsible for energy of −1.06±0.51kcalmol−1.
At same time, identical interactions can be seen between
His816 imidazole ring and ceftazidime propylcarboxy moiety
(−1.04±0.18kcalmol−1). Hydrophobic and dipole–dipole inter-
actions are the main forces between Gln2218 and ceftazidime
propylcarboxy moiety (−1.30±1.11kcalmol−1). At same time
Ser2219 forms dipole–dipole interactions with the same moiety,
which correspond to interaction energy of−1.09±0.38kcalmol−1.
Based on the above analysis, two important conclusions can be
obtained: (1) Residue Ile756 and is common site for "-amanitin
and ceftazidime. (2) Our results indicate that ceftazidime interact
with bridge helix residue His816.
Finally, for RNAP II/silybin binding the key residues are seven
(Figs. 5d and 6d). The binding energy of silybin to Ile756 is
−1.58±0.27kcalmol−1, corresponding to a CH–! interaction
between Ile756 alkyl and silybin phenyl group. The interac-
tion energy of Asn757 with silybin phenyl ring has energy of
−1.06±0.81kcalmol−1, which mostly results of NH–! interac-
tions. Gln760 side-chain nitrogen forms a hydrogen bond with
silybin O56 (−1.50±0.79kcalmol−1) (Table 1). Dipole–dipole
interactions between residues Ser769, Val770, Gly819, Gly820
and Arg821 with silybin result in the energies contributions
of −1.25±0.14, −1.01±0.10, 0.95±0.29, −1.40±1.17 and
−0.95±0.50kcalmol−1, respectively. Silybin phenyl ring contacts
with Glu822 alkyl group to generate a hydrophobic CH–! inter-
action (−1.38±0.60kcalmol−1). The Gly823 forms a hydrogen
bond with silybin O4 (−1.49±0.89kcalmol−1) (Table 1). The !–!
contacts and dipole–dipole interactions between residue His1085
and silybin diphenol ring result in an energy contribution of
−1.50±0.07kcalmol−1. From these results, we can conclude: (1)
Residues Ile756, Gln760, Gly819, Gly820, Glu822 and His1085 are
common sites for "-amanitin and silybin. (2) Our results indicate
that silybin interact with bridge helix residues Gly819, Gly820 and
Glu822 and TL residue His1085.
4. Conclusions
In this study, docking and MD simulation coupled with MM-
GBSA energy decomposition have been carried out to clarify the
inhibition mechanism of RNAP II by "-amanitin and to provide a
new insight into the plausible mechanism of action of three anti-
dotes used in amatoxin poisoning.
We hypothesize that TL residues Leu1081, Asn1082, Thr1083,
His1085 and Gly1088, and bridge helix residues Gly819, Gly820
and Glu822 contribute for the high binding affinity of "-amanitin
with RNAP II. Our data clearly reinforces the hypothesis of an
important role of the bridge helix [23] and TL in the elongation
process and are consistent with the existence of a network of
functional interactions between the bridge helix and TL that con-
trol fundamental parameters of RNA synthesis. Our data suggest
that "-amanitin interferes with bridge helix movement during the
translocation and with the movement of the TL, which closes over
the active site during the nucleotide incorporation (Fig. 1). More-
over, according to Kaplan et al. (2008),we show that the interaction
of "-amanitin with His1085 contributes for the inhibition of the
enzyme. This is supported by the findings that a substitution of ala-
nine or phenylalanine at position 1085 specifically renders RNAP II
highly resistant to "-amanitin [22]. Also, there are evidences that
residue 1085 may play a critical role in the catalytic mechanism
[24]. Taken together our results are in good agreement with all
literature data.
In the analysis of the antidotes we focused on the TL, bridge
helix and other additional residues that are involved in"-amanitin
binding. It seems that benzylpenicillin, ceftazidime and silybin,
although binding to the same RNAP II binding site, cannot replicate
"-amanitinbindingmode. Theantidotesestablishconsiderably less
intermolecular interactions and the ones existing are essential con-
fine to thebridgehelix andadjacent residues. The therapeutic effect
of the studied antidotes on "-amatoxin poisoning seems not to be
directly related with binding to RNAP II.
These structural insights about the molecular aspects of RNAP
II inhibition can provide a reliable platform for the structure-based
drugdesignagainst"-amatoxinpoisoning.Wesuggest that an ideal
drug should be a competitive RNAP II binder able to strongly inter-
act with Arg726, Ile756, Ala759, Gln760 and Gln767, but not with
bridge helix and TL residues.
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Abstract 
Amanita phalloides is responsible for more than 90% of mushroom-related fatalities and 
no effective antidote is clinically available. α-Amanitin, the most powerful toxin of A. 
phalloides, causes hepatic and kidney failure and its main toxicity mechanism relies on the 
inhibition of RNA polymerase II (RNAP II). In the present study, in silico and in vivo 
studies involving RNAP II were performed to find a potential α-amanitin antidote among 
clinically available drugs. In silico studies included docking and molecular dynamics (MD) 
simulation coupled to molecular mechanics-generalized born surface area method (MM-
GBSA) energy decomposition on RNAP II, were performed with a clinically used drug with 
chemical similarities to α-amanitin, polymyxin B. The obtained results show that 
polymyxin B potentially binds to RNAP II in the same interface of α-amanitin, preventing 
the toxin from binding to RNAP II without interfering with messenger ribonucleic acid 
(mRNA) synthesis. In vivo studies proved the efficacy of this potential antidote. A single 
dose of α-amanitin (0.33 mg/kg) followed by a multiple polymyxin B administration (3 × 
2.5 mg/kg, at 4, 8 and 12 h post-α-amanitin as to mimic the real human intoxication 
scenario) was carried out. The short-term study (24 h) corroborated the in silico results 
since the inhibition of the mRNA transcripts in the kidneys elicited by α-amanitin was 
efficiently reverted by polymyxin B. Moreover, polymyxin B significantly decreased the 
hepatic and renal α-amanitin-induced injury as seen by the histology and plasma 
biomarkers. In the survival rate assay, all animals exposed to α-amanitin died within 5 
days, whereas 50% survived up to 30 days when polymyxin B was administered 4, 8 and 
12 h post α-amanitin. A single dose of polymyxin B (2.5 mg/kg) administered 
concomitantly with α-amanitin was able to guarantee 100% survival until the 30th day post 
exposure.  
Taken together, these results demonstrate that polymyxin B acts on RNAP II, preventing 
α-amanitin binding to this crucial target. This effect protects RNAP II from inactivation 
leading to an effective increase of survival and a decrease in organ damage in α-amanitin-
treated animals, prompting the use of polymyxin B as an antidote for A. phalloides 
poisoning in humans. 
 
Keywords: α-amanitin, RNA polymerase II, polymyxin B, liver, kidney. 
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Abbreviations 
 
  
ALT Alanine aminotransferase 
AST Aspartate aminotransferase 
Ct Cycle threshold 
DNA Deoxyribonucleic acid 
i.p. Intraperitoneal 
mRNA Messenger ribonucleic acid 
RNA Ribonucleic acid 
RNAP II RNA polymerase II 
ROS Reactive oxygen species 
RT-PCR Real-time polymerase chain reaction 
SD Standard deviation 
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1. Introduction 
The gathering and consumption of wild mushrooms has increased during recent years due 
to their delicate flavors and textures as well as their attributed high nutritional value 
(Cheung 2010). Despite warnings, edible and toxic mushrooms such as A. phalloides are 
frequently misidentified by mushroom collectors. This species is responsible for more 
than 90% of the fatalities caused by mushroom poisoning worldwide (Vetter 1998). The 
clinical importance of A. phalloides poisoning relies on the presence of powerful toxins 
such as cyclic octapeptides. These cyclic octapeptides are known as amatoxins and α-
amanitin is the main responsible for the severe liver and kidney injury observed after A. 
phalloides poisoning. It is well established that α-amanitin inhibits RNA polymerase II 
(RNAP II), thereby interfering with the transcription process (Wieland 1983). However, 
other toxic mechanisms have been suggested, namely oxidative stress, which may play a 
critical role (Leist et al. 1997; Zheleva 2013; Zheleva et al. 2007). In addition, α-amanitin 
may also act synergically with endogenous cytokines (e.g. tumor necrosis factor-α) to 
promote apoptosis (Leist et al. 1997).  
Unfortunately, so far, no consensual antidote for mushroom poisonings has been found 
and therefore amatoxin poisoning is generally associated with a poor outcome, mainly due 
to liver or kidney failure. Several treatments have been applied after human intoxications 
with A. phalloides, including hormones (e.g., insulin, growth hormone, and glucagon), 
steroids, vitamin C, vitamin E, cimetidine, α-lipoic acid, antibiotics (benzylpenicillin, 
ceftazidime), N-acetylcysteine, and silybin. From these, only benzylpenicillin, ceftazidime, 
N-acetylcystein, and silybin proved to have some degree of therapeutic efficacy, though the 
death rate remains extremely high (Poucheret et al. 2010). The survival of individuals 
depends largely on the severity of liver damage, the rate of hepatic regeneration and the 
management of complications that may develop during the intoxication treatment course 
(Koda-Kimble et al. 2012). Liver transplantation is considered a last resort, however it 
remains the cornerstone of treatment in patients with fulminant hepatic failure 
(Broussard et al. 2001; Pinson et al. 1990).  
Considering the main toxicity mechanism of amatoxins, the inhibition of RNAP II activity, 
the ideal therapeutic approach against A. phalloides intoxications would be to displace 
and / compete with amatoxins binding to RNAP II without impairing its normal 
transcription activity. Therefore, in the present study, we aimed to identify an effective 
antidote for Amanita mushroom species poisonings, by proposing an innovative in silico 
and in vivo approach based on the binding of α-amanitin to RNAP II and the screening of 
clinically used drugs that show bioisosterism with amatoxins. This bioisosterism will be 
tested in the same in silico models to assess a putative competition and displacement from 
amatoxins binding site with RNAP II. After in silico studies, one of the most promising 
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candidates, polymyxin B was chosen for further in vivo proof of concept, mainly focusing 
in the target organs of α-amanitin toxicity, kidney and liver in a mice model. Several 
parameters were evaluated, namely survival rate, histological damage, protein 
carbonylation, NF-κB nuclear activation, total RNA and specific mRNA quantification, in 
order to validate the effectiveness of polymyxin B in protecting mice against α-amanitin 
poisoning. 
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2. Material and methods  
 
2.1. In silico study 
 
2.1.1. Molecular docking on RNAP II   
 
Molecular docking plays an important role in the rational design drugs and is helpful in 
elucidating key features of ligand–receptor interactions. This in silico method allows 
predicting the preferred orientation of putative antidotes when bound to RNAP II, 
forming a complex with overall minimum energy. Molecular docking studies were 
performed on polymyxin B according to our previous reported data (Garcia et al. 2014). 
The crystal structure of RNAP II complexed with α-amanitin (Protein Data Bank entry 
3CQZ and 2VUM) was used to obtain the starting structures for the molecular docking 
(Bushnell et al. 2002) and only subunits Rpb1 and Rpb2 were used. The optimized Rpb1 
and Rpb2 subunits were docked with polymyxin B. The docking procedure was made with 
the AutoDock 4 program (Morris et al. 2009; Mowry et al. 2013). This automated docking 
program uses a grid-based method for energy calculation of the flexible ligand in complex 
with a rigid protein. The program performs several runs in each docking experiment. Each 
run provides one predicted binding mode. The Lamarckian genetic algorithm (LGA) was 
used in all docking calculations. The 48×44×44 grid pointed along the x, y and z axes was 
centered on the α-amanitin, which was large enough to cover all possible rotations of the 
polymyxin B. The distance between two connecting grid points was 0.375 Ǻ. The docking 
process was performed in 250 LGA runs. The population was 150, the maximum number 
of generations was 27,000 and the maximum number of energy evaluations was 2.5×106. 
After complete execution of AutoDock ten conformations of polymyxin B in complex with 
the receptor were obtained, which were finally ranked on the basis of binding energy. The 
resulting conformations were obtained in the Visual Molecular Dynamics (Humphrey et 
al. 1996). After analysis of all the solutions obtained, the best docking solution was chosen 
as starting structure for the subsequent minimization and molecular dynamic studies. 
 
2.1.2. Optimization of polymyxin B  
The structure of polymyxin B was constructed and optimized in Gaussian at the HF/6-
31G* level of theory. Two optimizations were performed: in vacuum and in the condensed 
phase. The partial charges were calculated resorting to the RESP method.  
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2.1.3. Molecular dynamic simulations 
The enzyme was first neutralized by adding Na+ ions and solvated in a cubic box of TIP3P 
water molecules, such that there were at least 10.0 Ǻ of water between the surface of the 
protein and the edge of the simulation box. The initial geometry optimization of the 
enzyme was minimized in two stages. In the first stage only the hydrogen and water atoms 
were minimized; in the second stage the entire system was minimized. The parameters of 
the chosen models were validated with molecular dynamics (MD) simulations in explicit 
solvent. The MDs were performed with ff99SB force field and the generalized amber force 
field (Gaff) (Case et al. 2005). An initial minimization was performed followed by an 
equilibration of 500 ps. The equilibration was performed in a NVT ensemble using 
Langevin dynamics with small restraints on the protein (100 kcal/mol). Then 10 ns of 
production simulation were performed. This represented a substantial computational 
effort, since each system is composed by ≈44000 atoms containing protein, 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Temperature was maintained at 
300 K in the NPT ensemble using Langevin dynamics with a collision frequency of 1.0 ps-1. 
The time step was set to 2 fs. The trajectories were saved every 500 steps for analysis. 
Constant pressure periodic boundary was used with an average pressure of 1 atm. 
Isotropic position scaling was used to maintain the pressure with a relaxation time of 2 ps. 
SHAKE constraints were applied to all bonds involving hydrogen. The particle mesh 
Ewald (PME) method was used to calculate electrostatic interactions with a cutoff distance 
of 8.0 Å.  
 
2.1.4. Calculation of the binding energy  
Molecular mechanics with generalized Born and surface area solvation (MM-GBSA) was 
applied to compute the binding energy between the RNAP II/polymyxin B complex and to 
decompose the interaction energies on a per residue basis by considering molecular 
mechanic energies and solvation energies (Kollman et al. 2000). The energy 
decomposition was performed for gas-phase energies, desolvation free energies calculated 
by GB model (Onufriev et al. 2000) and nonpolar contributions to desolvation using the 
linear combinations of pairwise overlaps (LCPO) method (Weiser et al. 1999). 
 
2.2. Experimental studies 
 
2.2.1. Chemical and drugs 
α-Amanitin, polymyxin B, 1-octanesulfonic acid sodium salt, 2,4-dinitrophenylhydrazine, 
TRIzol and RNALater were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). 
Methanol and xylene were obtained from Fisher Scientific (Waltham, Massachusetts, 
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USA). Sodium chloride, potassium chloride, sodium hydrogen phosphate, potassium 
dihydrogen phosphate, perchloric acid, Histosec paraffin pastilles, magnesium chloride, 
sodium hydroxide, ethylenediaminetetraacetic acid (EDTA) and disodium phosphate, 
were purchased from Merck (Darmstadt, Germany). Eosin 1% aqueous was obtained from 
Biostain (Traralgon, Australia) and Harris hematoxylin from Harris Surgipath (Richmond, 
Illinois, USA). Water was purified with a Milli-Q Plus ultra-pure water purification system 
(Millipore, Bedford, Massachusetts, USA). Bio-Rad DC protein assay kit, Clarity™ 
Western ECL Substrate, iScript cDNA Synthesis KitH, and SYBR Green PCR Master Mix 
were purchased from Bio-Rad Laboratories (Hercules, California, USA). Horseradish 
peroxidase conjugated anti-rabbit antibody, ECL chemiluminescence reagents, and 0.45 
µm Amersham Protran nitrocellulose blotting membrane were purchased from GE 
Healthcare Bio-Science (Pittsburgh, Pennsylvania, USA). Dinitropenhyl-KLH rabbit IgG 
antibody was purchased from Invitrogen/Life Technologies (Grand Island, New York, 
USA). NF-κB p50 rabbit polyclonal IgG and goat anti-rabbit IgG F(ab’)2 AP conjugated 
were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). All primers were 
purified through high pressure liquid chromatography and purchased to STAB VIDA 
(Caparica, Lisboa, Portugal). The kit for DNase digestion step and the ultrapure water was 
obtained from Qiagen (Carnaxide, Portugal). 
 
2.2.2. Animals  
Male CD-1 mice (20-30 g) were purchased from Harlan (Udine, Italy), and kept in the 
vivarium of Faculty of Sports, University of Porto. Room temperature was maintained at 
22 ± 2 ºC, relative humidity at 60 ± 10%, and a 12 h light/dark cycle. Water and standard 
rodent chow 4RF21 GLP certificate diet (Mucedola, 113 Settimo Milanese, Italy) were 
provided ad libitum. All procedures were carried out to provide appropriate animal care, 
minimizing their suffering. Housing and experimental treatment of the animals were in 
accordance with the guidelines defined by the European Council Directive (2010/63/EU) 
transposed into Portuguese law (Decreto-Lei n.º 113/2013, de 7 de Agosto). Moreover, the 
experiments were performed with the approval of the Ethical Committee of the Faculty of 
Pharmacy, University of Porto (nº 10/06/2013). Animals were acclimated for 5 days 
before starting the experiments.  
 
2.2.3. In vivo study design 
The murine model has been used as a reliable model for α-amanitin poisoning (Schneider 
et al. 1987; Schneider et al. 1992; Tong et al. 2007; Yamaura et al. 1986; Zhao et al. 2006), 
with similar hepatic toxic responses to amatoxins as humans (Tong et al. 2007). In this 
model, the intraperitoneal (i.p.) administration ensures the bioavailability of α-amanitin 
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and it has been the preferred route used in previous studies in mice in search for antidotes 
against amatoxins poisoning (Schneider et al. 1987; Schneider et al. 1992; Tong et al. 
2007). In the present work, two in vivo studies were performed to evaluate the putative 
effectiveness of polymyxin B against α-amanitin toxicity: a short-term study (24 h) and a 
survival study (30 days). α-Amanitin and polymyxin B were always dissolved in 0.9% 
saline solution. In both studies, all α-amanitin-exposed animals received an i.p. dose of 
0.33 mg/kg. This dose was chosen since it was previously reported to be the lethal dose 
(LD50) of α-amanitin in mice (Wieland and Faulstich 1978) and it has been used in several 
studies aiming to test antidotes efficacy after amatoxin poisoning (Schneider et al. 1987; 
Schneider et al. 1992; Tong et al. 2007; Vogel et al. 1984).  
 
2.2.3.1. Short-term study 
Our work started with a short-term (24 h) study to evaluate the effectiveness of polymyxin 
B in protecting liver and kidney against the toxicity of α-amanitin. In order to create a real 
scenario of intoxication, since intoxicated people only arrive to emergency rooms hours or 
even days after mushrooms ingestion, polymyxin B was only administered to animals 4 h 
post α-amanitin administration. This 4-h delay in the administration was also used in 
several studies that aimed testing the efficacy of antidotal therapies in mice models 
(Schneider et al. 1992; Tong et al. 2007). Three consecutive doses of polymyxin B (2.5 
mg/kg) with 4 h interval between each dosage were given to animals. According to the 
allometric scaling standardly used (West and Brown 2005), the 3 doses of 2.5 mg/kg of 
polymyxin B in mice, sums up to approximately 1 mg/kg in a 70 kg human. The current 
recommended dose of intravenous polymyxin B for patients with normal renal function is 
1.5–2.5 mg/kg/day in two doses administered as 1 h infusions (Zavascki et al. 2007). 
Moreover, the three polymyxin B administrations at different time-points (4, 8 and 12 h) 
after α-amanitin injection are based on a previous pharmacokinetic study in mice with 
polymyxin B, in which the serum concentration of polymyxin B (3 mg/kg) is non-
detectable at 4 h post-administration (He et al. 2013).   
Animals were randomly divided into four groups that were treated as follows: (i) control 
group, animals subjected to four 0.9% saline solution i.p. administrations (0, 4, 8 and 12 
h); (ii) α-amanitin group (Ama), animals exposed to one dose of α-amanitin (0.33 mg/kg 
i.p.) followed by three 0.9% saline solution i.p. administrations at different time points (4, 
8 and 12 h) post α-amanitin administration; (iii) polymyxin B group (Pol), animals 
exposed to a 0.9% saline solution followed by three 2.5 mg/kg i.p. administrations of 
polymyxin B at different time-points (4, 8 and 12 h); (iv) α-amanitin plus polymyxin B 
(Ama+Pol), animals exposed to one dose of α-amanitin (0.33 mg/kg i.p.) followed by three 
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2.5 mg/kg i.p. administrations of polymyxin B at different time-points (4, 8 and 12 h). 
Twenty-four hours after α-amanitin administration, all animals were anesthetized with 
isoflurane and sacrificed by exsanguination. The blood, liver and kidney were collected for 
further analysis. 
 
2.2.3.2. Survival rate study 
Following the promising in silico and short term in vivo studies, the next step was to 
perform a long-term in vivo study, to evaluate survival rate and animals welfare of 
animals intoxicated with α-amanitin and treated with polymyxin B.  In the α-amanitin 
group, animal suffering was expected, thus we reduced the number of animals to the 
minimum. Twenty four animals were randomly divided into five groups that were treated 
as follows: (i) control group, animals treated with 0.9% saline solution i.p.; (ii) α-amanitin 
group (Ama), animals exposed to one dose of α-amanitin (0.33 mg/kg i.p.); (iii) polymyxin 
B group (Pol), animals treated with 0.9% saline solution followed by 3 × 2.5 mg/kg 
administrations i.p. of polymyxin B at different time-points (4, 8 and 12 h); (iv); α-
amanitin plus polymyxin B group (Ama+Pol conc), animals concomitantly exposed to 
administration of one dose of α-amanitin (0.33 mg/kg i.p.) and polymyxin B (1 × 2.5 
mg/kg i.p.); (v) α-amanitin plus polymyxin B group (Ama+Pol), animals exposed to α-
amanitin (0.33 mg/kg i.p.) followed by 3 × 2.5 mg/kg i.p. administrations of polymyxin B 
at different time-points (4, 8 and 12 h). Body weight, motor activity, dyspnea, and overall 
welfare of the animals were observed every day, for 30 days.  
 
2.2.4. Short-term study (24 h) evaluations 
2.2.4.1. Blood collection 
In the short-term study, the blood was taken from the inferior vena cava into EDTA-
containing tubes. The blood was immediately centrifuged at 920 g for 10 min (4ºC). The 
plasma supernatant was collected into tubes and stored at -80ºC until determination of 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, urea and 
total bilirubin. Plasma biochemical parameters were measured on an AutoAnalyzer 
(PRESTIGE 24i, PZ Cormay S.A.). 
 
2.2.4.2. Tissue processing for biochemical analysis 
After blood collection, liver and kidneys were removed, weighed, and processed as follows: 
(i) slices of liver and kidney were kept in RNAlater and stored at -80ºC for future total 
RNA quantification and quantitative PCR analysis;  (ii) segments of liver and kidney were 
placed in 4% paraformaldehyde [diluted in phosphate buffer solution (PBS) 1X, 2.5% 
sucrose, 0.1% glutaraldehyde, pH 7.2-7.4] and used for histological and 
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immunohistochemistry analysis; and (iii) a section of liver and kidney was placed in 
complete RIPA buffer [50 mM Tris–HCl, 150 mM NaCl, 1% Igepal CA-630 (v/v), 0.5% 
sodium deoxycholate (w/v) and 0.1% SDS (w/v), pH 7.4, (supplemented with 0.25 mM 
PMSF, 1 mM Na3VO4, 10 mM NaF and 0.5% (v/v) complete protease inhibitor cocktail)] 
and stored at -80ºC for carbonyl quantification.  
 
2.2.4.3. RNA extraction and real-time PCR 
Total RNA isolation was performed by adding 500 µL of TRIzol reagent to liver and kidney 
samples according to the manufacturer’s instructions. All specimens were homogenized by 
mechanical disruption using the Ultra-Turrax Mixer (IKAH) instrument and total RNA 
was extracted in RNAse-free environment. A DNase digestion step with RNase-Free 
DNase Set was included and the total RNA obtained was ressuspended in ultrapure water. 
The RNA concentration was determined by OD260 measurement using a NanoDropH 
ND-1000 Spectrophotometer (NanoDrop Technologies, USA), and the purity of the total 
RNA extracted was assessed by measuring the absorbance at 230 and 280 nm. 200 ng of 
total RNA was reverse-transcribed using the iScript Select cDNA Synthesis Kit (Bio-Rad, 
Hercules, California, USA) according to the manufacturer’s protocol. All cDNA samples 
were stored at -20 ºC until quantitative real-time PCR (qPCR) analysis. qPCR was 
performed in iQTM 5 Real-Time PCR detection System (Bio-Rad, Hercules, California, 
USA) in 96-well plates with a reaction volume of 20 µL and runs up to 40 cycles using 
iQTM SYBER® Green Supermix. The final PCR reaction mixture of 10 µL contained 0.25 µL 
of cDNA sample, 5 µL of iQTM SYBR® Green Supermix, 0.25 µL of each primer and 4.25 µL 
of RNase-free water. The cycling conditions were set as follows: Taq DNA polymerase 
activation at 95 ºC for 3 min, amplification steps: denaturation at 95 ºC for 15 s, annealing 
at 60 ºC for 15 s, and extension at 72 ºC for 15 s with fluorescence acquisition. Two highly 
stable reference genes for RNAP II were chosen (β-actin, GAPDH) as well as two 
ribosomal 18S and 28S genes transcribed by RNA polymerase I. All cDNA samples were 
measured in duplicate, and the relative transcript levels were quantified by the threshold 
cycle (Ct) value. All primers were designed using the Beacon Designer Software (version 
7.2, PREMIER Biosoft International, Palo Alto, CA, USA). 
 
2.2.4.4. Histological analysis of liver and kidney 
In the short-term study, routine histological procedures for qualitative structural analysis 
of the liver and kidney were performed in four mice from each group. The 4% 
paraformaldehyde-fixed transverse section of the liver and kidney was processed for the 
routine hematoxylin-eosin staining. The slides were examined and photographed with a 
Carl Zeiss Imager A1 light microscope equipped with an AxioCam MRc 5 digital camera 
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(Oberkochen, Germany). Histopathological evidences of tissue damage were calculated 
according to their severity and incidence in every slide (Dores-Sousa et al. 2015). Both 
liver and kidney, at least 50000 cells per slide were analyzed in a blind fashion in order to 
semi quantify the severity of the following parameters: i) cellular degeneration, ii) 
interstitial inflammatory cell infiltration, iii) necrotic zones, and iv) loss of tissue 
organization. The severity of cellular degeneration was scored according to the number of 
cells showing any alterations (dilatation, vacuolization, pyknotic nuclei, and cellular 
density) in the light microscopy visual field: grade 0 = no change from normal; grade 1 = a 
limited number of isolated cells (until 5% of the total cell number); grade 2 = groups of 
cells (5 to 30% of cell total number); and grade 3 = diffuse cell damage (30% of total cell 
number). The severity of necrosis was scored as follows: grade 0 = no necrosis; grade 1 = 
dispersed necrotic foci; grade 2 = confluence necrotic areas; grade 3 = massive necrosis. 
The inflammatory activity was graded semi-quantitatively into: grade 0 = no cellular 
infiltration; grade 1 = mild leukocyte infiltration (1 to 3 cells by visual field); grade 2 = 
moderate infiltration (4 to 6 leukocytes by visual field); and grade 3 = heavy infiltration by 
neutrophils. The severity of tissue disorganization was scored according to the percentage 
of the affected tissue: score 0 = normal structure; score 1 = less than one third of tissue; 
score 2 = greater than one third and less than two thirds; score 3 = grater of two thirds of 
tissue. For each visual field the highest possible score was 12 and the lowest was 0.  
 
2.2.4.5. Determination of NF-κB through immunohistochemistry 
In the short-term study, the determination of NF-κB nuclear translocation was performed 
both in the liver and kidney. The 4% paraformaldehyde-fixed transverse section of the 
liver and kidney was processed as indicated in 2.2.4.4 section and then the paraffin-
embedded tissues were deparaffinized and re-hydrated. The slides were rinsed in distilled 
water and incubated in PBS for 10 min. Thereafter, antigens were unmasked by the 
microwave antigen retrieval procedure: slides were immersed in 10 mM citrate buffer, pH 
6.0, at 100ºC and placed in a full-powered microwave for 20 min and then cooled for 30 
min. After washing four times (5 min each) with PBS solution, the sections were blocked 
with 3% bovine serum albumin (w/v) in PBS containing 0.05 % Tween 20 (v/v) (PBS-T), 
for 30 min to suppress nonspecific binding. Following the blocking step, each slide was 
incubated with anti-NF-kB p50 polyclonal rabbit antibody (1:50) in PBS-T overnight 
(4ºC). After washing four times (5 min each) with PBS solution, the sections were 
incubated for 2 h, at 37ºC with a goat anti-rabbit IgG alkaline phosphatase secondary 
antibody (1:100) in PBS-T. The sections were then washed four times (5 min) under gentle 
stirring and incubated with Fast Red reagent for 5 min. After washing, the slides were then 
counterstained with a solution of hematoxylin-water (1:5) for 3 min and once again 
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washed. Finally, slides were mounted in Crystal Mount medium with coverslips and 
analyzed by light microscopy. Negative controls were performed as described, with the 
omission of the primary antibody incubation step. 
A minimum of 40 cells per area were evaluated and for each section six areas in each zone 
were seen. In the liver, cell quantification was possible and the number of nuclear staining 
in hepatocytes and macrophage-like cells were expressed in number of positive cells per 
area (µm2). 
 
2.2.4.6. Protein carbonylation assay 
In the short-term study, protein carbonylation, an index of protein oxidation, was 
determined in the liver and kidney. Liver and kidney sections were homogenized in ice-
cold RIPA buffer through sonication. The homogenates were centrifuged at 13000 g, for 
10 min, at 4ºC, and supernatants were kept at -80 ºC until analysis. Samples containing 
20 µg of protein were then processed as previously described (Barbosa et al. 2012). 
Immunoreactive bands were detected using the Clarity™ Western ECL Substrate, 
according to the supplier`s instructions, and digital images were acquired using a 
Molecular Imager® ChemiDocTM XRS+ System (Bio-Rad Laboratories, California, USA) 
and analyzed with Image LabTM Software (Bio-Rad Laboratories California, USA). Optical 
density results were expressed as % of control values. 
 
2.2.5. Statistical analysis 
All data obtained were expressed as mean ± standard deviation (SD). All statistical 
analysis was performed using GraphPad Prism® (version 6.00, GraphPad Software, San 
Diego, California, USA). Comparisons among the survival curves were performed using 
Log-rank (Mantel–Cox) test. The Shapiro-Wilk test was performed to check normality of 
the data. Statistical comparisons were done using the one-way ANOVA (in case of normal 
distribution) followed by the Bonferroni post hoc test or Kruskal-Wallis (in case not 
normal distribution) followed by the Dunn´s post hoc test. P values lower than 0.05 were 
considered as statistically significant.  
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3. Results 
 
3.1. In silico study 
 
3.1.1. Identification of critical residues for polymyxin B binding 
A docking study with polymyxin B on RNAP II to determine the preferred orientation of 
the molecule on RNAP II was performed. To gain a broad insight of the most important 
residues in the polymyxin B dynamical interaction with RNAP II, we performed and 
analyzed MD simulations on docked complex of RNAP II/polymyxin B. Ten ns of MD 
simulation have been successfully performed for the polymyxin B/RNAP II complex. 
Figure 1 shows superposition of the average structures of α-amanitin polymyxin B during 
the simulations. The polymyxin B binding site is located in the same interface of α-
amanitin. In order to more easily and accurately grasp the interactions between the RNAP 
II and polymyxin B, an energy decomposition analysis of the simulations was also done 
(Table 1). We resorted to the MM-GBSA method, since computational studies using MM-
GBSA calculations on different complexes of protein/ligands showed good correlations 
with experimental data (Onufriev et al. 2000).  Our aim was to investigate the interaction 
features in detail and obtain insights into the contribution of each component to the RNAP 
II/polymyxin B binding. The individual energy decompositions of all residues in the 
complex were calculated in order to identify key residues involved in polymyxin 
B binding to RNAP II. 
Figure 2 depicts the relative position of the polymyxin B and important residues in the 
binding complex by using the lowest root-mean-square deviation RMSD structure in 
respect to the average of the simulation. The polymyxin B interacts with residues Arg720, 
Ala1087, Gly1088, Val1089, Val1094, Met1285, Ala1357, and Gly1360. The guanidinium 
group of Arg726 forms dipole-dipole interactions with L-α-γ-diaminobutyric acid (Dab) 
residue of polymyxin B, which corresponds to energy of -1.97 kcal/mol. The binding 
energy of residue Ala1087 is -1.41 kcal/mol, thus agreeing with a hydrogen bond between 
Ala1087 oxygen atom and polymyxin B N22 (Table 2). At the same time, Gly1088 oxygen 
atom also forms a hydrogen bond with polymyxin B N15 (-2.81 kcal/mol) (Table 2). 
Dipole-dipole interactions were observed between Val1089 and polymyxin B (-2.25 
kcal/mol). Hydrophobic interactions may be the main force between Val1094 and side-
chain leucine residue of polymyxin B, which correspond to energy of -2.25 kcal/mol. 
Met1285 alkyl group forms CH-π interactions with polymyxin B phenyl group (-1.83 
kcal/mol). Finally, Ala1357 and Gly1360 alkyls groups interact with polymyxin B methyl-
octanoic acid group by hydrophobic interactions (-0.63 kcal/mol).  
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Figure 1. Superposition of RNAP II average structure/α-amanitin (cyan) and RNAP II 
average structure/ polymyxin B (magenta). ( representation of α-Amanitin is in red and of 
polymyxin B is in yellow spheres). 
Figure 2. RNAP II geometries of key residues that produce some favorable interactions 
with polymyxin B, plotted in the complexes, according to the average structure from the 
MD trajectory. 
α-Amanitin
!Polymyxin!
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Table 1. Binding energy calculation between the polymyxin B and Rpb1 and Rpb2 
subunits (all energies are in kcal/mol) 
 
 ΔGele: electrostatic energy. ΔGvdw: van der waals energy; ΔGint: internal energy; ΔGGas: total gas phase energy (sum 
ΔGele, ΔGvdw, ΔGint); ΔGGBSUR: nonpolar contribution to solvation; ΔGGB: the electrostatic contribution to the solvation 
free energy; ΔGGBSOL: sum of nonpolar and polar contributions to solvation; ΔGGBELE: sum of the electrostatic solvation 
free energy and electrostatic energy; ΔGTOT: estimated total binding energy. 
 
 
 Table 2. Hydrogen bonds formed between the polymyxin B and RNA polymerase IIa 
 
 aHydrogen bonds were analyzed in the average structures from MD simulation. bThe geometric criterion for the 
formation of H-bonds is common with an acceptor-donor distance less than 3.5 Ǻ and the donor-H-acceptor angle larger 
than 120°. 
 
3.2. Polymyxin B is able to prevent the hepatic and kidney damage induced by 
α-amanitin in vivo  
 
3.2.1. Polymyxin B significantly abolished the increase of plasma 
aminotransferase elicited by α-amanitin  
Plasma biomarkers were determined at 24 h after α-amanitin administration as shown in 
Figure 3. AST and ALT were significantly increased in the α-amanitin group (359.10 ± 
190.40 and 120.20 ± 83.20 U/L for AST and ALT, respectively) as compared with control 
group (63.80 ± 8.63 and 37.80 ± 6.94 U/L for AST and ALT, respectively). This increase 
was prevented with the 3 × 2.5 mg/kg administration of polymyxin B (68.46 ± 23.92 and 
32.70 ± 8.45 U/L for AST and ALT, respectively) (Figure 3A and 3B). On the other hand, 
urea and creatinine show a small tendency to increase in the α-amanitin group, however 
without reaching statistical significance (Figure 3C and 3D). The ratio AST/ALT and the 
total bilirubin showed no differences between treatments (Figure 3E and 3F). 
  
Complex ΔGele ΔGvdw ΔGInt ΔGGas ΔGGBSUR ΔGGB ΔGGBsol ΔGGBele ΔGtot 
 
RNAPII/Polymyxin B 
 
 
-62.50 
 
-57.64 
 
0.00 
 
-120.14 
 
-8.45 
 
110.40 
 
101.95 
 
47.90 
 
-18.19 
Toxin/Antidote Donor AcceptorH Acceptor Distanceb(A) Angle
b (°)    
 Ala1087:O Polymyxin B:2H14 PolymyxinB:N22 2.48 140.27  
Polymyxin B Gly1088:O Polymyxin B:2H10 PolymyxinB:N15 1.82 168.67 
 Val1089:N Polymyxin B:2H10 PolymyxinB:N15 2.11 148.55 
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Figure 3. Plasma levels of (A) aspartate aminotransferase (AST), (B) alanine 
aminotransferase (ALT), (C) urea (D) ratio AST/ALT (E) creatinine and (F) total 
bilirubin in control, 3 × 2.5 mg/kg polymyxin B (Pol), 0.33 mg/kg α-amanitin (Ama), and 
α-amanitin plus polymyxin B (Ama+Pol) groups. Results are presented as means ± 
standard deviation, and were obtained from 4-5 animals from each treatment. Statistical 
comparisons were made using Kruskal-Wallis ANOVA on Ranks followed by the Dunn’s 
post hoc test (*p < 0.05, Ama vs. control; #p < 0.05, Ama vs. Ama+Pol).  
 
3.2.2. α-Amanitin caused significant decrease in hepatic weight  
As an indirect measure of organ damage, we quantified the ratio of both liver and kidney 
weight to total body weight in the 24 h study (Table 3). The relative liver weight from the 
α-amanitin group showed a significant decrease (5.75 ± 0.58 mg/g) in comparison to 
control group (6.77 ± 0.64 mg/g), and the treatment with polymyxin B prevented this 
effect (5.94 ± 0.52 mg/g) (Table 3). No differences were seen in ratios of kidney 
weight/body weight values among control and treatment groups. 
 
 
Table 3. Ratios of liver weight / body weight and kidney weight / body weight 
 
 
 
 
3.2.3. Polymyxin B prevented the total RNA decrease in the kidney of α-
amanitin treated animals  
Since α-amanitin rapidly inactivates RNAP II with a consequent decrease on mRNA 
transcription, we quantified the total RNA content in the liver and kidney of animals in all 
experimental groups. These total RNA levels were further normalized to organ weight. 
Results from α-amanitin-intoxicated animals revealed that the kidney total RNA 
significantly decreased (0.981 ± 0.645 µg/mg kidney) compared with control (3.331 ± 
0.466 µg/mg kidney) (Figure 4A). This effect was reverted in the α-amanitin plus 
 Control Polymyxin B α-Amanitin 
α-Amanitin + 
polymyxin B 
Liver 6.77 ± 0.64 
 
6.04 ± 0.26 
 
5.75 ± 0.58 * 
 
5.94 ± 0.52 
Kidney 
 
0.97 ± 0.03 
 
0.85 ± 0.11 
 
0.92 ± 0.09 
 
0.85 ± 0.10 
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polymyxin B group (3.622 ± 1.550 µg/mg kidney). On the other hand, no differences were 
found for total RNA in the liver of α-amanitin-intoxicated animals (Figure 4B).  
Figure 4. (A) Total RNA liver levels and (B) total RNA kidney levels of control, 3 × 2.5 
mg/kg polymyxin B (Pol), 0.33 mg/kg α-amanitin (Ama), and α-amanitin plus polymyxin 
B (Ama+Pol) groups. Results were obtained from 4 animals from each treatment group. 
Statistical comparisons were made one-way ANOVA, followed by the Bonferroni post hoc 
test, (*p < 0.05, Ama vs. control; #p < 0.05, Ama vs. Ama +Pol). 
3.2.4. Polymyxin B abrogated the α-amanitin-induced alteration of the 
transcription process  
The evaluation of the genetic transcription by RNAP II was based on GAPDH and β-actin 
mRNA quantitative analysis.  The relative transcript levels were quantified by the Ct value, 
which increases with a decreasing amount of template. 
Data from α-amanitin-intoxicated kidney indicated that the transcription of GAPDH and 
β-actin mRNA significantly decreased (16.29 ± 1.31 and 17.83 ± 0.36, respectively) when 
compared with control group (12.98 ± 0.46 and 14.20 ± 0.3, respectively) (Table 4). This 
effect was reverted in the α-amanitin plus polymyxin B group (13.16 ± 0.30 and 15.08 ± 
0.68 for GAPDH and β-actin mRNA, respectively).  
Although the transcript levels of GAPDH mRNA in the liver samples of α-amanitin-treated 
showed a tendency to a decrease (17.28 ± 5.47), it failed to reach statistically significance. 
Nevertheless, this α-amanitin-treated tendency was reverted by the treatment with 
polymyxin B (14.80 ± 1.24).  
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On the other hand, no differences were found for β-actin mRNA levels for liver samples 
(Table 4). Importantly, RNA polymerase I was not affected by α-amanitin poisoning since 
the transcription of ribosomal proteins S18 and S28 by RNA polymerase I was always 
similar, regardless of the organ or experimental group analyzed (Table 4). 
 
 Table 4. Relative mRNA levels of S28, S18, GAPDH and β-actin genes in liver and kidney 
samples. 
 
 
3.2.5. Polymyxin B prevented α-amanitin-induced renal and hepatic damage  
Given the known toxic effects of α-amanitin in the liver and kidney, we proceed to a 
histopathological analysis to evaluate the putative protective tissue effects of the 
polymyxin B antidote. As expected, liver samples from the control and polymyxin B 
groups presented a normal structure at light microscopy, without evidences of edema, 
necrosis or cellular infiltrations (Figure 5A and 5B, Table 5). On the other hand, α-
amanitin caused prominent hepatic cellular edema, cytoplasmic vacuolization and 
interstitial inflammatory cell infiltration (Figure 5C, Table 5). Moreover, the α-amanitin 
group showed some necrotic foci in the liver (Figure 5C and Table 5), which were more 
evident in the centrilobular zone. The group of α-amanitin plus polymyxin B showed a 
significant decrease in α-amanitin-induced necrosis, edema and cytoplasmic vacuolization 
(Figure 5D, Table 5). However, polymyxin B was not able to prevent the α-amanitin-
induced increase in interstitial infiltration of inflammatory cells (Figure 5D, Table 5).  
Regarding the kidney, control and polymyxin B groups presented a normal renal structure 
at light microscopy (Figure 6A and 6B, Table 5). Histological examination of α-amanitin-
treated kidney (Figure 6C, Table 5) revealed severe degenerative changes: 1) the renal 
 
 RNAP I RNAP II 
 S28
 S18 GAPDH β-Actin 
Liver 
    Control 34.3 ± 0.7 31.7 ± 1.4 14.5 ± 1.5 17.4 ± 2.5 
Polymyxin B 34.9 ± 1.5 31.6 ±1.8 14.7 ± 1.4 17.3 ± 1.6 
α-Amanitin 33.9 ± 0.4 30.7 ± 0.6 17.3 ± 5.5 16.1 ± 1.8 
α-Amanitin+ 
polymyxin B 34.5 ± 0.4 31.0 ± 0.5 14.8 ± 1.2 16.5 ± 1.3 
Kidney 
    
Control 34.9 ± 0.8 31.1 ± 0.8 13.0 ± 0.4 14.2 ± 0.4 
Polymyxin B 33.8 ± 0.4 30.8 ± 0.3 12.5 ± 0.4 14.9 ± 0.4 
α-Amanitin 34.4 ± 1.4 30.9 ± 1.7     16.3 ± 1.3****      17.8 ± 0.4**** 
α-Amanitin+ 
polymyxin B 32.8 ± 0.7 29.5 ± 0.9     13.2 ± 0.3
####      15.1 ± 0.7#### 
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corpuscles appear heterogeneous, with a wide capsular space, and thickened external 
Bowman capsule; 2) proximal tubules showed necrotic cells vacuolization and edema; and 
3) distal tubules cells had signs of atrophy and degeneration, while a large amount of a
protein-related material caused enlargement and obstruction of these tubules (Figure 6C). 
Noteworthy, in the α-amanitin plus polymyxin group, the damage induced by α-amanitin 
was significantly attenuated, particularly the regarding the necrotic foci and the 
obstruction of distal tubules (Figure 6D, Table 5). 
!
Figure 5. Liver histopathology: (A) Light micrograph from the control group, showing 
normal morphology and structure; (B) Light micrograph from the polymyxin B group, 
showing normal morphology and structure; (C) Light micrograph from α-amanitin group. 
The presence of cellular edema (yellow arrows), cytoplasmic vacuolization (white arrow), 
inflammatory cells (green arrows), as well as some necrotic zones can be seen (cyan 
arrows); (D) Light micrograph from α-amanitin plus polymyxin B group. The edema and 
cytoplasmic vacuolization and necrosis were significantly attenuated by polymyxin B. 
50 µm 
A 
50 µm 
B 
50!µm 
C 
50!µm 
D 
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Figure 6. Kidney histopathology: (A) Light micrograph from the control group, showing 
normal morphology and structure; (B) Light micrograph from the polymyxin B group, 
showing normal morphology and structure; (C) Light micrograph from α-amanitin group. 
The presence of cellular edema (yellow arrow), cytoplasmic vacuolization (green arrow), 
large amounts of protein-related material cause enlargement and obstruction of distal 
tubules (black arrow), as well as some necrotic zones can be seen (cyan arrow); (D) Light 
micrograph from α-amanitin plus polymyxin B group. The obstruction of distal tubules, 
edema, cytoplasmic vacuolization and necrosis, were significantly attenuated after 
polymyxin B 
50 µm 50 µm 
A B 
50 µm 
C 
50 µm 
D 
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Table 5. Semi-quantitative analysis of the morphological injury parameters of control, α-
amanitin and α-amanitin plus polymyxin B groups.  
Liver 
Control Polymyxin B α-Amanitin α-Amanitin + 
polymyxin B 
Cellular 
degeneration 
0.00 ± 0.00   0.25 ± 0. 44 2.02 ± 0.42**** 0.44 ± 0.50* #### 
Necrosis 0.00 ± 0.00   0.16 ± 0.49* 1.62 ± 0.49**** 0.42 ± 0.50* #### 
Inflammatory 
activity 
0.25 ± 0.43   0.23 ± 0.42 2.09 ± 0.35**** 2.04 ± 0.20**** 
Kidney 
Cellular 
degeneration 
0.27 ±0.45 0.20 ± 0.41 2.26 ± 0.44**** 1.08 ± 0.33**** #### 
Necrosis 
0.00 ± 0.00 0.00 ± 0.00 2.06 ± 0.62**** 0.61 ± 0.55**** #### 
Inflammatory 
activity 
0.22 ± 0.42 0.19 ± 0.40 1.81 ± 0.42**** 1.66 ± 0.48**** 
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3.2.2.6. α-Amanitin caused NF-κB nuclear translocation that was not reverted 
by polymyxin B 
The translocation of the NF-κB factor to the nuclei was assessed by 
immunohistochemistry in the liver and kidney (Figure 7 and 8) in the short term study. 
The liver of control and polymyxin B groups showed mainly cytoplasmic staining without 
marked nuclear staining cells (Figure 7A and 7B). On the other hand, α-amanitin caused 
significant nuclear translocation of NF-κB mainly in the macrophage-like cells (0.0397 ± 
0.0168 cells/µm2) when compared to control group (0.0018 ± 0.0027 cells/µm2) (Figure 
7C and 7E). Moreover, α-amanitin was also able to cause a significant increase of 
hepatocytes staining positive as a result of activated nuclear NF-κB (0.0151 ± 0.0093 
cells/µm2)  (Figure 7C and 7F) when compared to the control group (0.0012 ± 0.0049 
cells/µm2). The α-amanitin plus polymyxin B group (0.0048 ± 0.0319 and 0.0019 ± 
0.0129 cells/µm2 for macrophage-like cells and hepatocytes, respectively) showed similar 
results to α-amanitin group, therefore polymyxin B was not able to revert the pro-
inflammatory effects of α-amanitin (Figure 7D, 7E and 7F). 
Regarding the kidneys, the results showed predominant cytoplasmic staining in control 
and polymyxin B groups (Figure 8A and 8B), whereas in both α-amanitin and α-amanitin 
plus polymyxin B groups an increase of macrophage-like cells staining positive for 
activated NF-κB was observed (Figure 8C and 8D). Due to the heterogeneity of the tissue, 
the accurate nuclear staining count of the type of cell marked was difficult, therefore only 
the representative light micrographs of the kidney (Figure 8) are presented. 
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Figure 7. Immunohistochemistry of NF-κB activation in the liver by light microscopy: 
(A) Light micrograph from the control group, showing only cytoplasmic staining without
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marked nuclear staining cells; (B) Light micrograph from polymyxin B group showing 
only cytoplasmic staining without marked nuclear staining cells; (C) Light micrograph 
from α-amanitin group showing a greater number of cell staining positive for activated 
NF-κB in the macrophage-like cells (yellow arrows) and in the hepatocytes (cyan arrows). 
(D) Light micrograph from α-amanitin plus polymyxin B group showing a greater number
of cells staining positive for activated NF-κB in the macrophage-like cells (yellow arrow).
(E) Number of macrophage-like cells staining positive for activated NF-κB. (F) Number
of hepatocytes staining positive for activated NF-κB of control, 3 × 2.5 mg/kg polymyxin B 
(Pol), 0.33 mg/kg α-amanitin (Ama), and α-amanitin plus polymyxin B (Ama+Pol) groups. 
Results were expressed as means ± standard deviation. Results were obtained from 4 
animals from each treatment group. Statistical comparisons were made using Kruskal-
Wallis ANOVA on Ranks followed by the Dunn’s post hoc test (****p < 0.0001, Ama and 
Ama+Pol vs. control). 
Figure 8. Immunohistochemistry of NF-κB activation in the kidney by light microscopy. 
(A) Light micrograph from the control group, showing only cytoplasmic staining without
20!µm 
A
20!µm 
B
20!µm 
C
20!µm
D
Study V: Discovery of an effective antidote for Amanita phalloides poisoning: a precious extension of polymyxin B 
pharmacotherapy 
143 
marked nuclear staining cells. (B) Light micrograph from polymyxin B group showing 
only cytoplasmic staining without marked nuclear staining cells. (C) Light micrograph 
from α-amanitin group showing cell staining positive for activated NF-κB in the 
macrophage-like cells (yellow arrow). (D) Light micrograph from α-amanitin plus 
polymyxin B group showing cell staining positive for activated NF-κB in the macrophage-
like cells (yellow arrow).  
3.2.2.7. Polymyxin B prevented the α-amanitin increase of hepatic protein 
carbonylation  
Protein carbonylation is an indicator of severe oxidative damage, which often leads to a 
loss of protein function. As shown in Figure 9A, liver protein carbonylation increased 
significantly in α-amanitin group (127.6 ± 7.1 %) when compared to control group (100.0 ± 
10.1 %). Treatment with polymyxin B significantly attenuated hepatic α-amanitin-induced 
increase of protein carbonylation (107.8 ± 16.1 %). In the kidneys, although a tendency to 
increase was observed in the α-amanitin group (122.9 ± 34.3 %), when compared to 
control (100.0 ± 13.3 %), no statistical significance was reached (Figure 9B). 
Figure 9. (A) Protein carbonylation levels in the liver; (B) Protein carbonylation levels 
in the kidney, in control, 3 × 2.5 mg/kg polymyxin B (Pol), 0.33 mg/kg α-amanitin (Ama), 
and α-amanitin plus polymyxin B (Ama+Pol) groups. Results were expressed as 
percentage variation of control values and expressed as means ± standard deviation. 
Results were obtained from 4 animals from each treatment group. Statistical comparisons 
were made one-way ANOVA, followed by the Dunn’s post hoc test, (*p < 0.05, Ama vs. 
control; #p < 0.05, Ama vs. Ama +Pol). 
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3.2.3. Survival rate and welfare examination  
A long-term survival study (30 days) was done with two different polymyxin B treatment 
regimens after α-amanitin (0.33 mg/kg i.p.): 1) polymyxin B was administered at 4, 8 and 
12 h (3 × 2.5 mg/kg i.p.), and 2) polymyxin B (1 × 2.5 mg/kg) was concomitantly 
administered with α-amanitin. 
All mice exposed to 0.33 mg/kg of α-amanitin died within 5 days (Figure 10). All deaths 
occurred within 2 to 5 days α-amanitin post administration. α-Amanitin treated animals 
became hunched and lethargic soon after dosing. Subsequently, mice showed apathy, 
reduced mobility, respiratory problems, seizures, and disorientation until death within 24 
h of these symptoms arousal.  
The concomitant administration of α-amanitin and polymyxin B resulted in 100% of 
survival. The group that received concomitant administration of polymyxin B with α-
amanitin showed moderate signs of discomfort at day five, namely involuntary movements 
of the head that persisted without improvement until the end of the experiment.  
The group that received multiple doses of polymyxin B and α-amanitin, a 50% survival 
rate was observed. All deaths occurred within 5 to 7 days. In the surviving animals that 
received multiple doses of polymyxin B and α-amanitin, no poisoning signs were observed.  
Neither the polymyxin B group (3 × 2.5 mg/kg i.p.) nor the control group showed any 
other signs of discomfort during the 30 days experiment. 
Figure 10. Survival rate curves after concomitant i.p. administration of 0.33 mg/kg of α-
amanitin and polymyxin B (2.5 mg/kg) and administration of polymyxin B (2.5 mg/kg) 4, 
8 and 12 h after initial administration of α-amanitin. Results are expressed as percent 
survival. Results were obtained from 4 animals from each treatment. Statistical 
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comparisons were made using Log-rank (Mantel-Cox) test (*p < 0.05, Ama + Pol 2.5 
mg/kg vs. Ama; **p < 0.01, Ama + Pol 2.5 mg/kg vs. Ama;  ##p < 0.01, Ama vs. control). 
Blue line represents saline-control treatment, dark purple represents polymyxin B 
treatment; violet line represents the treatment with α-amanitin, yellow line represents the 
concomitant treatment with α-amanitin and polymyxin B (2.5 mg/kg), magenta line 
represents the administration of polymyxin B (3x2.5 mg/kg) 4, 8 and 12 h after α-amaniti 
4. Discussion
The present work reports the discovery of what we believe will be the first effective 
antidote for A. phalloides poisoning: polymyxin B. The present study provides 
unequivocal in silico and in vivo evidence that polymyxin B confers a potent protection 
against α-amanitin induced-toxicity, by interfering with its main mechanism of toxicity, 
the inhibition of RNAP II activity. Outstandingly, the in silico studies on RNAP II were 
shown to be of outmost importance in the development process, and the successful in vivo 
studies allow the suggestion of immediate use of the antidote in addition to the current 
therapeutic measures, as polymyxin B is a therapeutic drug with a well-established clinical 
use.  
We started with the application of in silico methods, taking advantage of the description of 
the X-ray structure of α-amanitin with yeast RNAP II that revealed several key molecular 
interactions that may contribute to inhibition of RNAP II activity (Bushnell et al. 2002). 
Based on that structure, we have recently reported an in silico study in which we provided 
new insights into the inhibition mechanism of RNAP II by α-amanitin; additionally the 
mode of interaction of α-amanitin and three clinically used antidotes (benzylpenicillin, 
ceftazidime and silybin) with RNAP II, using docking methods and molecular dynamics 
simulations was investigated (Garcia et al. 2014). Multiple relevant interactions between 
α-amanitin and RNAP II are located in the bridge helix and the trigger loop. Thus, α-
amanitin may block RNAP II translocation by interacting with the bridge helix, preventing 
the conformational change of the trigger loop and consequent transcriptional elongation. 
Benzylpenicillin, ceftazidime and silybin were shown to be able to bind to the same site as 
α-amanitin, although not replicating the unique α-amanitin binding mode. These drugs 
establish considerably less intermolecular interactions than α-amanitin and the ones that 
exist are essentially confined to the bridge helix and adjacent residues (Garcia et al. 2014). 
These results show that the therapeutic effect of these drugs does not seem to be directly 
related with the binding with RNAP II but to other mechanisms. Therefore, an antidote 
that regenerates the RNAP II or that prevents the α-amanitin binding to RNAP II does not 
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yet exists and clinical efficacy of the treatments after A. phalloides is still low (Garcia et al. 
2015). 
Herein, we have applied the same in silico methodology to a peptide with similar 
composition and molecular weight of amatoxins, polymyxin B, and confirmed its ability to 
displace α-amanitin from RNAP II. Polymyxin B was never tested as an antidote for α-
amanitin. Docking and MD simulations (10 ns) were carried out to study the mode of 
interaction of RNAP II/polymyxin B complex using binding energy decomposition based 
on the MM-GBSA approach, as reported before for other molecules (Garcia et al. 2014). 
Three valuable findings could be observed in silico: (1) polymyxin B binding site is located 
in the same interface of α-amanitin, which can prevent the binding of the toxin; (2) 
polymyxin B does not interact with bridge helix residues allowing the transcription 
process; (3) hydrogen bonds, CH–π and hydrophobic interactions drive the bindings of 
polymyxin B to RNAP II. Therefore, the polymyxin B binding location on RNAP II can 
potentially protect RNAP II from the α-amanitin-induced impairment. In fact, 
competition between polymyxin B and α-amanitin and/or displacement of α-amanitin 
from RNAP II by polymyxin can occur depending on the affinity of each molecule for the 
RNAP II binding site. 
To prove the applicability of our in silico results, we used an in vivo model often used to 
study α-amanitin toxicity (Schneider et al. 1987; Schneider et al. 1992; Tong et al. 2007; 
Yamaura et al. 1986; Zhao et al. 2006). Since RNAP II is considered the main target for α-
amanitin toxicity, mRNA levels can be used as a measure of its inhibition (Larson 2011) 
and our results showed that inhibition of kidney GAPDH and β-actin mRNA transcription 
elicited by α-amanitin was efficiently reverted by polymyxin B. Still, in the liver changes on 
mRNA levels of GAPDH and β-actin did not reach significance. This apparent discrepancy 
between the liver and kidney could be explained, at least partially, by the process of mRNA 
turnover. The turnover of mRNA is complex, organ/cell specific, and the several critical 
mechanisms are not yet fully understood (Beelman and Parker 1995; Guhaniyogi and 
Brewer 2001; Ross 1995). Moreover, the mRNA half-live varies greatly between different 
cell types. In rat hepatocytes, the half-life for β-actin mRNA is 9 h (Reuner et al. 1995), 
whereas in HepG2 cells it is reported as 5-6 h (Gao et al. 2003). In addition, a half-life of 
6.6 h and 13.5 h in human leukemia Nalm-6 (B-cell derived) and CCRF-CEM (T-
cell derived) cells, respectively, was reported for the same mRNA transcript (Leclerc et al. 
2002). Furthermore, the regulation of mRNA stability is likely to be an essential 
component in the tissue response to toxins exposure, and it differs among organs (Ross 
1995). To the best of our knowledge, in CD-1 mice, the half-lives of hepatic or renal 
GAPDH and β-actin mRNA are not known. Moreover, in the present study, GAPDH 
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seemed to be a more sensitive marker for α-amanitin intoxication at 24 h in the kidney. 
However, organ differences of α-amanitin accumulation may also have an important 
influence in the observed results. 
Polymyxin B not only had a strong impact on genetic expression, but it also caused a clear 
protection against α-amanitin-induced injury. Serum aminotransferases (ALT and AST) 
have been used as sensitive indicators for liver injury caused by amatoxins (Chang and 
Yamaura 1993; Yamaura et al. 1986; Zhao et al. 2006) and, in accordance, in our model, 
AST and ALT were significantly increased in the α-amanitin-intoxicated group. That α-
amanitin-induced increased was totally reverted by administration of multiple doses of 2.5 
mg/kg polymyxin B. Moreover, the plasma findings were corroborated by histological 
observations. The liver of mice administered with α-amanitin evidenced evident damage, 
with cellular edema, cytoplasmic vacuolization and interstitial inflammatory cell 
infiltration, as well as some centrilobular necrotic zones. These histological phenotypes 
are in agreement with previous reports of α-amanitin studies in mice (Kaya et al. 2014; 
Wills et al. 2005; Zhao et al. 2006). α-Amanitin (1 mg/kg i.p.)-treated Balb/c mice showed 
vacuolar degeneration of liver cells, 1 h and 6 h after poisoning (Kaya et al. 2014), whereas 
α-amanitin (0.327 mg/kg intravenous) caused liver fatty degeneration and necrosis 48 h 
after treatment in the same mice strain (Zhao et al. 2006). Moreover, histopathological 
hepatic damage in laboratory animals is similar to those found in humans after A. 
phalloides intoxication, namely regarding features of hepatic massive centrilobular 
necrosis and vacuolar degeneration (Fineschi et al. 1996).  
Regarding the kidney, although less studied in humans, it is also a target organ for A. 
phalloides poisoning. Human data indicates that acute tubular necrosis with kidney 
failure occurs in amatoxins-intoxicated patients (Mydlik and Derzsiova 2006). In animal 
models, intense tubular necrosis was described in Balb/c mice 48 h after α-amanitin 
(0.327 mg/kg intravenous) (Zhao et al. 2006). In our work, the histological examination of 
α-amanitin-intoxicated kidney revealed extensive damage and a significant intratubular 
obstruction. Although the nature of that obstruction is unknown, the reduced tubular 
epithelial cell proliferation as a consequence of inhibition of RNAP II and cellular necrosis 
may lead to that material accumulation. Noteworthy, the administration of polymyxin B 
protected against the occurrence of the majority of the renal damage inflicted by α-
amanitin, namely cellular edema, cytoplasmic vacuolization and necrosis. However, 
polymyxin B was not able to revert the hepatic and renal pro-inflammatory effect that 
occurred after α-amanitin. Indeed, in the present work, NF-κB was strongly activated in 
the liver and kidney exposed to α-amanitin, whereas polymyxin was not able to revert that 
NF-κB activation. The nuclear factor NF-κB pathway has been considered a prototypical 
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pro-inflammatory signaling, based on the role of NF-κB in the expression of pro-
inflammatory genes including cytokines, chemokines, and adhesion molecules (Lawrence 
2009). To the best of our knowledge, this was the first time that NF-κB factor was shown 
to play an important role on α-amanitin toxicity. Moreover, NF-κB activation can promote 
liver injury through the genetic transcription of TNF-α and IL-6 (Murr et al. 2002; Zhang 
et al. 2007; Zhao et al. 2005). In fact, TNF-α has been implicated in α-amanitin induced 
hepatotoxicity in vivo, since after α-amanitin (3 mg/kg i.p.), the levels of hepatic TNF-
messenger RNA were shown to increase, concurring to hepatocytes apoptosis (Leist et al. 
1997). Consistently, mice deficient for the 55-kilodalton TNF receptor were protected from 
α-amanitin–induced toxicity (Leist et al. 1997). The authors suggested that the synergism 
between TNF-α and α-amanitin may explain the highly hepatotoxic potential of α-
amanitin in vivo (Leist et al. 1997). NF-κB could regulate TNF-α expression (Zhao et al. 
2005), and therefore the development of therapies aimed to block TNF-α and/or NF-κB 
could be of outmost importance against amatoxins toxicity. In the present work, it is 
reasonable to assume that the pro-inflammatory effect of NF-κB may be responsible for 
some of the late deaths on the survival study when polymyxin B was only administered 4 h 
after α-amanitin. On the other hand, when administered concomitantly, polymyxin B 
possibly prevented α-amanitin to reach RNAP II, therefore avoiding any significant side 
effect. The link between α-amanitin RNAP II inhibition and NF-κB activation should be 
further investigated as it could stablish other pathways for antidotal therapy against this 
toxin.  
α-Amanitin toxicity has been associated with oxidative stress and protein carbonylation is 
seen as a stable biomarker of oxidative stress as protein turnover can take hours or days 
(Dalle-Donne et al. 2003). Herein, protein carbonylation increased significantly in liver of 
mice exposed to α-amanitin, relatively to the control group, suggesting that α-amanitin is 
able to alter protein redox status. This effect was abrogated by the multiple administration 
of polymyxin B. Available data regarding α-amanitin ability to induce oxidative stress is 
elusive. Mice treated with α-amanitin (1 mg/kg i.p.) and sacrificed 20 h after poisoning 
showed liver superoxide dismutase activity increase (Zheleva et al. 2007). The authors 
concluded that in vivo α-amanitin liver accumulation could lead to reactive oxygen species 
(ROS) formation, in particular superoxide anion radical (Zheleva et al. 2007). Recently, 
the levels of ROS in kidney homogenates isolated from α-amanitin (1 mg/kg i.p.)-treated 
mice were found to be increased (Zheleva 2013), whereas in vitro, the formation of 
phenoxyl radical after oxidation of α-amanitin was demonstrated (Zheleva 2013). 
Although NF-κB pro-inflammatory activity is often associated with oxidative stress, in the 
present study, polymyxin B was able to abrogate α-amanitin induced protein 
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carbonylation and not NF-κB activation, suggesting that the mechanisms involved are 
dissimilar. 
The hindrance of α-amanitin-overall toxicity by polymyxin B was established by a 30 days 
survival study. The administration of polymyxin B at 4, 8 and 12 h post α-amanitin 
resulted in a 50% of survival rate, whereas α-amanitin-treated animals died within 5 days. 
In this experimental approach, polymyxin B was administered 4 h after α-amanitin 
exposure, seeking a more realistic treatment approach, since hospitalization after A. 
phalloides human poisoning usually occurs only hours after ingestion. Importantly, the 
concomitant administration of polymyxin B and α-amanitin resulted in 100% survival 
until the 30th day post exposure, confirming the antidote efficacy.  
Taken together, the in silico and the in vivo data obtained in the present study 
demonstrated that polymyxin B acts on RNAP II and prevents α-amanitin toxicity. The use 
of polymyxin B in human mushroom poisonings will be the main goal to prove the validity 
of the present work. Clinical assays in intoxicated humans are feasible with polymyxin B 
since the doses used in this pre-clinical study are considered safe (Zavascki et al. 2007), 
when allometric scaling is applied. The 3 doses of 2.5 mg/kg of polymyxin B in mice sums 
up to approximately 1 mg/kg in humans, according to the allometric scaling (West and 
Brown 2005). This polymyxin B dose is below the recommended dose of intravenous 
polymyxin B for the treatment of infections caused by Pseudomonas aeruginosa in 
patients with normal renal function (Zavascki et al. 2007). The data presented herein 
demonstrate that polymyxin B may be used as a novel pharmacological approach to the 
treatment of A. phalloides poisoning. Thus, its rapid introduction in the therapeutic 
antidotal response will be of the outmost importance to increase the patient’s survival rate 
of the putative fatal A. phalloides intoxication. For ethical reasons, however, polymyxin B 
should be added to the ongoing therapeutic protocol to improve A. phalloides survival and 
not replace it as to guaranty the maximal efficacy of the clinical pharmacological weapons 
available.  
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Table legends 
Table 1. Binding energy calculation between the polymyxin B and Rpb1 and Rpb2 
subunits (all energies are in kcal/mol). 
Table 2. Hydrogen bonds formed between the polymyxin B and RNA polymerase IIa. 
Table 3. Ratios of liver weight / body weight and kidney weight/body weight. Results are 
presented as means ± standard deviation from 4 animals of each treatment group. 
Statistical comparisons were made using the One-way ANOVA followed by Dunn’s post 
hoc test (*p < 0.05 vs. control). 
Table 4. Relative mRNA levels of S28, S18, GAPDH and β-actin genes in liver and kidney 
samples. Results are presented as mean ± standard deviation of threshold cycles from 4 
animals from each treatment group. Statistical comparisons were made using ANOVA 
followed by Bonferroni post hoc test (****p < 0.0001, Ama and vs. Control; ####p < 
0.0001, Ama and vs. Ama+Pol). 
Table 5. Semi-quantitative analysis of the morphological injury parameters of control, α-
amanitin and α-amanitin plus polymyxin B groups. Results of hematoxylin-eosin staining, 
given in scores, are presented as means ± standard deviation from 4 animals from each 
treatment group. Statistical comparisons were made using Kruskal-Wallis ANOVA on 
Ranks followed by the Dunn’s post hoc test (*p < 0.05, ****p < 0.0001, treatment vs. 
control; ####p < 0.0001, Ama group vs Ama+ Pol). 
Study V: Discovery of an effective antidote for Amanita phalloides poisoning: a precious extension of polymyxin B 
pharmacotherapy 
151 
REFERENCES 
Barbosa DJ, Capela JP, Oliveira JM, et al. (2012) Pro-oxidant effects of Ecstasy and its 
metabolites in mouse brain synaptosomes. Br J Pharmacol 165(4b):1017-33  
Beelman CA, Parker R (1995) Degradation of mRNA in eukaryotes. Cell 81(2):179-183  
Bidnychenko Y (2001) Detecting Mushroom Peptide Toxins in Body Fluids by Capillary 
Electrophoresis. LCGC 19(9):1000-1002  
Broussard CN, Aggarwal A, Lacey SR, et al. (2001) Mushroom poisoning--from diarrhea to 
liver transplantation. Am J Gastroenterol 96(11):3195-8  
Bushnell DA, Cramer P, Kornberg RD (2002) Structural basis of transcription: alpha-
amanitin-RNA polymerase II cocrystal at 2.8 A resolution. Proc Natl Acad Sci USA 
99(3):1218-22  
Case DA, Cheatham TE, 3rd, Darden T, et al. (2005) The Amber biomolecular simulation 
programs. J Comput Chem 26(16):1668-88 
Chang I-M, Yamaura Y (1993) Aucubin: A new antidote for poisonous Amanita 
mushrooms. Phytother Res 7(1):53-56  
Cheung PCK (2010) The nutritional and health benefits of mushrooms. Nutrition Bulletin 
35(4):292-299  
Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R (2003) Protein carbonyl 
groups as biomarkers of oxidative stress. Clin Chim Acta 329(1-2):23-38  
Dores-Sousa JL, Duarte JA, Seabra V, Bastos Mde L, Carvalho F, Costa VM (2015) The age 
factor for mitoxantrone's cardiotoxicity: Multiple doses render the adult mouse 
heart more susceptible to injury. Toxicology 329:106-19  
Fineschi V, Di Paolo M, Centini F (1996) Histological criteria for diagnosis of amanita 
phalloides poisoning. J Forensic Sci 41(3):429-32 
Gao C, Guo H, Downey L, Marroquin C, Wei J, Kuo PC (2003) Osteopontin-dependent 
CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 24(12):1871-
8  
Garcia J, Carvalho AT, Dourado DF, Baptista P, de Lourdes Bastos M, Carvalho F (2014) 
New in silico insights into the inhibition of RNAP II by alpha-amanitin and the 
protective effect mediated by effective antidotes. J Mol Graph Model 51:120-7  
Garcia J, Costa V, Carvalho A, et al. (2015) Amanita phalloides poisoning: mechanisms of 
toxicity and treatment. submitted  
Guhaniyogi J, Brewer G (2001) Regulation of mRNA stability in mammalian cells. Gene 
265(1-2):11-23  
He J, Gao S, Hu M, Chow DS, Tam VH (2013) A validated ultra-performance liquid 
chromatography-tandem mass spectrometry method for the quantification of 
polymyxin B in mouse serum and epithelial lining fluid: application to 
pharmacokinetic studies. J Antimicrob Chemother 68(5):1104-10  
Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics. J Mol Graph 
14(1):33-38  
Kaya E, Surmen MG, Yaykasli KO, et al. (2014) Dermal absorption and toxicity of alpha 
amanitin in mice. Cutan Ocul Toxicol 33(2):154-60  
Kempe S, Kestler H, Lasar A, Wirth T (2005) NF- kB controls the global pro-
inflammatory response in endothelial cells: evidence for the regulation of a pro-
atherogenic program. Nucleic Acids Res 33(16):5308-5319  
Koda-Kimble MA, Alldredge BK, Corelli RL, Ernst ME (2012) Koda-Kimble and Young's 
Applied Therapeutics: The Clinical Use of Drugs. Wolters Kluwer Health 
Kollman PA, Massova I, Reyes C, et al. (2000) Calculating structures and free energies of 
complex molecules: combining molecular mechanics and continuum models. Acc 
Chem Res 33(12):889-97  
Larson DR (2011) What do expression dynamics tell us about the mechanism of 
transcription? Current opinion in genetics & development 21(5):591-9 
Lawrence T (2009) The Nuclear Factor NF- kB Pathway in Inflammation. Cold 
Spring Harb Perspect Biol 1(6):a001651 
Study V: Discovery of an effective antidote for Amanita phalloides poisoning: a precious extension of polymyxin B 
pharmacotherapy 
 152 
Leclerc G, Leclerc G, Barredo J (2002) Real-time RT-PCR analysis of mRNA decay: half-
life of Beta-actin mRNA in human leukemia CCRF-CEM and Nalm-6 cell lines. 
Cancer Cell Int 2(1):1  
Leist M, Gantner F, Naumann H, et al. (1997) Tumor necrosis factor-induced apoptosis 
during the poisoning of mice with hepatotoxins. Gastroenterology 112(3):923-34 
Morris GM, Huey R, Lindstrom W, et al. (2009) AutoDock4 and AutoDockTools4: 
Automated docking with selective receptor flexibility. J Comput Chem 
30(16):2785-91  
Mowry JB, Spyker DA, Cantilena LR, Jr., Bailey JE, Ford M (2013) 2012 Annual Report of 
the American Association of Poison Control Centers' National Poison Data System 
(NPDS): 30th Annual Report. Clin Toxicol 51(10):949-1229  
Murr MM, Yang J, Fier A, Kaylor P, Mastorides S, Norman JG (2002) Pancreatic elastase 
induces liver injury by activating cytokine production within Kupffer cells via 
nuclear factor-Kappa B. J Gastrointest Surg 6(3):474-80  
Mydlik M, Derzsiova K (2006) Liver and kidney damage in acute poisonings. Bantao 
Journal 4(1):30-32 
Onufriev A, Bashford D, Case DA (2000) Modification of the Generalized Born Model 
Suitable for Macromolecules. J Phys Chem B 104(15):3712-3720  
Pinson CW, Daya MR, Benner KG, et al. (1990) Liver transplantation for severe Amanita 
phalloides mushroom poisoning. Am J Surg 159(5):493-9  
Poucheret P, Fons F, Dore JC, Michelot D, Rapior S (2010) Amatoxin poisoning treatment 
decision-making: pharmaco-therapeutic clinical strategy assessment using 
multidimensional multivariate statistic analysis. Toxicon 55(7):1338-45  
Reuner KH, Wiederhold M, Dunker P, et al. (1995) Autoregulation of actin synthesis in 
hepatocytes by transcriptional and posttranscriptional mechanisms. European 
journal of biochemistry / FEBS 230(1):32-7  
Ross J (1995) mRNA stability in mammalian cells. Microbiol Rev 59(3):423-50  
Schneider SM, Borochovitz D, Krenzelok EP (1987) Cimetidine protection against alpha-
amanitin hepatotoxicity in mice: a potential model for the treatment of Amanita 
phalloides poisoning. Ann Emerg Med 16(10):1136-40  
Schneider SM, Michelson EA, Vanscoy G (1992) Failure of N-acetylcysteine to reduce 
alpha amanitin toxicity. J Appl Toxicol 12(2):141-2 
Tong TC, Hernandez M, Richardson WH, 3rd, et al. (2007) Comparative treatment of 
alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, 
thioctic acid, and silybin in a murine model. Ann Emerg Med 50(3):282-8  
Vetter J (1998) Toxins of Amanita phalloides. Toxicon 36(1):13-24  
Vogel G, Tuchweber B, Trost W, Mengs U (1984) Protection by silibinin against Amanita 
phalloides intoxication in beagles. Toxicol Appl Pharmacol 73(3):355-62 
Weiser J, Shenkin PS, Still WC (1999) Approximate atomic surfaces from linear 
combinations of pairwise overlaps (LCPO). J Comput Chem 20(2):217-230  
West GB, Brown JH (2005) The origin of allometric scaling laws in biology from genomes 
to ecosystems: towards a quantitative unifying theory of biological structure and 
organization. J Exp Biol 208(9):1575-1592  
Wieland T (1983) The toxic peptides from Amanita mushrooms. Int J Pept Prot Res 
22(3):257-276 
Wieland T, Faulstich H (1978) Amatoxins, phallotoxins, phallolysin, and antamanide: the 
biologically active components of poisonous Amanita mushrooms. CRC Crit Rev 
Biochem 5(3):185-260  
Wills BK, Haller NA, Peter D, White LJ (2005) Use of amifostine, a novel cytoprotective, 
in alpha-amanitin poisoning. Clin Toxicol (Phila) 43(4):261-7 
Yamaura Y, Fukuhara M, Takabatake E, Ito N, Hashimoto T (1986) Hepatotoxic action of 
a poisonous mushroom, Amanita abrupta in mice and its toxic component. 
Toxicology 38(2):161-73  
Study V: Discovery of an effective antidote for Amanita phalloides poisoning: a precious extension of polymyxin B 
pharmacotherapy 
153 
Zavascki AP, Goldani LZ, Li J, Nation RL (2007) Polymyxin B for the treatment of 
multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 
60(6):1206-15  
Zhang XP, Zhang L, Chen LJ, et al. (2007) Influence of dexamethasone on inflammatory 
mediators and NF-kappaB expression in multiple organs of rats with severe acute 
pancreatitis. World J Gastroenterol 13(4):548-56  
Zhao J, Cao M, Zhang J, Sun Q, Chen Q, Yang ZR (2006) Pathological effects of the 
mushroom toxin alpha-amanitin on BALB/c mice. Peptides 27(12):3047-52  
Zhao YF, Zhai WL, Zhang SJ, Chen XP (2005) Protection effect of triptolide to liver injury 
in rats with severe acute pancreatitis. Hepatobiliary Pancreat Dis Int 4(4):604-8  
Zheleva A (2013) Phenoxyl radicals formation might contribute to severe toxicity of 
mushrooms toxin alpha-amanitin-an electron paramagnetic resonance study. TJS 
11(1):33-38  
Zheleva A, Tolekova A, Zhelev M, Uzunova V, Platikanova M, Gadzheva V (2007) Free 
radical reactions might contribute to severe alpha amanitin hepatotoxicity-a 
hypothesis. Med Hypotheses 69(2):361-7  
  
 
 
 
 
 
  
 
 
 
 
 
CHAPTER IV 
 
 DISCUSSION AND CONCLUSIONS 
    
  
 
 
 
 
 
CHAPTER IV 
 
 157 
4.1 Discussion and conclusions 
 In this section, the results obtained and included in this dissertation are discussed 
and integrated. The conclusions will be inferred considering the overall results of the 
dissertation and the findings of other published reports.  
 The key findings of this thesis were: 1) Amatoxins and phallotoxins are not equally 
distributed in the A. phalloides fruiting body and environmental conditions play a 
significant role in the mushrooms content of these toxins; 2) A new HPLC method using 
DAD and EC detectors was successfully applied to measure α-amanitin in rat liver and 
kidney allowing, in a clinical case, to confirm the diagnosis of amatoxins poisoning; 4) 
RNAP II α-amanitin binding was characterized in silico and can be divided into specific 
zones with different properties. The model developed provided a reliable platform for the 
structure-based drug design of novel antidotes for amatoxins poisoning. 5) α-Amanitin 
affects RNAP II transcription by compromising the trigger loop and bridge helix functions. 
6) The therapeutic effect of the antidotes (benzylpenicillin, ceftazidime and silybin) used 
in amatoxins poisoning does not seem to be directly related with RNAP II binding. 7) In 
silico studies showed that polymyxin B binding site is located in the same interface of α-
amanitin, which may prevent the toxin from binding to RNAP II without interfering with 
mRNA synthesis. 8) In vivo, the inhibition of the transcription specific kidney genes 
elicited by α-amanitin (0.33 mg/kg) was efficiently reverted by multiple doses of 
polymyxin B (3 × 2.5 mg/kg). 9) Polymyxin B significantly decreased the hepatic and renal 
α-amanitin-induced injury as supported by the histology and plasma damage biomarkers 
data. 10) Fifty percent of animal exposed to polymyxin B (3 × 2.5 mg/kg) 4, 8 and 12 hours 
after α-amanitin (0.33 mg/kg) survived, while all animals treated with α-amanitin died 
until day 5. 11) A single dose of polymyxin B (2.5 mg/kg) administered concomitantly with 
α-amanitin (0.33 mg/kg) was able to guaranty 100% survival until the 30th day post 
exposure.  
 Amanita phalloides poisoning is a global problem arising from the naturally 
fruiting of the body in many parts of the globe. It is one of the most poisonous known 
toadstools, being associated with severe symptoms, high morbidity and mortality (85, 
125). Despite warnings, wild edible and A. phalloides mushrooms are frequently mistaken 
and every year several cases of intoxications are reported (6, 50, 120, 126, 127). Other 
authors has indicated a potentially significant variation in the amount of amatoxins 
contained in mushrooms collected at different geographical areas (27). Therefore, it is of 
great importance to characterize the toxicological profile of A. phalloides mushrooms 
throughout the world. Taking into account that no works are available regarding toxins’ 
CHAPTER IV 
 
 158 
composition of A. phalloides growing in Portugal, the composition of Portuguese A. 
phalloides carpophores collected from two different sites of Trás-os-Montes (Vinhais and 
Mogadouro) were analyzed (study I). Since α-amanitin is the main toxin responsible for 
the toxic effects of A. phalloides, the study I was focused on the quantification of this 
toxin. The analysis was made in 3 separated parts of the fruit body; caps, stipe, and volva. 
The results showed that the caps contained the highest amount of α-amanitin (783.94 ± 
2.66 µg/g and 666.00 ± 1.45 µg/g in caps from Vinhais and Mogadouro, respectively), 
whereas the volva had the lowest content (103.87 ± 1.84 µg/g and 73.16 ± 1.66 µg/g in 
volva from Vinhais and Mogadouro, respectively), which are consistent with previous data 
(27). Qualitative analyses of the β-, γ-amanitin, phalloidin, phallisin, and phallacidin based 
on LC-MS and HPLC-DAD were also performed. The results showed that the contents and 
distribution of amatoxins and phallotoxins in the different carpophore tissues are 
markedly different and vary from one area to another. In fact, caps have the highest 
content of amatoxins, whereas the volva was richest in phallotoxins, which is in 
accordance with previous reports (27-29). Moreover, our study supports the hypothesis 
that environmental conditions (mainly the soil type) clearly have an effect on the 
phallotoxin composition of A. phalloides carpophores. Vinhais and Mogadouro have 
significant topographic (128) and climatic differences (129) that have a significant impact 
in the soil type where the mushrooms grow. Leptosols are dominant in Mogadouro, 
whereas cambisols are the most representative soils of Vinhais (130). The highest 
phalloidin concentration was found in the stipe from Mogadouro, whereas the highest 
phallisin concentration was found in the stipe from Vinhais. These results corroborated a 
previous report indicating that the soil characteristics appear to have higher influence on 
phallotoxin composition than on amatoxins composition (29).  
 A lack of analytical methods to quantify α-amanitin in biological samples hinders 
the quantification of this toxin in tissues. According to the literature, liquid 
chromatography is the method of excellence for α-amanitin quantification (131, 132). 
Despite the availability of several HPLC methods in the literature for the analysis and 
quantification of α-amanitin in different matrices, they have been mainly applied in 
mushrooms (27-29, 75, 76), plasma (131, 133) and urine (134). Besides, these methods 
seem matrix specific. To the best of our knowledge, only two studies have been validated, 
namely a LC method for α-amanitin analyses in tissues. Leite et al. developed an analytical 
methodology of ultra performance liquid chromatography-tandem mass spectrometry 
(UPLC–MS/MS), following liver sample preparation by protein precipitation with organic 
solvents, and solid phase extraction procedure with a limit of detection of 10.9 ng/g (135). 
Filigenzi et al. described a LC-MS/MS/MS method for the analysis of α-amanitin in liver 
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(131). Liver was prepared by homogenization with aqueous acetonitrile and subsequent 
removal of acetonitrile was done using methylene chloride. The aqueous phase was then 
extracted using mixed-mode C18/cation exchange solid phase extraction cartridges. The 
detection limit of this method was 0.50 ng/g (131). These methods are time consuming 
and use equipment not common in all Toxicology Laboratories with 
 use of organic and environmentally detrimental reagents. Moreover, to date there are no 
published HPLC with EC detection methods for the analysis of α-amanitin in biological 
tissues. The determination of amatoxins in serum by HPLC was greatly improved by using 
EC detection, particularly as far as minimum detectable amounts are concerned (136). 
Consequently, we developed a simple and efficient analytical method for quantification of 
α-amanitin in liver and kidney tissues, since they are the α-amanitin main target organs 
(study II). The study II was focused on the development, optimization and application of a 
HPLC method with in-line connected DAD and EC detectors to quantify α-amanitin in 
biological samples (namely liver and kidney). Kidney and liver samples preparation was 
achieved by a simple and unique deproteinization step with perchloric acid. Specificity, 
linearity, recovery, intra and inter-assay precision, and detection and quantification limits 
were determined, in order to guarantee reliability of the analytical results. The developed 
method proved to be specific and linear in the range of 0.025-10 µg/mL, and showed 
coefficients of correlation greater than 0.994. The extraction recovery presented good 
results for the concentrations analyzed, with values ranging from 96.87 to 101.45% for 
both matrices. Precision was checked at three levels and in three different days over 3 
weeks, with intra-day and inter-day coefficients of variation lower than 15.3%. The limit of 
detection values for α-amanitin based on visual evaluation ranged from 0.05 (DAD) to 
0.025 µg/mL (EC) in liver and 0.125 (DAD) to 0.100 µg/mL (EC) in kidney. Limit of 
quantification values based on visual evaluation ranged from 0.250 (DAD) to 0.025 
µg/mL (EC) in liver and 0.250 (DAD)–0.100 µg/mL (EC) in kidney. This method was also 
successfully applied to quantify α-amanitin in human plasma since there were no 
endogenous substances in the samples co-eluting with α-amanitin. To prove the 
applicability of our method, we performed an in vivo study (Wistar rats) with different α-
amanitin doses (10 and 21,4 mg/kg, i.p.) and sacrifice times (2 and 4 hours). Our results 
showed higher levels of total α-amanitin in kidney than in liver, explained by the fact that 
the kidney serves as an elimination organ of α-amanitin. Therefore the validated analytical 
method was able to be successfully applied to toxicokinetics studies. Importantly, we 
validated the method using two detectors (DAD and EC) since HPLC-EC instruments are 
not available in many laboratories. Noteworthy, the results showed that the limits of 
detection and quantification for α-amanitin could be improved through the use of an EC 
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detector. The validated analytical method presents a high potential in the identification, 
detection and determination of α-amanitin in hepatic and renal samples offering a 
significant improvement in diagnosis, postmortem confirmation of amatoxin 
intoxications, tissues analysis and other toxicokinetics studies (study II). Moreover, it can 
be also successfully applied to other matrices like urine and gastric juice samples as we 
demonstrated in a clinical case of amatoxins poisoning (study III). This was an unusual 
case of amatoxins poisoning since no amatoxin symptoms and toxicity were observed. The 
patient was taken to the hospital emergency room 3 hours after mushrooms ingestion due 
to the rapid hallucinogenic symptoms. These hallucinogenic symptoms lead to the 
suspicion of isoxazoles-containing mushrooms poisoning, which was confirmed by the 
presence of muscimol in the urine analyzed by GC-MS. Our validated HPLC-DAD method 
was applied to the gastric juice sample, revealing the presence of α-amanitin at 1.12 µg/mL 
concentration. The rapid hospitalization and the history of mushrooms ingestion, led to an 
early therapeutic intervention for amatoxins poisoning, which consisted of gastric lavage, 
oral-activated charcoal, silybin and N-acetylcysteine administration. Usually, the 
amatoxins’ intoxicated patients arrive at the emergency room hours or even days after 
mushrooms ingestion when clinical symptoms are evident. The most widely used 
antidotes are benzylpenicillin, ceftadizime, silybin and N-acetylcysteine (5), although their 
precise mechanisms of action remain to be elucidated. Benzylpenicillin appears to inhibit 
uptake of amatoxins by hepatocytes (137), but high doses are required for that 
pharmacological action, which narrows the therapeutic/safety margin (97). Ceftazidime is 
stated to have the same pharmacological mechanisms of benzylpenicillin (97), but no 
study was conducted to prove it. Silybin and N-acetylcysteine have been used due to their 
antioxidant proprieties; however other mechanisms may be involved. So far, none of these 
antidotes have proven to be of clinical efficacy as controlled studies are lacking and 
experimental data in animals are equivocal. Thus, the main objective of this dissertation 
was to discover an effective antidote for amatoxins poisoning. For that purpose, the most 
known toxic mechanism of α-amanitin was explored (study IV). α-Amanitin inhibits 
RNAP II, a vital enzyme in the transcription process, being responsible for the synthesis of 
mRNA (explained in the theoretical background of this dissertation) (9). With this in 
mind, the elucidation of the inhibition mechanism of RNAP II by α-amanitin, using in 
silico studies, was performed (study IV). In silico methodologies have become a crucial 
component to study the interactions between biomolecules and their environment (138) 
allowing to elucidate the mechanisms of action of many compounds and to identify 
innovative therapeutic treatments (139). Another main advantage of the in silico 
techniques is their effectiveness in reducing costs and the number of experimental animals 
(140). Therefore, firstly, we used in silico studies to elucidate RNAP II structure and its 
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interaction with α-amanitin and with classically-used antidotes. The structure of RNAP II 
in a complex with α-amanitin has been determined by X-ray crystallography (56). The 
structure of the complex indicated the likely basis of inhibition and gives unexpected 
insights into the transcription mechanism (56). Bushnell et al. suggested that α-amanitin 
interferes with bridge helix movement during translocation since it binds to the free RNAP 
II core adjacent to the bridge helix (56). This X-ray structure allowed us to study in silico 
the mode of interaction of α-amanitin with RNAP II. Study IV started with molecular 
docking, an effective tool for unveiling RNAP II-α-amanitin molecular recognition (141). 
This procedure allowed to predict the α-amanitin conformation and orientation (or 
posing) within the RNAP II binding site. However, the docking process considered the 
target binding site and the ligand as rigid elements. The incorporation of flexibility 
properties in the molecular recognition process was achieved by using MD (142). MD was 
applied to study the physical movements of atoms that composed the complex (RNAP II-
α-amanitin) interacting for a period of time, giving a view of the motion of the atoms. 
Moreover, MD simulations allowed exploring of additional druggable binding sites 
(cryptic or allosteric) in the RNAP II. To provide a more detailed understanding of 
molecular recognition in RNAP II-α-amanitin interactions, we resorted to the MM-GBSA 
method. This is one of the most important post processing methods for free-energy 
estimation (143). The binding free energies obtained from molecular mechanics with MM-
GBSA calculations using MD trajectories is the most popular procedure to measure the 
strength of interactions between a ligand and its receptor (143). The results showed that 
α-amanitin affects RNAP II transcription by compromising trigger loop and bridge helix 
functions. The observed direct interactions between α-amanitin and trigger loop residues 
(Leu1081, Asn1082, Thr1083, His1085 and Gly1088) and bridge helix residues (Gly819, 
Gly820, Glu822, His816 and Phe815) interfere with the elongation process and thus 
impair the transcription process. These results clearly corroborated the hypothesis of an 
important role of the bridge helix and trigger loop as fundamental elements in the 
synthesis of mRNA (58). Moreover, previous findings suggested that α-amanitin affects 
the trigger loop movement, which closes over the active site during nucleotide 
incorporation (58). To provide a new insight into the plausible mechanism of action of the 
three classically-used antidotes in amatoxins poisoning (benzylpenicillin, ceftazidime and 
silybin), we used the same in silico methodologies described above. The results showed 
that the antidotes are able to bind to the same site as α-amanitin in RNAP II, although not 
reproducing the distinctive α-amanitin binding mode. It is not surprising that these drugs 
fail to reproduce the binding mode of α-amanitin, since the ligands are small molecules 
that establish much less intermolecular interactions with RNAP II than α-amanitin. From 
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the in silico study (study IV), we demonstrated that the therapeutic effect of these 
antidotes does not seem to be directly related with competition to RNAP II. From the 
knowledge of the recognition modes of RNAP II/α-amanitin binding, we began to search 
novel ligands with therapeutic potential against amatoxins poisoning (study V). Molecular 
docking with putative ligands began with a database of peptide compounds with similar 
composition and molecular weight to that of amatoxins, to predict relative ligand binding 
affinities. Then MD and mm-GBSA methodologies were applied in order to provide new 
insights into the possible therapeutic mechanism of action of the chosen compounds. This 
study provided, for the first time, a promising compound in amatoxins poisoning, 
polymyxin B. In silico results showed that polymyxin B binding site is located in the same 
interface of α-amanitin, which can prevent the toxin from binding, and hence possibly 
protect RNAP II from α-amanitin-induced impairment. To validate these results, a rodent 
model (CD-1 mice) was used. Mice have been used in several studies of amatoxins 
poisoning since their response to hepatic toxins is considered analogous to that of 
humans, mainly with renal and hepatic impairment (101, 144-147). As oral absorption of 
amatoxins in mice is poor, the bioavailability was guaranteed by intraperitoneal 
administration. Moreover, the intraperitoneal administration has been the preferred route 
in previous studies that evaluate putative new and the classical antidotes used against 
amatoxins poisoning (101, 112, 144, 145, 148). The selected dose of α-amanitin to be 
assayed (0.33 mg/kg) was based on LD50 in white mice (the strain was not specified) (36), 
however other doses have been reported in mice (0.15 to 0.5 mg/kg) (149). The previously 
described i.p. LD50 of α-amanitin in male Swiss mice (20-25 g) was 0.8 mg/kg, and the 
LD95 was 1.2 mg/kg (150). In a study conducted by Wills et al. the i.p. 0.68 mg/kg dose 
represented a LD90 in female Swiss mice (21-24 g) (145), whereas the intravenous LD50 
dose of α-amanitin was 0.327 mg/kg in male BALB/c mice (20 ±2.0 g) (147). These 
differences may be due to the sex, age, and mouse strains suggesting that these are 
important factors determining the susceptibility of mice to the toxic action of α-amanitin.  
 In this dissertation, two types of in vivo studies were performed in order to prove 
the efficacy of polymyxin B against α-amanitin intoxication: a short-term study (sacrifice 
time at 24 hours) and a survival study. The first study was conducted to examine 
histological damage, protein carbonylation, NF-κB activation, total RNA and specific 
mRNA quantification in liver and kidney. The subsequent survival study aimed 
to evaluate the long-term effectiveness of polymyxin B.  
 In the short-term study, all polymyxin B-treated animals received three i.p. doses 
of 2.5 mg/kg (4, 8 and 12 hours after α-amanitin injection). This dose regimen was chosen 
based on a previous pharmacokinetic study, in which an UPLC–MS/MS method was used 
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for the quantification of polymyxin B in mice serum samples after a intravenous dose of 3 
mg/kg, showing that polymyxin B is non-detectable at 4 h post-administration (151). In our 
study, the regimen of polymyxin B was initiated 4 hours after intoxication of mice with α-
amanitin, a lag time that confers realism to a possible therapeutic scheme to be applied to 
intoxicated humans. The interaction of polymyxin B and RNAP II seen in silico was 
corroborated in this in vivo study, as mRNA quantification revealed that inhibition of 
specific mRNAs transcripts elicited by α-amanitin was efficiently reverted by polymyxin B 
in the kidney. Therefore, a competition between α-amanitin and polymyxin B and/or 
displacement of α-amanitin from its RNAP II binding site by polymyxin B may occur. For 
the first time, a competitive RNAP II binder has been reported. 
 As the hepatic damage is the main concern after amatoxins poisoning, plasma liver 
damage biomarkers were assessed, namely plasma aminotransferases (AST and ALT). 
Plasma aminotransferases have been used as sensitive indicators for liver injury caused by 
amatoxins in animals and humans. In humans, plasma levels of hepatic aminotransferases 
have been the most accurate predictive indicators of recovery or death (18), whereas in 
mice studies they have been used as indicators to demonstrate the putative benefits of 
treatments (101, 152). Our results demonstrate that the increase on plasma 
aminotransferases after α-amanitin administration was abrogated by polymyxin B. This 
lower damage was accompanied by a marked decrease in histological hepatic damage 
namely necrosis, cytoplasmic vacuolation and cellular edema that occurred after α-
amanitin. 
 While our study showed that polymyxin B prevented aminotransferase rise after α-
amanitin, in a study conducted to analyze the efficacy of the classical antidotes used in 
amatoxin poisoning namely benzylpenicillin, silybin, and N-acetylcysteine, none of them 
prevented such α-amanitin-induced increase of aminotransferases in mice (101). In that 
study, the classical antidotes (benzylpenicillin, silybin and N-acetylcysteine) were 
administered 4 hours after the i.p. LD50 (0.6 mg/kg) of α-amanitin and plasma 
aminotransferases were analyzed 48 hours after α-amanitin administration (101). Based 
on that data, the authors concluded that these antidotal therapies were not effective in 
limiting hepatic injury after α-amanitin poisoning (101).  
 In our in vivo study, kidney damage was also evaluated, since it is also a target 
organ of toxicity of α-amanitin. Our results showed extensive cell damage (tubular 
necrosis, edema and cytoplasmic vacuolation) with a significant intratubular obstruction 
and inflammation in α-amanitin-intoxicated kidney. Amatoxins are excreted in large 
quantities in urine during the first days after mushrooms ingestion and remain high in the 
kidney for long periods (96 hours after ingestion of mushrooms) (19), which results in 
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kidney damage. That injury leads to high values of plasma creatinine and urea, 
culminating in renal failure (153, 154). Human kidney biopsy of amatoxins’ intoxicated 
patients showed massive acute tubular necrosis, mainly in the proximal convoluted tubule, 
and mild interstitial infiltration by mononuclear cells (155). Thus, our mice model also 
closely mimics human renal injury induced by α-amanitin. Moreover, the renal damage 
was drastically attenuated by the multiple administration of polymyxin B. This finding 
demonstrates that this antidote provides protection to both target organs of amatoxins: 
liver and kidney.  
In study V, it was observed that the inflammatory activity elicited by α-amanitin 
was not prevented by polymyxin B. In fact, a powerful activation of NF-κB in both organs 
(liver and kidney) was observed after α-amanitin administration. This effect was not 
prevented by polymyxin B. NF-kB is a pivotal transcription factor implicated in the 
regulation of many genes, particularly those of the inflammatory and immune responses 
and has both cytoprotective and cell death promoting effects (156). To the best of our 
knowledge, this was the first time that an association between NF-κB activation in liver 
and kidney with α-amanitin administration was described.  
 After an in vivo administration of α-amanitin (i.p. 3 mg/kg), the levels of hepatic 
TNF-messenger RNA increased, suggesting that the synergism between TNF-α and α-
amanitin may increase the hepatotoxicity of α-amanitin (65).  Moreover, an association 
between NF-κB activation and TNF-α may also exist, since TNF-α is known to be 
regulated by NF-κB activation (157). A study that aimed to investigate the effect of the 
inflammatory response and NF-kB activation in mice renal injury concluded that in the 
acute inflammatory response induced by ischemia/reperfusion, the activation of the TNF-
α/NF-kB signal pathway plays a key role in renal injury (158). Moreover, the activation of 
NF-kB can promote liver injury in rats with acute pancreatitis by inducing the genetic 
expression of TNF-α (159). These findings favor the research of novel treatments targeting 
the NF-κB inhibition, since it may play an important role in the protection against α-
amanitin-induced hepatic and renal toxicity. A finding that supports our hypothesis 
concerns triptolide (an anti-inflammatory and immunosuppressive compound) that was 
able to reduce pathological damage in the liver by inhibiting the activation of NF-κB and 
therefore decrease the release of inflammatory mediators in mice with severe pancreatitis 
(160).  
 Oxidative stress has also been implicated in α-amanitin-induced liver injury 
(explained in the theoretical background of this thesis) (67, 68). In this dissertation, 
carbonylation was used as a stress oxidative biomarker, since protein carbonylation occurs 
early after oxidative stress and is relatively stable (161). In our in vivo study, it was 
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performed, by the first time the protein carbonylation analysis after α-amanitin 
administration. The results showed that protein carbonylation levels increased 
significantly in liver of mice exposed to α-amanitin relatively to the control group, an 
effect that was prevented by polymyxin B. Our results corroborate previous findings, 
suggesting that ROS may have an important role in α-amanitin-induced liver toxicity (67, 
68). Although ROS are commonly involved in mechanisms that drive to NF-kB nuclear 
activation (162), polymyxin B was able to hinder α-amanitin induced protein 
carbonylation but not NF-κB activation, suggesting that the mechanisms involved in the 
two pathways are different.  
 The survival study used the same dose regimen and scheme of the short-term study 
as well as a concomitant regimen, in which a single polymyxin B (2.5 mg/kg) was 
administered concomitantly with α-amanitin. The results showed 50% of survival of the 
polymyxin B-treated mice in comparison with 100% of mortality of α-amanitin-exposed 
mice. Moreover, a single dose of polymyxin B (2.5 mg/kg) concomitantly administered 
with α-amanitin resulted in the full survival of the α-amanitin treated animals. These 
results secure the potential use of polymyxin B as an antidote against α-amanitin-induced 
liver and kidney toxicity. To the best of our knowledge, no survival study was done with 
the classical antidotes and these studies are the gold standard for evaluating the long-term 
efficacy of the antidotes.  
The findings of our in vivo study, allow proposing polymyxin B as novel therapeutic 
approach for amatoxins poisoning. Since polymyxin B is already clinically used as an 
antibiotic, the rapid introduction as an antidote may be of the outmost importance to 
increase patient survival on the putative fatal A. phalloides intoxication. For ethical 
reasons, however, polymyxin B should be added to the present protocol on A. phalloides 
intoxication and it should not replace the current protocol. We believe that this addition 
will improve the overall survival of intoxicated patients. 
 With this study, it was given an important step in the treatment of α-amanitin 
poisoning. Due to the importance of this study, the pharmacological use of polymyxin B as 
antidote in α-amanitin intoxication is being patented. 
  
 
Conclusions and future perspectives 
 
In summary, from the experimental, the in silico and the in vivo studies herein described, 
it was possible to conclude that: 
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• The toxins composition of A. phalloides varies greatly, depending on the soil and 
environmental conditions. 
 
• HPLC with DAD and EC detectors is able to accurately and specifically measure α-
amanitin in liver and kidney samples. 
 
• α-Amanitin compromises the trigger loop and the bridge helix functions of RNAP 
II, which alters the elongation process contributing to the inhibition of this 
enzyme. 
 
 
• The action mechanisms of the current antidotes (benzylpenicillin, ceftazidime and 
silybin) used in amatoxins poisoning do not seem to be directly related with 
binding to RNAP II. 
 
• Polymyxin B binding site is located in the same interface of α-amanitin, which can 
prevent the toxins from binding, and hence protect RNAP II from α-amanitin-
induced impairment. 
 
• mRNA analysis was in agreement with in silico results showing that polymyxin B 
may compete and/or displace α-amanitin from its RNAP II binding site. 
 
• The effectiveness of polymyxin B was confirmed by the reversion of the increases of 
plasmatic aminotransferases elicited by α-amanitin as well as attenuation of α-
amanitin-induced liver and kidney damage.  
 
• Multiple dose therapy of polymyxin B iniciated 4 hours after α-amanitin 
administration resulted in 50% of survival rate of the treated mice vs 0% in α-
amanitin control group. 
 
• Concomitant administration of polymyxin B with α-amanitin resulted in full 
survival of the animals. 
 
• Polymyxin B should be introduced as therapeutic drug to be used against α-
amanitin toxicity and it has high potential to be immediately applied in humans, 
since it is already in clinical use for other pathologies. 
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Concerning future perspectives, the pathway of the trigger loop is still missing. 
Thus it will be of great value to unveil the full trigger loop movement using in silico studies 
to confirm if α-amanitin impairs it. Moreover, the role of NF-κb in α-amanitin-induced 
inflammation should be further investigated. Additionally, other inflammation pathways 
should be explored. The putative pro-inflammatory properties of α-amanitin may be due 
to its interactions with cellular signaling cascades involving cytokines, regulatory 
transcription factors, and the expression of pro-inflammatory genes. Cytokines (IL-1α, IL-
1β, IL-6, IL-8, and TNF-α) deserves experimental evaluation.  
Future projects are required to continue with the pre-clinical studies to explain, in 
more detail, the mode of action of polymyxin B in the protection against α-amanitin -
induced liver and kidney injury, but also pre-clinical studies, particularly those aimed to 
synthesize new polymyxin B derivatives in attempt to guarantee full animals survival or 
the use of polimedication, namely polymyxin B together with anti-inflammatory drugs.  
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